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ABSTRACT
This study was carried out to synthesize 
qualitative research data on innovation 
strategies of Healthcare, and Food and 
Drink companies in Ireland involved in 
biotechnology research and development 
in Ireland, for the purpose of 
determining in a pragmatic manner the 
level of activity and types of 
innovation strategies pursued.
Several types of innovation strategies 
through biotechnology have been 
identified. These strategies vary 
according to company type, company size 
and industry sector. Furthermore, those 
companies which represent a potential of 
considerable creativity in the 
innovation of products through 
biotechnology in Ireland have been 
identified.
Thus, the medium involvement long-term 
planners identified in this study 
represent a source of entrepreneurial 
potential for the commercialisation of 
biotechnology in Ireland.
Policy makers must investigate the 
implication of this for further 
biotechnology development in Ireland.
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CHAPTER 1: 
RESEARCH STUDY 
OUTLINE
1
1.1 INTRODUCTION
This section of the present thesis outlines the research problem 
and the thesis outline. The section also includes a discussion on 
the importance of the two industrial sectors chosen as the focus of 
the study in the context of the Irish economy. The operational 
definition of certain terms employed during the present research 
study are outlined also.
1.2 THE RESEARCH PROBLEM
This study involves an examination of the innovation strategies 
associated with companies involved in the development of a 
research field. The research field selected for the study is 
biotechnology. In the history of its development, the technology 
has passed through two major "paradigm" shifts of which the most 
recent, associated with the developments in genetic engineering 
methods, or "third-generation" biotechnology, is still unfolding.
The development of biotechnology appears to be characterised by 
considerable science-push. The breakthroughs which provide the
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core of this new technological trajectory originated in research 
undertaken within academia. Moreover, prior to this point, the key 
underpinning discipline in this area of endeavour - molecular 
biology, had not made its mark on industrial research and 
development efforts. This suggested that an examination of 
innovation strategies in the new biotechnology might provide an 
insight into other new science-based technological fields.
As an innovation or set of innovations, technologies can be seen as 
having two distinct kinds of development paths. On the one hand, 
there is the trajectory of the innovation process itself; the path from 
basic science or fundamental invention, through systematic 
application and early development to more specific and advanced 
development. What characterises the biotechnologies is the 
compression of this internal innovation chain - the time from basic 
discovery to advanced development, has grown shorter and 
shorter especially in the last decade.
On the other hand, there is the diffusion process by which 
innovations are spread into the economy. Biotechnology appears 
to be a new attempt to integrate these processes. Therefore, it is 
the infusion of scientific knowledge into the manufacturing process 
by which marketable products are made out of biological
3
phenomena that represents the challenge and enormous potential 
of biotechnology.
Industry plays the pivotal role in transforming new biotechnology 
into an economic force and it is assumed that present industrial 
involvement and strategies are an indication of future economic 
developments. Therefore, to gain insight into these strategies it is 
suggested that organisational studies of companies involved in the 
technology are appropriate.
From preliminary research as part of the present study it was 
established that industrial biotechnology in Ireland is mainly in the 
Healthcare and Food & Drink industry sectors (See Section 7.4). 
These two sectors are very diverse, not only in the nature of their 
products but also in their industrial structure.
The Healthcare sector is mainly comprised of foreign owned 
subsidiaries of international companies, while the Food & Drink 
sector is mainly made up of indigenous companies.
The present study focuses on these two Irish industrial sectors.
4
Due to the differences associated with these two sectors it is 
suggested that an examination of the innovation strategies through 
biotechnology in each of these sectors might provide an interesting 
comparison of the innovation strategies of new high-technology 
based companies and established low-technology based 
companies operating in the same generic field - biotechnology.
Finally, the new opportunities emerging in the area of 
biotechnology promise to be quite pervasive in economic impact 
suggesting that the commercialisation of the particular "nascent" 
technology will be of quite general interest. This study is an 
attempt to synthesize qualitative research data on innovation 
strategies of Healthcare and Food & Drink companies involved in 
biotechnology research and development in Ireland, for the 
purpose of determining, in a pragmatic manner, the level of activity 
and types of innovation strategies pursued by those companies 
involved in the technology.
Within this overall objective of the research, the study has a number 
of specific aims:
(1) To establish those Healthcare and Food & Drink companies in 
Ireland involved in biotechnology research and development 
as a means towards innovation.
5
(2) To establish reasons for developing biotechnology activities.
(3) To determine the innovation strategies through 
biotechnology of Healthcare and Food & Drink companies in 
Ireland actively involved in biotechnology research and 
development.
1.3 LIMITATIONS OF THE STUDY.
A limitation is a factor that may or will affect the study in an 
important way. The potential limitations of the present study 
include the following:
(1) The willingness of individual companies to respond to the 
enquiry of the study. In this respect, every possible effort 
was made to make individual companies respond to the 
research enquiry. During the preliminary stage of the 
research study, it was necessary to establish those 
companies in Ireland involved in biotechnology research and 
development. However, a limitation of the study is that 18% 
of the sample population were not willing to respond to such
6
enquiry and thus are not included in the research results. 
(See Section 8.2)
(2) The ability of respondents to answer research enquiries: This 
potential limitation was overcome by directing enquiries at 
individuals within the companies studied who were deemed 
capable of providing accurate information. (See Section 7.3)
(3) The willingness of respondents to respond accurately is a 
limitation of the study which is not under the control of the 
researcher. However, every possible effort was made by the 
researcher to make the respondent aware of the importance 
of accurate information for the success of the research 
study.
(4) The study is limited to Healthcare and Food & Drink 
companies in Ireland, to keep the sample size manageable 
considering the time and resources available to the 
researcher. However, focusing the research enquiry on 
these two industry sectors can be justified in several ways 
including:
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(A) These two sectors represent those sectors in which present 
and future applications of biotechnology developments have 
major impact (See Section 4.4);
(B) These two sectors are very important in the context of the 
Irish economy. The Food & Drink industry employs 26% of 
the Irish workforce. Exports in 1989 of food & drink were 
worth over two billion pounds or 24% of total exports. It is 
thus a very important sector and one in which biotechnology 
can play an important role. The Healthcare sector is also 
important for Ireland and has undergone considerable 
growth in recent years. As part of Irish industrial policy, the 
Industrial Development Authority (IDA) has implemented a 
policy of attracting foreign manufacturing industry to Ireland, 
including Healthcare companies. Ireland now has 110 
Healthcare company plants, including 10 of the world’s top 
15 pharmaceutical companies. Ireland is now the 10th 
largest exporter of pharmaceuticals in the world. Within the 
Healthcare industry in Ireland there has been a particularly 
encouraging growth in the Medical Diagnostics area. Several 
indigenous companies operate in this sector. Thus the 
Healthcare sector is very important to the Irish economy and 
one in which biotechnology can play an important role.
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(C) Furthermore, as indicated in Section 1.1, by focusing the 
present research on the innovation strategies through 
biotechnology in each of these sectors, a comparison of the 
innovation strategies of new high-technology based 
companies and established low-technology based 
companies operating in the same generic research field 
could be made.
1.4 DEFINITION OF OPERATIONAL TERMS
(1) BIOTECHNOLOGY
The question of definition with regard to biotechnology has been 
difficult. However, these are the principles which have been 
followed and the terms which have been used with regard to 
biotechnology:
Classical biotechnology is thousands of years old. During the last 
several decades numerous scientific and technological advances 
have turned biotechnology into an increasingly efficient set of 
techniques, referred to as Modern biotechnology. Since the late 
1970s, the discovery particularly of recombinant DNA techniques 
and cell fusion has led to a radical acceleration of progress and to
9
a multiplication of both tools and applications. This is referred to as 
New biotechnology.
Classical, Modern and New biotechnology is not a distinct sector, 
but a broad enabling technology which affects many industrial 
sectors. It is not in contradiction with this that this study also uses 
the terms Biotechnology Industry or Biotechnology Companies. 
These refer to the industrial enterprises which carry out the bulk of 
industrial research and development in "Modern biotechnology" 
and "New biotechnology", irrespective of the sector of activity. 
Whenever a precise definition of biotechnology was required, 
particularly during preliminary research and depth interviews (see 
Section 7.5) with industrial companies, the adapted OECD (1982) 
definition was employed: "Biotechnology is the application of 
scientific and engineering principles to the processing of materials 
by biological agents to provide goods and services. This term is 
understood to exclude bio-medicine and agriculture, excepting 
those areas which now involve the application of cellular or 
molecular biology."
(2) INNOVATION
Difficulties were similarly encountered in defining innovation in the 
present research study. However, innovation was taken to refer to
10
new product and/or new process developments, either new to the 
market or new to the company, (See also section 2.2).
1.5 THESIS OUTLINE
This thesis is organised into eight sections. The present section 
focuses on the research problem of the present study, specific 
research questions to be investigated, limitations of the study and 
definition of operational terms employed during the research 
employed in the study.
Section 2 draws on literature concerning industrial technological 
innovation, the economic role of research and development and 
turns to some of the prospective long-term economic impacts of 
technology, including impacts on trade and competitiveness. 
Particular reference is made to the technology research field 
selected for the present study, that is, biotechnology.
Section 3 focuses on the literature concerning strategic 
management and the innovating firm, in particular corporate
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strategy and innovation strategy and also on characteristics of 
successful technological innovation in the firm.
Section 4 and 5 outline the technological context of the study. 
Section 4 is largely descriptive, providing essential background 
information. It starts with a short history of the evolution of 
biotechnology and focuses on current and future perspectives. 
The global biotechnology situation is briefly discussed. Specific 
issues related to the development of biotechnology and its 
commercial application are discussed including finance, patent 
protection and public attitudes and acceptance of the technology - 
these issues being important when considering the 
commercialisation of new products or processes through 
biotechnology.
Section 5 discusses the future diffusion of biotechnology through 
the economy and particularly the probable time-scales and 
consequences. Parallels are drawn with the diffusion of the 
electronic computer and of electric power. This part also discusses 
biotechnology as a techno-economic paradigm accompanied by 
many changes including structural adjustments in the sectors 
affected by biotechnology. Finally, Section 5 reviews prospective 
employment impacts of biotechnology.
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Section 6 focuses on Ireland and innovation, the evolution of Irish 
Science and Technology and the Government Policy for Innovation 
through Biotechnology in Ireland.
Section 7 describes the research design of the study, focusing on 
the general research method, the research population and specific 
procedures employed.
Section 8 presents the findings and conclusions resulting from the 
present research study.
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CHAPTER 2: 
TECHNOLOGICAL 
INNOVATION IN THE 
ECONOMY
14
2.1 INTRODUCTION
This section of the present thesis draws on literature concerning 
industrial technological innovation; including models of the 
innovation process. The section also includes a discusssion on the 
economic role of research and development as a means towards 
innovation and turns to some of the prospective long term 
economic impacts of technological change, including impacts on 
trade and competitiveness, foreign direct investment and the 
process of globalisation.
Particular reference is made to the technology research field 
selected for the present study, that is biotechnology.
2.2 INDUSTRIAL INNOVATION
The establishment of research and development laboratories by 
industrial concerns must be understood in the context of the 
competitive pressures operating in the economic environment to 
innovate, through the introduction of new products or production
15
processes which have been described in the works of Karl Marx 
and Joseph Schumpeter, as well as many others.
Broadly, these pressures hinge on the necessity for companies to 
maximise profits. This endeavour may involve an attempt to 
secure, however briefly, competitive advantage through for 
example, increased market share or accumulated technological 
capacity.
For the individual firm, it is clear that failure to innovate results in 
commercial suicide:
... no firm ever yields returns indefinitely if only run 
according to unchanged p/an.1
Similarly on the macroeconomic level,
... without technological innovation, economic progress 
would cease in the long run and in this sense we are 
justified in regarding it as primary.2
In order to understand the role of science and technology in the 
innovation process it is necessary to clarify some of the terms used.
^Schumpeter, 1950
Freeman, 1974
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Strictly speaking the term technical or industrial innovation is more 
generally used to connote changes in technique, involving
the introduction and spread of new and improved products 
and processes in the economy.
In this study, technological innovation in those firms operating in 
certain sectors of Irish industry involved in biotechnology research 
and development is considered. Therefore the broad definition of 
Christopher Freeman of the Science Policy Research Unit of the 
University of Sussex, seems an appropriate definition to adopt.
The process of innovation is the first commercial 
introduction of new techniques. Inventions which are both 
introduced and updated into the regular system of 
production and provision of services are technical 
innovations.4
This definition embraces the techno-commercial activities which 
result in either the successful market adoption of a new or 
improved product of the firm, or the adoption of a new or improved 
process within the firm.
Interpretation of this definition suggests that the product or process 
innovation may be new at the level of the firm but not necessarily at
3Freeman, 1974
4Freeman, 1974
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the global or industrial level, and also that both radical and 
incremental innovations are included in the definition. With this 
definition of technological innovation and the innovation process it 
is necessary to enlarge on a number of aspects including the 
following;
(1) Much differentiation has been made in the literature between 
product and process innovation. This is especially true of 
the work of Abernathy and Utterback (1978) who use the 
"learning curve" concept to emphasise the changing profile 
of the mix of product and process innovation over the life­
cycle of the product. Interestingly, the term "output" is often 
used instead of the "product" as the firms output may in fact 
be a service or a process in the case of non-manufacturing 
industry. Equally, technological innovation may lead to the 
development of new and more efficient processes for the 
production of new or existing products.
(2) The interpretation of technological innovation allows the 
scope for distinction between "radical" innovation and 
"incremental" innovation. Numerous studies of industrial 
innovation have revealed that "technological innovation" is to
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a large extent based on the cumulative effect of small 
incremental innovation.5
However, innovations embodying large advances in 
knowledge although less common, are of great commercial 
importance. Such radical innovations have a pattern of 
diffusing through the economy by a process of largely 
imitative activity in which the original elements are adopted 
and re-adopted by more and more firms. Such imitative 
activity accounts for a good proportion of incremental 
innovation.
(3) Innovation is more than technological research and 
development. It can and does involve technological R & D 
as well as market R & D. However, the acquisition of 
licensing rights for a technological product and process or 
the adoption of a technological capability would be other 
valid routes to innovation. Similarly innovation is more than 
simply engineering design. It represents in scope the range 
of activities relevant to the commercialisation process from 
the recognition of new technological opportunities or latent 
market demands, through various stages of maturity, until 
commercial success is realised.
5Marquis, 1981
19
(4) Technological innovation need not necessarily involve so- 
called high technology or technology-intensive products. It 
can occur equally at "low" or "medium" technology levels. It 
can and does occur to the same extent in traditional well 
established sectors, such as the food and drink sector, as in 
newer sectors such as electronics. Wherever it occurs, 
technological innovation will result in raising the 
technological level and capability of the firm, whether the 
level be initially high or low.
In practice, it is difficult to describe the multidimensional dynamics 
of the innovation process. The process is a complex socio­
economic one for which many representations or models exist, the 
majority referring to the industrial innovation process. Many studies 
based their measurements of innovation at firm level on simple 
indicators of key characteristics and trends. The adequacy of such 
indicators is a factor not to be ignored in deriving conclusions from 
such studies. For example, R & D expenditures as a percentage of 
sales is one such indicator frequently used both at macro and 
micro level. This indicator ought to be used with care in 
considering innovation since innovation involves much more than 
R & D .
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While the problems involved in developing realistic models of the 
innovation process are both broad and complex, Robbins, Burke 
and Milliken (1977) have shown how useful these models can be 
when developed. They can be used in several ways, including the 
following:
* To help predict performance of a system when it is 
subjected to a set of various environmental conditions or 
stimuli, such as different forms of government intervention or 
changes in government politics.
* To analyse the functions of a system when various changes 
are made in its components.
To gain knowledge for decision making and problem 
solving.
* To contribute towards the optimisation of the design of the 
system by experimenting with various changes in its 
parameters.
While crude models or descriptions of the innovations process 
involve simplifications of reality, they nevertheless portray several 
important features of the real system. The complexity and
21
usefulness of models of the innovation process has grown with 
increased understanding of the innovation process.
Most models can be divided into broad groups as follows:- 
GENERALISED MODELS
This group includes a societal model followed, for comparison 
purposes, by models of innovation in the public and private 
sectors.
MODELS OF TECHNOLOGICAL INNOVATION IN MANUFACTURING 
INDUSTRY
These models range from basic linear models, through more 
complex non-linear models to those which place greater emphasis 
on human and environmental factors.
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2.3 GENERALISED MODELS OF THE 
INNOVATION PROCESS
Perhaps the earliest generalised model of the innovative process 
was developed by Hornig who defined innovation as the process 
by which knowledge is generated and applied to the operations of 
society.6 By this definition, therefore, innovation is more than 
discovery, more than invention, even more than engineering 
drawings. Until the know-how is incorporated into the operations of 
society, society does not benefit.
On the evidence of studies of a large number of innovative 
organisations, Hornig suggests a broad based model of the 
innovation process. He describes the process as an interactive 
one between three functionally different, interrelated 
"suborganisations", these include:
(1) Organisations that recognise the needs and desires to be 
satisfied, set goals and allocate the necessary resources i.e. 
management and decision-making organisation whether it 
be government, industry or components of either.
6Hornig, 1978
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(2) Organisations that educate people to staff the enterprise, 
generate scientific knowledge and new technology.
(3) Organisations which apply the new technology to society’s 
operations or use the technical knowledge in the formulation 
of policy.
In the highly "interactive process" of innovative activity, Hornig’s 
description of the necessary close interaction is shown 
diagrammatically in Figure 1.
Usually all three functions are found to some degree in each 
performing organisation and all three must interact to some degree 
with the outside world (society), as well as with each other.
While Hornig’s model is still the most popular generalised model of 
the innovation process, some further work has been carried out on 
the identification of the significant differences between the nature of 
the innovation process in the public sector, and its nature in the 
private sector.
Of interest to the present study is the private sector generalised 
model of the innovation process, developed by Robbins et al.
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FIGURE 1 HORNIG' S GENERALISED MODEL OF THE INNOVATION 
PROCESS ( 1 9 7 8 )
S o u r c e : H o r n i g ,  P . ,  ( 1 9 7 8 ) ,  " H e a l t h  o f  t h e  S c i e n t i f i c 
a n d  T e c h n i c a l  E n t e r p r i s e  -  An A d v i s o r y  R e p o r t "
NTIS P u b l i c a t i o n ,  W a s h i n g t o n ,  D . C .
FIGURE 2 ROBBINS ET AL ( 1 9 7 7 )  PRIVATE SECTOR 
GENERALIZED MODEL OF THE INNOVATION PROCESS
RESEARCH DEFINITION
I
RESEARCH EXPERIMENTATION, ANALYSIS & EVALUATION
\r
PRODUCT OR PROCESS CONCEPTION
I
TECHNICAL FEASABILITY STUDY & ASSESSMENT
I
TECHNICAL INITIATION (LABORATORY DEVELOPMENT)
4
PROTOTYPE COMPONENT & OVERALL DEVELOPMENT & DESIGN
I-
PILOT TEST
I
PREPARATORY PRODUCT AND PROCESS ENGINEERING
I
PRODUCTION & PLANT INSTALLATION
S o u r c e :  R o b b i n s ,  M.D. e t  a l ,  ( 1 9 7 7 ) ,  The  T e c h n o l o g i c a l  
I n n o v a t i o n  P r o c e s s  i n  t h e  P r i v a t e  S e c t o r , 
W e s t v i e w  P r e s s ,  B o u l d e r ,  C o l o r a d o .
which, having nine sequential stages described in Figure 2, has a 
technology-push orientation.7
In addition to the technological stages described in Figure 2, 
Robbins also states that environmental factors affect the flow of 
innovation throughout its progression.
These factors may be internal or external to the firm, and they may 
have either a positive or negative effect on innovation.
Five categories of institutional factors have been identified as 
having major impacts on the success or failure of an innovative 
idea.8
(A) Marketing and Market - Related Factors
(B) Regulatory and Standard Setting Factors
(C) Capital Related Factors
(D) Human Resources - Related Factors, including 
management, organisation, and staffing.
7Robbins et al., 1977
8Robbins et a l, 1977
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(E) Technology Related Factors.
2.4 MODELS OF TECHNOLOGICAL INNOVATION 
IN MANUFACTURING INDUSTRY
Leaving aside the more generalised models of the innovation 
process discussed in Section 2.3, this section will discuss a number 
of models of technological innovation in manufacturing industry, 
ranging from the basic linear model type, to the more complex 
models involving human and environmental factors.
Basic linear models of "technology-push" and "demand/need - pull" 
type have been proposed by many researchers.
The Organisation for Economic Co-operation and Development9 
propose a linear model described in Figure 3. This model 
describes only product innovation but states that process 
innovation is analogous. Not showing a market input in the earlier 
stages of the process, this model could be considered a 
"technology-push" type model as described in Section 3.8.
9OECD, 1978
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A further linear model of technological innovation in manufacturing 
industry has been suggested by Haeffnerto describe
... a piece of systematic innovation work.10
Having six stages, Haeffner argues, starting backwards, that it is 
reasonable that full scale industrial exploitation should be preceded 
by a sales testing period. This implies that at least a pilot part 
production is already underway. Before a pilot plant is decided on, 
the product, process or method has passed a stage of 
development that might be called an objective or mission oriented 
industrial research and development phase.
This must be preceded by an idea generating phase. The 
argument to support the phase described as "specification of 
innovation needs", is made on the basis that about three quarters 
of successful innovations need to be stimulated while the rest might 
be characterised as recognition of a technical opportunity. This 
model represented in Figure 4, could therefore be regarded as a 
"demand/need - pull" type model (see Section 3.8) as it starts with 
the identification of a market need.
10Haeffner 1979
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FIGURE 3 OECD ( 1 9 7 8 )  GENERALISED LINEAR MODEL OF THE 
INNOVATION PROCESS IN MANUFACTURING INDUSTRY
R&D ENGINEERING 
& DESIGN
PROTOTYPE PILOT
PLANT
MANUFACTURE 
& MARKET
S o u r c e :  OECD. ( 1 9 7 8 ) ,  " P o l i c i e s  f o r  t h e  S t i m u l a t i o n  o f
I n d u s t r i a l  I n n o v a t i o n " ,  Volume 1,  A n a l y t i c a l 
R e p o r t .  P a r i s ,  1 9 7 8 .
FIGURE 4 HAEFFNER'S LINEAR MODEL OF THE INNOVATION 
PROCESS IN MANUFACTURING INDUSTRY ( 1 9 7 9 )
SPECIFICATION OF INNOVATION NEEDS
I
PRODUCT IDEAS
I
DEVELOPMENT
I
PILOT PLANT
I
TRIAL SALES 
1
EXPLOITATION
S o u r c e :  H a e f f n e r .  A . E . ,  ( 1 9 7 9 ) ,  " I n n o v a t i o n  S t r a t e g i e s  
f o r  I n d u s t r i a l  C o r p o r a t i o n s  a n d  f o r  S a t i s f y i n g  
N a t i o n a l  N e e d s " .  T he  Mac M i l l a n  P r e s s ,  L o n d o n .
One of the important additional features of this model is the explicit 
inclusion of five natural decision states, a choice between specified 
innovation requirements; decision to develop a product; decision to 
proceed with development work; decision to proceed with trial 
production and trial sales, and decision as to complete exploitation.
More complex models of the innovation process recognise the 
need for both technical and market input to the generation of ideas 
for successful innovations and the role of a "feedback" or iterative 
process.
In his description of the innovative process Marquis (1981) 
demonstrates the ongoing interaction between technical knowledge 
and market needs at all stages of the process. It also shows 
feedback between stages which is a good reflection of what 
actually happens in practice in most industrial sectors. The model 
shows a distinct departure from the linear thinking of the earlier 
models. For further discussion of Marquis’ model of the innovation 
process and a diagrammatic representation of the model see 
section 3.8, Figure 9.
Finally, the changing character of innovation and its changing role 
in corporate advance is discussed in this section.
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Seeking to understand the variables that determine successful 
innovation strategies, Abernathy and Utterback (1978) focus on 
three stages in the evolution of a successful enterprise: its period 
of flexibility, in which the enterprise seeks to capitalize on its 
advantages where they offer greatest advantages; its intermediate 
years in which major products are used more widely; its full 
maturity, when prosperity is assured by leadership in several 
principal products and technologies.
The above authors examined different types of innovations and 
their relationships by looking at the successive steps in the 
development of a line of business which is described as follows:
The business starts through the origination of one or more 
product innovations. These are usually stimulated by users’ 
needs through frequent interaction with users of innovation. 
Exploitation o f the product's potential in different 
applications follows. Rising production volume may lead to 
the need for innovation in the production process. 
Demands for greater sophistication, uniformity, and lower 
cost in the product create an ongoing demand for the 
development and improvement of both product and 
process.11
This means that product and process design become more and 
more closely interdependent as a line of business develops.
Abernathy and Utterback, 1978
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As a result of this interdependence, Abernathy and Utterback 
(1978) suggest that a shift from radical to evolutionary product 
innovation will occur. This shift is accompanied by heightened 
price competition and increased emphasis on process innovation.
Thus, changes in innovative pattern, production processes and 
scale, and kind of production capacity will all occur together in a 
consistent predictable way.
Abernathy and Utterback (1978) propose a mode of industrial 
innovation which indicates the changing character of innovation 
and its changing role in corporate advance. See Figure 5.
Obviously, this model has important implications in the study of 
innovation strategies as the innovation strategy of a firm will change 
as the firm’s business develops.
2.5 THE ECONOMIC ROLE OF RESEARCH AND
DEVELOPMENT
That innovation is not wholly incremental and that major 
breakthroughs in knowledge are sometimes critical, reflects the
30
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relative autonomy of technological development or change, and 
economic forces.
This theme is implicit in most attempts to characterise the evolution 
of technological fields, including that by Granberg and Stankiewicz 
(1978).
The development of a technological field begins with the 
recognition of the potential of some range of phenomena, such as 
processes, effects and properties, for serving some specialised 
function. The phenomena in question may or may not be newly 
discovered. The essential point is that they have not previously 
been used for the given purpose.
Once the generic idea or technical concept of such phenomena 
and their utilisation has emerged, it initiates a process which 
consists of the reorganisation of existing knowledge and the 
generation of new problems for solution.12
Within the ideal type proposed by Granberg and Stankiewicz, the 
early development of a technological field is characterised by 
systematic research and development, and the emergence of a
Graberg and Stankiewicz, 197819
31
core group of researchers, interested in and committed to the 
solution of problems raised by the technical concept, followed by 
the utilisation of these solutions through innovation and its eventual 
decline as the number of research problems lessens.
It is clear in a general sense that companies need to utilise available 
resources of scientific and technological knowledge if they are to 
sustain innovative activity. Furthermore, by privately funding 
research and development activities, companies add to the total 
stock of knowledge as well as simply drawing on that which is 
publicly available.
Studies of innovation reveal that, averaging across a range of 
industries, some 60% of the knowledge applied by companies in 
innovation is derived from their in-house research and development 
efforts.1314
This appears to contradict the concept of technology being a 
general stock of knowledge from which companies draw, prevalent 
in much classical economics’ treatment of the subject. The reason
13Robbins et al., 1977
Freeman, 1974
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for this probably lies in the very targeted nature of innovative efforts 
necessitated by the economic pressure to compete for markets.
Specificity is crucial to commercial success at the level of product 
differentiation. It is also an essential prerequisite if firms are to 
appropriate the knowledge embodied in a given innovation and so 
secure commercial success in a competitive market. As Pavitt 
remarks,
... most of the knowledge applied by firms in innovations is 
not general purpose and easily transmitted and reproduced, 
but appropriate for specific applications and appropriated by 
specific firms.15
Furthermore it is revealed that on average some three quarters of 
industrial research and development expenditure is accounted for 
by development work.16 It is in this area that the specificity issue 
especially obtains, and that information or knowledge is least 
transmissible.
Nevertheless, at the research end of industrial research and 
development, where inventive activity is perhaps most crucial, there 
are also benefits accruing from a firm’s decision to invest. When
15Pavitt, 1987
Abernathy and Utterback, 1978
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research is focussed in the selective fashion highlighted by Dosi 
(1982), there is scope for ordered progress:
... inventions usually result from a systematic attack on a 
problem.'17
Furthermore, companies investing in both research and 
development are better able to exercise control over their 
innovative efforts, and to ensure that these efforts are not wasted. 
This has been very elegantly argued by Dosi in a theoretical 
contribution in which he characterises industrial research and 
development (taken together) as a search activity, and suggests a 
theory of knowledge as
capability for efficient search18
He further argues that the stronger the knowledge base a company 
is able to draw on, the greater its ability to make rational decisions 
about where to search, and thus, the greater the returns on its 
investment in R & D. In short,
... basic research ... enhances the productivity o f applied 
research and development.19
17Dosi, 1982
18Dosi, 1982
19Dosi, 1982
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Industrial R & D often generates new knowledge as well as new 
techniques, which itself is relevant to the next round of search. 
Rosenberg (1976) has shown that companies do not generally 
possess knowledge of all the possible lines of investigation and 
further, that companies are in any case constrained in their choices 
about which alternatives to pursue, by the state of their existing 
knowledge and skills. For further discussion on this topic see 
Section 3.6.
In a similar vein, Moweny (1981) has argued that the cumulative 
nature of industrial innovative R & D does not generally cover high 
risk and complex projects.
Concerning the selection of new technological paths, it has been 
suggested that the greater the discontinuity of capability involved in 
moving from an existing technological area to a new one, the 
greater the risk and uncertainty and the greater the reticence-20 
Furthermore, the benefits of investing in relatively more open-ended 
research activities are not always as apparent as are those of 
undertaking development work.
20Dosi, 1982
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Recognition of the general importance of technological advance to 
economic progress provides the major economic justification for 
the public funding of R & D and especially of fundamental research.
Three possible economic benefits of science, in general, have been 
investigated.21 First the long term benefits of providing 
knowledge to industrial innovation; Second, the technological 
benefit of "spin-off1 to industry; finally, the benefits accruing through 
the training of skilled personnel, who are then employed in R & D in 
industry. Of these benefits, Irvine and Martin suggest that the third 
is the most tangible and may well have the greatest impact.
From studies of industrial innovation22 23 private companies ten to 
"underinvest" in basic science and research. Reasons for such 
underinvestment may be associated first with the risk factor, and 
second with the question of appropriability, that is, how relevant the 
basic research is with regard to potential commercial applications 
of products or processes; the results of basic research are 
generally long term and unpredictable and are not usually in a form 
which can be easily "appropriated".
21 Irvine and Martin, 1980
22 Freeman, 1974
23Robbins et al., 1977
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For these reasons, it could be suggested that money spent on 
basic research undertaken in academic and other non-commercial 
institutions is more productive, the fundamental objective of these 
institutions being the advance of knowledge. Hence, governments 
are obliged to commit resources to basic knowledge in a particular 
technological area, and in effect, undertake to support the longer 
term interests of industry by conducting more speculative search 
operations on its part.24
Furthermore, it has been argued that because of the burden of 
R & D expenditures on smaller companies, government support of 
science and technology is one way of countering the monopolistic 
trends of larger firms. As Dosi remarks,
If we want to maintain our enterprise economy, basic 
research must be a matter of conscious social policy.25
It could be argued therefore, that there is an economic basis for the 
division of labour between academia and industry with respect to 
research and development activities.
The extent to which industry is likely to do university-type science is 
limited by the breadth of knowledge involved and by the inevitably
24Faulkner, 1986
25Dosi, 1982
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long term nature of any returns from it. Similarly, universities 
lacking the competitive pressure to innovate are unlikely to 
undertake any sizeable development work. Thus the two 
institutions perform complementary roles proportionate with their 
institutional objectives. It can be further suggested that the 
promotion of academic - industry linkages in a particular research 
area would further facilitate innovation by merging the 
complementary roles of each organisation.
Thus on the micro-economic level, public sector R & D represents a 
source of knowledge which firms may access with ranging degrees 
of success. What matters in the competitive market is the marginal 
advantage captured by adding in-house knowledge to public 
knowledge.
2.6 TECHNOLOGY, COMPETITIVENESS AND 
COMPARATIVE ADVANTAGE
For the economist, the rationale of international business lies in the 
theory of comparative advantage, the same theory which in effect 
lies at the heart of all economic specialisation. Countries, like
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individuals, are well advised to concentrate on those things they do 
best, and, as far as they can, buy other things from someone else 
who will accept their products in payment. The theory of 
comparative advantage was developed more than a century ago by 
David Ricardo, John Stuart Mill and other English followers of Adam 
Smith. The theory of comparative advantage is a closely reasoned 
doctrine which, when properly stated is unassailable.26
In a dynamic, innovation-driven economy, comparative advantage 
is hard to distinguish from competitiveness as expressed itself by 
the price, quality and novelty of products. At certain periods, 
competitiveness is in fact, strongly determined by the type of 
competition which Schumpeter defined as,
... competition from the new commodity, the new 
technology, the new source of supply, the new type of 
organisation ... competition which commands a decisive 
cost or quality advantage and which strikes not at the 
margins of the profits and the outputs of the existing firms 
(and possibly even entire economies) but at their 
foundations and their very lives.27
After having been virtually ignored by mainstream and neo-classical
international trade economists for many decades, there has been
initial recognition of this Schumpeterian approach by the leading
trade economists.
26Samuelson, 1948
Schumpeter, 1943
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As stated by Johnson,
... innovative capacity should be viewed as a basic source 
of difference in comparative advantage and technological 
change as a chronic disturber of existing patterns of 
comparative advantage.28
These "chronic disturber" effects of technology may occur in two 
main ways29, (OECD 1989).
(1) By modifying trade flows as a result of the marketing either 
of totally new products or of products or of new, better and 
differently sourced substitutes, whether they are material 
inputs to industry or products for final consumption, and;
(2) By creating new gaps between countries, or suddenly 
widening gaps which were previously being reduced as a 
result of international transfers or technology.
A closer examination of the trade modifying effects of technology 
shows that these can occur through four main channels or 
mechanisms-30
28Johnson, 1975
29OECD, 1989
30OECD 1989
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(A) The creation of new trade (either along existing overall 
international trade patterns or with a recognisable change in 
patterns) through the marketing through exports of totally 
new products. Stress is placed here on the words through 
exports to indicate that in the area of high technology (Eg.. 
R & D intensive) industries, the world-wide marketing of new 
products may take place through delocated manufacture 
and the foreign operations of multinational enterprises 
(MNES) and have little effect on trade flows per se.
(B) Shifts in the structure of trade, marked by the reduction, and 
at some stage possibly the outright disappearance of 
particular trade flows, resulting from the creation of entirely 
new substitutes for previous products.
(C) Shifts in the structure of trade, again marked by the
reduction of particular trade flows, resulting from the
introduction of new production processes which change 
major factor proportions (Eg., capital/labour ratios) and 
reduce trade flows based on an abundant cheap labour type 
of comparative advantage.
(D) Shifts in the structure of trade, also involving a reduction in
the level of trade flows, which stem from the reduction of
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material inputs to production as a consequence of a number 
of parallel and/or related processes of economisation and 
substitution.
This fourth process which is of particular importance in modern 
biotechnology has been overlooked for a long time but has recently 
been studied fairly systematically by trade experts and international 
organisations in relation to fall in developing countries’ exports of 
primary metals and agricultural raw products.31
The results of such studies has given support to what a number of 
economists and technologists now designate as,
a generally neglected dimension of long term structural 
change which can be characterised as a ''dematerialisation" 
of production that is, a shift in the composition of demand in 
industrialised countries away from the products of the more 
intensely raw material - consuming industries and a 
diminution in the intensity of raw material use in existing 
manufacturing industries.
31 UNCTAD, 1986
32UNCTAD, 1986
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2.7 INNOVATION CAPABILITIES, TRADE 
IMPACTS AND THE ABILITY TO SHAPE NEW 
TECHNOLOGICAL PARADIGMS
If the distinction proposed by Freeman and Perez (1986) between
(i) incremental innovations; (ii) radical innovations; (iii) 
technological revolutions and (iv) historical transitions to new 
technological paradigms is accepted, the three latter types of 
innovation may all be expected to have trade creating, substituting 
or displacing impacts. However, even incremental innovations will 
influence the process of dematerialisation (see Section 5.1). In 
periods of technological revolution or historical change in basic 
paradigms, the impacts on trade are likely to be accelerated, 
possibly with dramatic effects on the production and export of 
given products.
The extent and nature of such impacts on international trade 
patterns and country specializations will depend on a number of 
factors: the scale and speed with which new output related to 
radical or revolutionary technologies is marketed; the level of 
development, wide and narrow trade specialization and industrial 
sophistication of national economies, and also of course on the 
overall economic climate in which the trade impacts take place.
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The trajectories of new technologies are rarely "natural" (Eg., in the 
sense of being commanded essentially by endogenous scientific 
and technological factors). Economic and social factors are of 
paramount importance in shaping trajectories and determining the 
way in which the new techno-industrial paradigms emerge.33
The process is one of selection through the play of economic, 
political and social factors, at the basis of which lies of course a 
sufficient degree of indigenous, technological and industrial 
capacity to be able to participate in this selection process.
Countries, industries and firms with strong scientific and 
technological capacities may be predicted to be on the initiating 
end of such processes or at least to have a reasonable hope of 
adjusting to them successfully, through investments in R & D, 
innovation, and related shifts in industrial specialisation. As 
previous history has shown, on the contrary,
... countries with weak scientific and technological
capabilities will often be on the receiving end of such 
processes and may consequently be forced to bear the full 
brunt of adjustment through painful changes in exchange 
rates, employment and real incomes.34
33Piore & Sabel, 1984
4Chesnais, 1986
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2.8 TECHNOLOGY, FOREIGN DIRECT 
INVESTMENT 
AND THE PROCESS OF GLOBALISATION
The commercialisation of products through exports is only one of 
the several ways in which firms can exploit the temporary 
monopoly-advantages and firm-specific assets stemming from 
technological lead times and unique experience with new 
technologies. Such advantages are more and more often exploited 
through foreign direct investment and the international network of 
delocated production units based on transnational or multinational 
enterprises or corporations.
A number of factors lie behind this development in particular:
(A) The large range of factors which place a premium on 
delocated production inside foreign economies, inter alia 
non-tariff, and regulatory barriers to trade (some of which 
may take the form of government regulations regarding 
health and safety) but also proximity to scientific and 
technical skills; and
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(B) The special imperatives of ogliopolistic competition in 
industries where concentration has developed and where 
firms must be present on a fairly large scale inside the home 
markets of major competitors in order to wage competition 
successfully.
In industries where R & D costs are high, market niches for new 
products in the early stages of innovation are small and hence cash 
flows from innovation investment are low in relation to R & D and 
start-up investment. These factors, coupled with the imperatives of 
rapid commercialisation may often push firms to accentuate their 
multinational production and marketing strategies at the expense of 
exports. A generally considerably less advantageous form of 
recouping R & D costs and reaping benefits from innovation is 
through foreign licensing and/or establishment of joint ventures and 
other interfirm technological and industrial co-operation 
agreements. This course is one which small innovative firms or else 
larger firms with lower levels of multinationalisation may be forced 
to adopt because they do not possess the complete range of 
assets required to reap the profits stemming from their innovations.
Delocated production and the emergence of global competition on 
a world level in markets with a small number of competitors, have
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two major implications for the level and pattern of foreign trade and 
the international competitiveness of national economies.35
(i) Delocated production resulting from foreign investment will 
tend to replace trade flows.
(ii) Firms will choose their competitive strategies on the basis of 
considerations pertaining to world markets and the global 
relationships with their main competitors.36
They will forego national or even regional, for example, European, 
considerations when shaping their strategies, thus complicating the 
attempts made by governments to formulate and apply policies 
aimed at enhancing national or regional competitiveness.
2.9 BIOTECHNOLOGY, TRADE AND 
COMPETITIVENESS
The concern by governments with future competitiveness in 
biotechnology, as well as with the effects of biotechnology on the
35OECD, 1989
36Porter, 1986
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overall competitiveness of domestic economies and on the scale of 
technology driven structural adjustment is well-founded and 
legitimate.37
Biotechnology has all the requisites necessary to usher in a set of 
technical and organisational paradigms in many industrial areas, 
including healthcare and agriculture. Consequently, biotechnology 
also has the requisites of the type of competition described by 
Schumpeter (1943) (see Section 3.2); it will create trade, but it will 
also have strong trade displacement effects.38
Other studies have already suggested that in the case of 
biotechnology, a number of factors
... preclude a traditional analysis of international 
competitiveness.39
The first factor relates quite simply to the impossibility at present of 
measuring and comparing performances.
OECD work has shown that competitiveness is as much, and in
new industries and technologies generally more, a question of
quality and novelty than of price. In such industries, indicators of
37OECD, 1989
38OECD, 1989
Office of Technology Assessment, OTA, Washington D.C. 1984
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relative cost (Eg., wage levels) and price simply do not represent 
meaningful proxies of competitiveness.40
Competitiveness has to be measured through foreign trade data 
and derived calculations, for example, shares in world exports, 
ratios of foreign penetration of domestic markets at the most 
disaggregated level possible. In the case of biotechnology, and in 
particular new biotechnology, the level of production and sales 
simply do not permit any such measurement.
The second point made by the 1984 O.T.A. report regarding 
competitiveness is of greater analytical interest, and may be more 
durable in its influence on the way competitiveness among 
industrialized countries will shape up to biotechnology.
Even with many more products on the market, a traditional 
competitive analysis might not be appropriate because an 
economic analysis of competitiveness usually addresses a 
specific industrial sector. The set of techniques that 
constitute biotechnology, however, are potentially applicable 
to many industrial sectors.41
Even if biotechnology seems, at present, a less pervasive generic
technology than for example, microelectronics (see Section 5.3), its
range is potentially very wide. One aspect of the highly ubiquitous
40Dosi, 1983, paper prepared for the 1983 OECD workshop on Technological 
Indicators and the Measurement of Performance in International Trade.
41 OTA, 1984
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nature of biotechnology, and the array of techniques it calls on, is 
that it offers in the long term, unique opportunities for creating 
totally new products, opening up totally new markets for which 
there exists at present no competition and so no issue of 
competitiveness.
A further novel feature of competitiveness in biotechnology is the 
fact that the contours of competition are shaped by previous 
processes of technological accumulation, industrial concentration 
and multinationalisation. Biotechnology has begun to grow not 
exclusively, but to a considerable extent within the framework of 
already strongly concentrated and highly globalised industries such 
as pharmaceuticals, chemicals and multinationalised food 
processing.
In conditions where profitable market niches are still small and 
current cash flows Insufficient to meet high R & D outlays, the 
pressure on firms to establish their strategies for the world-wide 
sourcing of scientific and technological resources and the global 
marketing of products is particularly strong (see Section 2.8). 
Firms may tend, perhaps more than in some other areas, to "go it 
their own way", without putting great expectations in national 
policies for competitiveness.
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These particular features have a number of implications for trade 
and competitiveness within OECD countries42, inter alia the fact:
(1) That initially at least, firms and countries will probably, to a 
fairly significant extent, seek to use biotechnology as a way 
of consolidating and enhancing their "comparative 
advantage" (in pharmaceuticals, agriculture, food processing 
etc.) based on technological accumulation undertaken in 
earlier phases of industrial development.
(2) That there is less risk, in the longer term at least, for "picking 
the winner" strategies by firms as by governments to create 
trade tensions and trade issues, since they are less likely 
than in the case of automobiles for example, to be 
concentrated on exactly the same products, and to occur in 
slow growth markets. It is true that today companies are 
pursuing the same few product developments principally in 
pharmaceuticals and that the race of firms to be first to 
commercialise these products on a world scale lies behind 
some major patent disputes and behind the trend of 
increasing secretiveness in R & D.43
42OECD, 1989
^O E C D , 1989
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However, it has been suggested that a prospective analysis 
of competitiveness and its related issues must emphasis that 
the present situation is necessarily temporary, that the 
number of new products arriving on the market are expected 
to increase fast in the coming years, and that the range of 
totally new or old, but hitherto, not addressed individual and 
collective needs which could be catered for, is potentially so 
large that if the needs were to be recognised and met, the 
market could be a very open and large one.44
(3) That for an OECD country today, being competitive in 
biotechnology has still essentially the meaning of taking the 
necessary steps to prepare for the future, to avoid being on 
the receiving end of the process of "creative destruction"45, 
and to participate as fully as it can in the scientific and 
industrial development of biotechnology, and so in the new 
commercial opportunities it will offer, and
(4) That large firms possessing an advantage in biotechnology 
may tend to establish their own competitive strategies 
without waiting for governments to act and without 
necessarily welcoming government plans.
^O E C D , 1989
45Schumpeter, 1943
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For reasons explained in this discussion, the use of the term 
"competitiveness" in biotechnology is, for the time being at least, 
somewhat different in its use from the context of many other 
technologies and industries. This does not mean however that 
countries can overlook the scientific and technological lead-times in 
terms of the time required to train the appropriate scientific and 
technical labour power, build the appropriate R & D infrastructures, 
and create the appropriate conditions for transferring the new 
technologies to industry.
A wide range of factors may have an effect on competitiveness, 
most notably the industrial base and the industry research interface 
along with technical manpower.
However complex the support base for competitiveness may be in 
relation to a technology such as biotechnology, and a given set of 
industries, such as those involved in biotechnology, ultimately 
competitiveness is dependent on the efficiency of the industrial 
base, and the competitive capacity of the final link in the chain, 
namely firms.
Furthermore, the fact that the new biotechnology is of particular 
importance in industrial sectors shaped by earlier processes of 
concentration and multinationalisation, raises a number of
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important issues for competitiveness in a national context. Two 
issues are of particular importance: the place of small firms in the 
industrial base and the possibilities offered to multinational 
enterprises of locating a part of their own firm-specific industrial and 
technological base outside their home country
Chesnais (1966) described the industrial structure which is 
emerging as a result of new biotechnology developments as 
"decentralised concentration". This structure, as well as the limited 
markets and high R & D expenditures encourage companies - big 
and small - to look for arrangements which make sure that possible 
returns on investment are not jeopardised, including in some cases 
, an international division of markets. Furthermore, "decentralised 
concentration" based on large companies, has helped the 
transformation of biotechnology know-how into products, and has 
familiarised companies with new patterns of research-oriented 
enterprise.46
Chesnais (1966) further argues that "decentralised concentration" 
places large firms n the principal form of industrial organisation 
through which the industry - research interface can be organised 
with a view to competitiveness. A number of implications stem from
46OECD, 1989
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this, notably the fact that the course of biotechnology’s future 
technological trajectories are likely to be traced principally by the 
strategies and earlier lines of development of those firms.
Furthermore the OECD (1989) report on biotechnology suggests 
that building the industrial base for national competitiveness in 
biotechnology around large well-established pharmaceutical, 
speciality chemical or food processing firms raises other issues for 
governments which derive from the multinational character of many 
of these firms, and the global nature of their research strategies.
Thus, it has been suggested that decentralised concentration will 
most likely remain an important form of industrial organisation for 
new biotechnology developments because it is the most 
appropriate solution for large research problems.47
However in the long term it does not have to remain the only form 
of industrial organisation on which biotechnology is based. In 
order to exploit the markets which the ubiquity of biological 
phenomena could create, the entrepreneurial potential of 
numerous, more traditional small and medium sized companies 
could be better mobilised.
47OECD., 1989
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The capability of small and medium sized companies to react 
quickly in regional markets and market niches, is an asset for the 
diffusion of biotechnology. Large companies may ignore such 
markets or leave them aside for cost reasons.
Furthermore, the OECD (1989) suggests that a precondition of 
faster diffusion of biotechnology is an improvement of the 
biotechnological qualification of traditional small and medium sized 
companies. Moreover, these companies may have to acquire more 
competence in large-scale marketing because many biotechnology 
products become profitable only if the national market segments of 
various countries are added together to form larger market and it is 
suggested that new instruments of economic policy and 
organisations may be able to assist the small and medium sized 
companies in this respect.48
48OECD, 1989
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CHAPTER 3: 
TECHNOLOGICAL 
INNOVATION AND 
STRATEGIC 
MANAGEMENT
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3.1 INTRODUCTION
This section of the present thesis focuses on the literature 
concerning strategic management and the innnovating firm, in 
particular corporate strategy and innovation strategy.
The importance of technology stategy as part of a firm’s innovation 
strategy is discussed, including technology strategy alternatives.
The determinants of innovative success and characteristics of 
successful technological innovation in the firms is illuminated.
This section also discusses corporate culture and its effect on 
innovation. Finally, the concept of technological discontinuities and 
institutional continues is briefly discussed.
3.2 STRATEGIC MANAGEMENT IN THE 
INNOVATING FIRM
In the 1980s, research into technology and the firm has been 
strongly stimulated through a variety of initiatives by the
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Organisation for Economic Co-operation and Development 
(OECD), Economic and Social Research Council (ESRC), and other 
research councils. Given the pressures to make academic 
research more obviously relevant to practical problems this is 
hardly surprising.
It is widely recognised that in industrialised countries both 
competitiveness of firms and more general welfare depend critically 
on the ability to keep up with the world frontier in innovative 
products and processes, and in their underlying technologies.
The best indicator of this recognition is what business firms actually 
do. Hence, the increased interest in the 1980s amongst 
management scholars, consultants and practitioners in the role of 
technology in such matters as corporate strategy, operations 
management, global competition, new product development and 
the like.
Although the importance of technological change has been 
acknowledged by the earlier writers it was Schumpeter (1950) who 
stressed the central importance of innovation in competition 
amongst firms, in the evolution of industrial structures, and in 
processes of economic development; and who gave us the most
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useful definition of innovation, comprising not just of new products 
and processes, but also of new forms of organisation, new markets 
and new sources of raw materials.
Schumpeter also made the distinction between administrative 
management of what is well known and entrepreneurship which is 
the creation and the implementation of the new. He believed that 
entrepreneurship depends on super-normal individuals with 
exceptional intelligence and energy, and that innovation is an act of 
will rather than intellect.
However, although Schumpeter had a theory of innovation and 
entrepreneurship, he never developed a theory of the innovating 
firm. He had little to say about the sources of innovation, and the 
importance of continuous incremental innovations or 
improvements. More specifically, he had little to say about the 
organisational and other characteristics of the major sources of 
technical change in established firms - that are large in some 
industries and small in others - and that maintain their existence 
over long periods by continuously changing their products, 
processes and markets.
As Freeman (1987) has concluded,
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the task ... is to develop a theory of the firm which ... does 
not assume as its foundation either hyper-rationality of 
individual; of entrepreneurs or groups, nor yet supernormal 
intelligence and energy.
3.3 CORPORATE STRATEGY AND INNOVATION 
RESEARCH AS BUILDING BLOCKS TO NEW 
PRODUCT STRATEGY RESEARCH
While the research in corporate strategy and innovation is 
extensive, the subject of new product strategy as a specific 
research topic lacks both conceptual modelling and methods for 
empirical testing. Nevertheless, as synopsised below, the existing 
strategy and innovation research points to a large number of 
important variables that, taken together with the new product 
strategy, affect the firm’s performance.
The goals and business implementation tactics that emerge from 
corporate strategy have a direct bearing on new product decisions. 
Accordingly, from a research prospective, the study of new project 
strategy should find a home in the corporate strategy literature.
Abell (1980) has described the complex interrelationships between 
defining business missions, developing functional strategies and
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allocating resources to implement strategies. Porter (1980) 
conceives the process of defining business activities in terms of 
differentiation, where the firm identifies specific market opportunities 
that are defined by the customer requirements and competitive 
analysis.
Lorange and Vancil (1977) focus on the process of strategic 
planning itself and present formal mechanisms for integrating 
planning that occurs at different levels of the organisation. 
Techniques for corporate planning and business portfolio 
management are a logical outgrowth of this research. However, 
new product strategy is treated as a tangential issue to this 
research and is commonly viewed as the outcome of market 
segmentation and other forms of market planning. It has further 
been suggested that the technology factor in new product 
activities, which would appear equally important as the target 
markets of new products, is the "orphaned child" of strategy 
research.
It is certainly there, but nobody knows what to do with i t 49
49Meyerand Roberts, 1986
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A second vein of strategy research is empirical in nature. This 
research has focussed on the relationship between patterns of 
business diversification and organisational structure.
Chandler (1986) defined the hypothesis that structure follows 
strategy, and supported it by tracking the developments within 70 
large corporations over a 20 year period. Rumelt (1974) expanded 
upon Chandler’s thesis with another sample of large corporations, 
demonstrating that corporations with related business units 
outperformed those with wider business diversity. Roberts and 
Berry (1985) most recently reviewed the research on diversification 
strategy at the level of a firm’s portfolio of businesses. But that 
research does not seem to extend downward to the product level.
The technological resources of the firm and their utilization also 
have a direct bearing on new product strategy. The forecasting of 
technological change has been explored in some depth, both at the 
general level50 51 and in terms of contrasting rates of product 
versus process innovation over time.52
Petrov (1982) describes how a firm may profile its technologies in a
fashion similar to standard portfolio management techniques, using
50Martino, 1969
51 Fusfield, 1970
52Utterback and Abernathy, 1975
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two parameters of technological "attractiveness" and "relative 
technological position" of technology units identified in the firm. 
Gluck and Foster (1975) indicate conceptually how this profiling 
approach can be applied to competitive analysis at the product 
level. Thus technology strategy research has many interesting 
components.
Innovation research provides a broader foundation for the basis of 
new product strategy. Research in this area has been both diverse 
and substantial. The subset most applicable to current research 
interests are the empirical studies of the sources of innovation. 
While research in this area has examined a broad range of 
innovation - facilitating factors, the outcomes are often presented in 
the context of the roles of "market/need-pull versus "technology 
push" in effective innovation.53 54 55 Those factors deemed 
important for new product successes by these researchers have 
included a clear understanding of user needs, strong marketing 
investments, active new product champions and sponsors, and the 
flow of relevant technical information into the organisation from 
external sources (for further discussion on the determinants of 
innovative success, see Section 3.8).
^M y e rs  and Marquis, 1969
54Langrish et al., 1972
55Rothwell et al., 1974
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Since the sample of the present study includes a number of small 
to medium sized technology based enterprises, (see Section 8), 
prior entrepreneurship research may also be of background utility. 
The "need to achieve" identified by Me. Lelland (1961) as the 
primary motivating force affecting entrepreneurs was further 
examined by Wainer and Rubin (1969) as a factor affecting 
performance of the young technology-based corporation.
Similarly, the role of prior business experience in successful 
technical entrepreneurship is examined in Cooper (1970) and 
Bruno (1977).
Roberts (1968) has identified a range of factors associated with 
success and failure of technology-based start-ups, including the 
presence of a diversified management team, the implementation of 
proactive rather than opportunistic marketing programs, and a high 
degree of technology transfer from former places of employment. 
However, none of these entrepreneurial studies has concentrated 
on product strategy issues.
Research that has specifically targeted new product strategy has 
usually focussed on multi-company samples of individual products 
or paired product comparisons.
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Calantone and Cooper (1981), for example, reported on 195 new 
product cases from 103 firms, finding 18 cluster dimensions that 
related to individual product success.
Marquis (1969) and Rothwell et al. (1974) cited above, and Cooper 
(1979) reported similar analyses on large samples of single 
products. But by their very nature studies of single product 
successes and/or failures within a company cannot empirically 
explicate the firm’s historical new product strategy.
To overcome the above problem Meyer and Roberts (1986) report 
on a method for relating the degree of "newness" within a firm’s 
portfolio of products and the firm’s economic success. Research 
on small-technology based companies was conducted. A two- 
dimensional "technology newness - market newness" grid is 
prepared for the product set of each firm, based on the conditions 
existent at the time of each product’s development. Alternative 
weighting schemes are used to generate a "newness index" for 
each firm. The degree of strategic focus is shown to relate directly 
to corporate growth in that small firms with more restricted degrees 
of technological and market change in their successive products 
outperform companies with wide diversity.
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The evidence from Meyer and Roberts’ (1986) research suggests, 
that some product "newness" is better than no "newness" and that 
more technological change can be effectively employed in small 
company product strategy than market change.
The above research studies are useful for a study of innovation 
strategies and they indicate the need to focus both on past and 
future innovation strategies in order to assess the current position 
of companies, operating in a particular technology area, such as 
biotechnology.
3.4 CORPORATE STRATEGY AND 
TECHNOLOGICAL STRATEGY
Technology is a core asset and a major resource of competitive 
advantage. In the present period of rapid technological change, 
firms therefore need to consider technology strategy. A technology 
strategy involves an understanding within a firm, manifest among 
senior management, but diffused throughout the entire 
organisation, of the importance or potential of technology for the 
firm’s competitive position, how in the future that potential is to be
67
realised and how this compliments the other aspects of strategy in 
the firm such as finance, marketing and personnel.
Technology strategy involves complex decisions. Foremost 
amongst these are decisions concerning choice between 
alternative new technologies, the criteria by which they are 
embodied into new products and processes and the deployment of 
resources that will allow their successful implementation, 
development and diffusion in the firm and its output.
The extraordinary range and potential uses of contemporary 
technology have important consequences for industrial and 
commercial firms. The industrial and organisational turbulence 
engendered by technological change and increasing international 
competitive pressures, provides threats and opportunities for firms. 
Therefore, an effective strategic approach to technology allows 
firms to cope better with these changes, and will reduce the threats 
and insecurities facing firms and their employees.
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3.5 THE IMPORTANCE OF TECHNOLOGY 
STRATEGY
According to Dodgson (1989) the main issues which bear on the
importance of corporate strategy for technology include:
(1) The need to cope with technological uncertainty, complexity 
and the discontinuous nature of technological development.
(2) The need for technology to be viewed in a global context.
(3) The need to attain "complementaries" internally between 
different elements of overall corporate strategy, and 
externally between companies’ strategies.
(4) The failure of existing strategies which do not integrate 
technology satisfactorily.
(5) Public technology policies.
Each of these main issues which support the importance of
corporate strategy for technology will now be examined.
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(1) TECHNOLOGICAL UNCERTAINTY AND COMPLEXITY
The new technologies pervade both new and traditional industries. 
Electronics, for example, has a number of industrial branches in its 
own right, but significantly affects whole economies through its 
diffusion into wide ranging applications from manufacturing 
systems to telecommunications. Biotechnology has also found 
application across a wide variety of industries, from Healthcare to 
Food Processing (see Section 4.5).
Some agree that technological development is increasingly 
discontinuous and that product life cycles are shortening and that 
this has profound consequences for companies’ technology 
strategies.56 There are however, different interpretations of just 
how profound these consequences will be for firms.
Tushman and Anderson (1987) in their study of the cement, airline 
and microcomputer businesses argue that technological change is 
characterised by periods of continuous incremental change 
punctuated by more radical discontinuous periods. These periods 
of more rapid change can be "competence-enhancing", usually 
derived from, and beneficial to existing firms, or "competence
56Urban, Hauser, Dholakia, 1987
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destroying" , usually exogenously sourced, and threatening to 
existing firms.
Pavitt (1987) contends that the formation of research and 
development laboratories in large firms is in part a means of 
internalising technological discontinuities and thereby ensuring 
institutional stability.
Whatever the source of technological breakthrough, it is companies 
with wider ranging R & D expertise that are more likely to recognise 
the significance and potential of both incremental and radical 
technological developments.
Broad R & D competences and skills are a method of 
dealing with discontinuities and turbulence; a way of 
technology-watching and keeping options open.57
The new technologies are enormously complex. Complexity results 
from the convergence of technologies between, for example, 
computers and communications technology to produce integrated 
digital networks or microelectronics and biotechnology to produce 
novel drug delivery systems.
57Dodgson, 1989
71
Pavitt et al. (1989), conjecture that one of the reasons for their 
finding that companies show greater diversification in their 
technological activities than in output is because of the complex 
nature of contemporary technological interdependencies. The 
sheer complexity of technological systems indicates the inclusion of 
technology among corporate concerns.
Strategic decisions need to be made on how to deal with this 
complexity; on how to match or better the opportunities is provides 
to existing or potential competitors.
Decisions on acquisition and collaboration as a means of dealing 
with technological complexity are an important component in 
technology strategy also.58
Technology strategy is important, therefore, to see firms through 
periods of technological turbulence and uncertainty and to deal 
with the high complexity and cost of technology.
(2) GLOBALISATION
Developing and marketing new technology are essentially 
international activities. The new pervasive or “generic" technologies
58Thomas and Miles, 1988
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such as information technology and biotechnology are world-wide 
phenomena.
There are numerous examples of public policies and private 
corporations’ strategies reflecting recognition of comparative 
technological advantages on a global scale.
The Japanese "Fifth Generation Computer Project" catalysed 
information technologies world-wide.59 Monsanto, a US biotech 
company invests heavily in biotechnology research at Oxford 
University.60
The evidence presented in this study reflects the international 
nature of both corporate technological development and of 
governmental policy responses to technological challenges. There 
are very real differences in the strategic competences of, for 
example, Irish, UK, and Japanese corporations and within the same 
countries, marked differences in the abilities of ministries to foster 
and direct technology strategies. Nonetheless, there are more 
similarities than differences in the manifestly world-wide pressures 
influencing private and public strategies for technological
59Arnold and Guy, 1986
60Dodgson, 1989
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development. For this reason, it is considered necessary to 
consider the situation with regard to biotechnology as a 
technological development in a multinational context, from the US, 
Japan and the rest of Europe including Ireland (see Section 4.6).
International intercorporate collaboration extends beyond sharing 
the heavy financial and intellectual burden of R & D in systems such 
as biotechnology, and includes manufacturing and marketing.
For Japanese corporations, the concept of globalisation of markets 
is paramount.61 Furthermore, Baba (1989) argues that direct 
foreign investment in manufacturing plants is a similarly crucial 
component of strategy.
(3) COMPLEMENTARITIES
Technology strategy is important as it needs to complement overall 
company strategy: encompassing business, marketing,
manufacturing, personnel, investment and financial strategy. 
Project SAPPHO showed that successful innovative firms matched 
their technological developments with complementary marketing,
61 Porter, 1987
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advertising and manufacturing efforts.62 The SAPPHO project also 
showed that successful innovators made use of external 
technology and scientific advice. Teece (1987) similarly refers to 
the importance of "complementary assets" (marketing expertise, 
distribution networks) in realising full returns from technological 
innovation. He also highlights the importance of accessing external 
technological expertise.
For a company to have an effective strategy for innovation, all the 
aspects of the innovation process have to be considered, and 
strategies for change merged into a cohesive and coherent whole. 
Baba (1989) also emphasises the need for a successful technology 
strategy to encompass both product and process innovations.
External complementarities are also required. An example of this 
point is the biotechnology industry in the US, where Hamilton 
(1986) found a widespread use of external links between firms, 
and these links were a significant part of the firm’s technology 
strategy.
Firms increasingly collaborate in their technological efforts. Joint- 
ventures and "strategic alliances" designed to merge firms’ specific
62Rothwell et al., 1974
75
technological competences are now a feature in a number of 
industries including biotechnology.63 64 65 66
Therefore, the contention is that contemporary technology extends 
the boundaries of the firm. It becomes essential to relate to the 
behaviour of firms in complementary horizontal and vertical 
activities, as the new technologies provide wider opportunities for 
those firms to affect competitiveness.
To overcome the problems of complexity, high cost and high risk, 
activities previously proprietorial to individual firms such as R & D 
and manufacturing may become shared between a number of 
firms.
As Dodgson (1989) states,
The necessary sacrifice of autonomy in the generation and 
diffusion of technology involves a strategy of sharing control 
in order to retain it. Without participation in multilateral 
technological arrangements, even the most advanced 
companies may lose their leadership positions.
(4) FAILURE OF EXISTING STRATEGIES
¡pHobday, 1986 
Hladik, 1985
65Mowery, 1987
66Faulkner, 1986
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Recent turbulence in world markets and extensive currency 
fluctuations compound and accentuate corporate uncertainty in 
existing strategies for growth and profitability. This added to the 
growing evidence which questions the strategic efficacy of recent 
acquisition booms, necessarily focuses attention on the importance 
and potential of key elements of corporations’ assets, most 
particularly on technology and innovation. Dodgson (1989) 
suggests that the reasons why technology demands greater 
strategic consideration are compounded by the failure of past 
corporate strategies. Furthermore, Dodgson cites corporate 
obsession with acquisition as the method for achieving growth, and 
short-termism in corporate investment as two of the major factors 
which have in the past discriminated against the formulation of 
coherent technology strategies, at least in the US and UK.
The long-term nature of technology strategies is apparent. 
Corporate ventures and new business developments can take up 
to ten years to become profitable.67
Industrial clubs take many years to fuse cohesively.68 Building the 
entrepreneurial ethos into large organisations, and providing the 
management structures and reward systems to stimulate product
67Uttler and Sweeting, 1984
Sharp and Shearman, 1987
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/champions and project leaders is a lengthy process.69 Doz and 
Prahaiad (1987) in their study of sixteen large multinational 
companies found that a change in strategy, once formulated, takes 
between three and ten years to implement.
Nevertheless, long-term commitments are required for the 
development of a particular technology and resulting innovation.
(5) PUBLIC TECHNOLOGY POLICY
Heightened international industrial competition has focussed 
attention on the sources of comparative industrial advantage, in 
particular, technological development. As the recent work by Patel 
and Pavitt (1987) shows, the behaviour of a limited number of key 
companies can determine the technological trajectory and 
economic competitiveness of industrial sectors in a company.
Public technology policy plays a major role in influencing and 
encouraging the extended boundaries of firms. There are 
nowadays few industrialised economies which do not have policies 
designed to encourage and support the growth of high-technology 
small firms.
69Burgelman and Sayles, 1986
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Porter (1987) has argued for the very important influence of 
governments’ use of political pressures on global strategies:
The political imperative is to concentrate activities in some 
industries where governments provide strong export 
incentives and locational subsidies.
Sharp (1987) shows how ESPRIT (European Scientific Programme 
for Research in Information Technology) has played a seminal role 
within Europe in changing attitudes and strategies amongst 
Europe’s top electronics firms. She argues that it has acted as a 
catalyst for the process of rationalisation now underway.
It is also important to understand the role played by firms in framing 
public policies. ESPRIT was formulated on the basis of 
representations by firms. It is essential for firms to represent a 
coherent argument on the need for public support, such as the 
Senior Advisory Group on Biotechnology’s efforts with regard to 
biotechnology public policies in Europe (see Section 4.6.3).
A strategic view of the necessity and nature of government 
intervention in technology development improves industry’s case 
for support.
70Porter, 1987, p.43
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Public research institutes are, of course, important sources of 
technology and technological support for industry. Some argue a 
convergence of technology with the science base.71 72 It becomes 
essential for companies not only to access scientific information 
and technologies from new sources, but also to learn how to 
transfer and integrate knowledge from these previously separate 
sources. There are now a plethora of public programmes and 
intermediary organisations and industrial firms.73 Among those 
relevant to biotechnology are the ECU\IR, FLMR, BAP and 
COMETT programmes which focus on biological sciences. 
Whether such efforts result in successful technological 
developments will depend on the strategies for technological 
receptiveness within firms.
3.6 TECHNOLOGY STRATEGY ALTERNATIVES
Technology strategy consists of the portfolio of choices and plans 
that enables the firm to respond effectively to technological threats 
and opportunities.
71Narin and Noma, 1985
72Dosi, 1988
73Rothwell, Dodgson and Lowe, 1988
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In formulating its technology strategy the firm must make choices in 
at least the following six areas.74
(1) Selection, specialisation and embodiment of the technology
(2) Level of technological competence
(3) Sources of technology
(4) Research and Development investment level
(5) Competitive timing
(6) Research and Development organisation and policies.
Since the technology strategy appropriate for an individual firm 
clearly depends on the corporate strategy of the firm, an 
examination of corporate strategy alternatives in high-technology 
industries is required.
For the purpose of this study four alternative strategies in high 
technology industries will be considered. The strategies discussed 
are based on a framework of strategies in high technology industry
74Maidique et al., 1988
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suggested by Maidique and Patch (1988) adapted from Ansoff and 
Steward (1967).
(A) FIRST-TO-MARKET OR LEADER STRATEGY
Such a strategy aims to get the product to the market before the 
competition. It provides the advantages of a temporary monopoly 
in exploiting a new technology during the period proceeding the 
adoption of the new technology by competitors. Such a strategy 
normally requires a strong commitment to applied research and 
development in order to achieve a position of technological 
leadership.
SECOND-TO-MARKET STRATEGY
This strategy involves entry early into the growth stage of the life 
cycle and quick imitation of innovations pioneered by competitors. 
This strategy generally requires a strong and nimble development 
and engineering capability with little attention to applied or basic 
research.
Marketing strategies will generally be more on winning customers 
away from the technological innovator, with less emphasis on
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primary demand generation as compared to the first-to-market 
strategy.
Such strategies also try to learn from the innovator’s mistakes so as 
to develop an improved, more reliable product that may include 
advanced features, while avoiding those innovations or features 
which prove to be market failures.
(C) LATE-TO-MARKET STRATEGY
Such a strategy achieves a relative cost advantage over 
competitors through economies of scale, through process and 
product design modifications to reduce costs and through 
overhead minimisation and operating cost control.
To achieve a low-cost position requires product and process 
engineering skills. Entry into the market is generally in the growth 
stage or later to allow market volume to grow to the point where 
significant economies of scale can be achieved.
(D) MARKET SEGMENTATION OR SPECIALIST STRATEGY
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This strategy focuses on serving small pockets of demand with 
special applications of the basic technology. Entry typically occurs 
in the early or growth stage of the product life cycle, but may also 
occur at later stages as the market is segmented further.
This specialist strategy requires a strong capability in applied 
engineering, a well as flexibility in the manufacturing area. Large 
size or mass production competence is not required for this 
strategy, and may even be a handicap, since the scheduling and 
control requirements for a large number of special applications can 
be exceedingly complex.
The essence of the late-to-market strategies is a reduced emphasis 
on basic and applied research and a resulting reduction in the risk 
associated with the R & D investment of the firm. Of course these 
defensive strategies do not absolve the firm of technological risk - 
risk of technological obsolescence in particular.
These strategies are also characterised by the increased 
investment (at least in relative terms) in various dimensions of the 
marketing and production activities of the firm, investments which 
carry their own risk.
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For firms selecting a given technology area, for specialisation, the 
early-market strategies require a higher level of competence in the 
technology, reflected in proximity to the state of the art in the 
particular technology and increased emphasis on basic research, 
while the second to market strategy would employ relatively more 
emphasis on developmental engineering.
The relation between strategy and technology policy can also feed 
back in the other direction from a technological policy to strategy. 
A high level of competence achieved through the commitment of 
substantial resources to basic and applied research can lead to 
discoveries of new products or processes which can provide an 
opportunity to lead competitors in introducing a product, although 
the firm might view itself as pursuing a second-to-market strategy in 
general.
For each of the strategies discussed, there are natural implications 
for the capabilities required of the different functional areas within 
the business. Typical functional requirements associated with each 
strategy are represented in Figure 10.
As suggested already the appropriate technological policies for an 
individual firm depend largely on the strategy adopted by the firm. 
The appropriate strategy depends, in turn, on the competitive
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opportunities and threats faced by the firm and on the objectives of 
the firm.
3.7 DIMENSIONS OF TECHNOLOGICAL POLICY
The following section discusses how individual dimensions of 
technological policy may vary with the strategy adopted by the firm. 
Building on the six dimensions of technology policy mentioned 
already one can examine the following dimensions of policy:
* Technology Selection or Specialisation
* Level of Technology Competence
* Sources of Technological Enquiry
* Research and Development Investment Level
* Competitive Timing
* Research and Development Organisation and Policies
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(1) TECHNOLOGY SELECTION OR SPECIALIZATION
Obviously the selection of the technology or particular area of a 
given technology in which the firm will specialise is of paramount 
importance for the technology-intensive firm.
For the smaller firm, technology specialisation may be simply 
determined by the skills of the founders, while for the larger firm, 
existing technological resources will heavily influence the firm’s 
choice with respect to technological specialisation.
The appropriate choice of technologies is an issue of particular 
importance for firms adopting the first-to-market strategy since they 
must adopt the technology to their product needs earlier in the 
development of the technology. However, the choices of a second- 
to-market firm trying to identify which of the technologies adopted 
by the first-to-market firms will prove successful, or of late-to-market 
firms trying to determine when to adopt a new technology for 
larger-scale development are not necessarily easier.
(2) LEVEL OF TECHNOLOGICAL COMPETENCE
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There are two factors to be considered by the firm in deciding the 
level of competence to attain in a given technology, namely 
proximity to the state of the art in the technology and relative 
emphasis on basic research, applied research and developmental 
engineering.
The following discussion focuses on each of these dimensions 
individually;
(A) PROXIMITY TO TECHNOLOGICAL STATE OF THE ART
Proximity to the state of the art is an important dimension of 
the nature of the technology commitment of a firm, and is 
closely related to the timing-to-market aspect of its strategy. 
It in turn, has important implications for the planning and 
control environment of the firm and for the research versus 
development mix within the R & D function of the business.
The first-to-market strategy often employs high proximity to, 
or development of, the state of the art. This often implies a 
significant emphasis on applied research.
The second-to-market strategy also requires proximity to the 
state of the art, although the emphasis shifts from original
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development to a monitoring function, followed by imitation 
developmental engineering.
The market segmentation and late-to-market strategies are 
typically a substantial distance from the state of the art, but 
are characterised by nimbleness in adopting new 
developments.
Proximity to the state of the art results in lower stability in the 
relevant technology for the firm and reduces predictability as 
to the direction in which the technology will change.
Thus strategies relying on mass production of products 
incorporating proven technologies are generally less 
susceptible to such rapid and unpredictable shifts. 
However, such competitors may find it more difficult to shift 
to new technology when it becomes economic to do so, 
since they are heavily committed to their technology through 
plant and equipment investment. Known competitors 
employing the same basic technology are unlikely to initiate 
rapid changes in technology.
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For these reasons, radical change usually comes from 
outside the industry or from smaller more flexible 
competitors in the industry.
The lack of stability and predictability associated with state of 
the art strategies implies greater difficulty in controlling and 
greater need for freedom and flexibility in the R & D function.
By way of contrast, the second-to-market and market 
segmentation strategies are more development intensive. 
Development intensive organisations are characterised by 
well-defined design specifications, highly directive 
supervision and structured sequencing of tasks and 
development responsibilities.75
(B) RELATIVE EMPHASIS ON BASIC RESEARCH. APPLIED RESEARCH 
AND DEVELOPMENTAL ENGINEERING
Basic research, applied research and developmental 
engineering differ with regard to the required creativity, risk, 
expenditure level and return on investment.
75Urban and Hauser, 1987
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They also differ in the sophistication of technical personnel 
required, the appropriate organisational environment and the 
types of control procedures which can be adopted. Thus 
the choice, with regard to the R & D emphasis of the firm 
affects its risk profile and organisational structure.
Since increased emphasis on being near the state of the art 
and on fast response to technological opportunities, has 
implications for the balance between fundamental research, 
applied research and developmental engineering, these 
strategic choices also affect the risk profile of the firm and its 
appropriate organisational structure. As suggested already 
the strategic choice with regard to the state of the art has 
direct implications for R & D emphasis.
The commitment to developing the state of the art in a given 
technology generally implies a commitment to applied 
research due to the fact that most basic research in a given 
technology is carried out in government and university 
laboratories and independent research contractors.
A commitment to meeting the state of the art through a 
second-to-market strategy implies at a minimum, a 
commitment to a strong developmental engineering
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capability and perhaps a limited capability to applied 
research so as to monitor and capitalise on new technology 
quickly, once it has been developed and brought 
successfully to the market.
(3) SOURCES OF TECHNOLOGICAL CAPABILITY
Although an internal R & D unit is a common source of 
technological capability for the firm, companies in many industries 
are increasing their search for new technology development 
outside the firm.76
Neuno and Oosterwald (1988) discuss technological alliances and 
draw a distinction between pre-competitive and competitive 
alliances. In the case of the former, the effort is far away from the 
industrial or commercial phase of development. A competitive 
alliance is where the companies involved in the alliance are 
competitors or the result of the alliance will provide two competing 
companies with a common component or product which will be 
integrated in their competing product(s).
76James, 1985
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A number of strategic alliances are illustrated by Beckers (1989) 
primarily as tools for technology transfer. These include licensing 
agreements, acquisitions, R & D cooperations and joint ventures.
Such strategic alliances can be an important alternative source of 
technology know-how, particularly for firms adopting a follower 
strategy, although some first-to-market firms could use it to good 
advantage.77
The reasons for forming a strategic alliance are many. Many 
companies form alliances due to the costs of development coupled 
with market and technological uncertainties.78
James (1985) not only cites the high development costs but also 
the long pay-back period as a motive for forming strategic 
alliances. Furthermore, it is not only small companies who need the 
financial support and technological input that strategic alliances 
offer, even large companies use such tools for technology transfer 
and "pooling of resources".
77Maidique and Patch, 1988
78Neuno and Oosterwald, 1988
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Finally, it should be noted that a strategic fit is vital for strategic 
alliances and the short-term and long-term benefits of such efforts 
must be considered for the individual firm to benefit.79 80
(4 ) RESEARCH AND DEVELOPMENT INVESTMENT LEVEL
Setting the aggregate level of investment in equipment and staff 
that is committed to understanding, development and application of 
the selected technologies is a fundamental decision for the firm 
participating in a given technology.
The firm that attempts to be first-to-market consistently needs to 
make a substantial R & D investment. This investment should be 
balanced between applied research and developmental 
engineering.
The second-to-market generally makes a smaller investment and 
emphasises product development and technology monitoring.
The investment made by the late-to-market firm is typically smaller, 
yet, though these firms may make substantial investment in process 
engineering.
79Porter and Fuller, 1985
80Doz, 1988
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Firms following a market segmentation strategy even if they adhere 
to early-to-market policies may require a lower R & D investment, 
for the fundamental technology may be developed by firms 
following broader market policies.81
(5) COMPETITIVE TIMING
A firm may wish to lead its competitors to market taking risks with 
regard to technological development and market acceptance to 
gain a competitive advantage such as a larger market share.
Alternatively, the firm may prefer to allow other competitors to take 
those risks and rely on superior marketing or manufacturing 
capabilities to respond with a more attractive or less expensive 
product later in the life cycle of the product. In so doing, the firm 
takes the marketing and financial risks associated with these 
strategies.
The issue of timing is particularly important for the execution of a 
second-to-market strategy. Given that customers normally 
experience some costs and inhibitions switching suppliers, earlier 
entry leaves a larger portion of the potential market available for 
penetration without having to overcome these switching costs. And
81Maidique and Patch, 1988
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of course, the competition for this market intensifies as more 
competitors bring their entries to the market.
(6) RESEARCH AND DEVELOPMENT ORGANISATION AND POLICIES
Maidique and Patch (1988) suggest that firms entering into a new 
technology early generally depend more on technological experts 
than firms that enter late. Such dependence may involve 
extraordinarily high levels of compensation for such experts and the 
establishment, if their scale of operations permits, of well equipped 
central R & D laboratories.
On the other hand, it is suggested that those firms emphasising 
competition through new technology later on in the technology life 
cycle experience ample availability of technical personnel with the 
requisite skills in the new technology.
For this reason, such firms are much less likely to adjust corporate- 
wide policies of the firm to satisfy the needs of the technical staff.
Thus the cumulative and differentiated nature of technological 
developments in firms suggest that the choices about the content 
of technological strategy, normally presented in the literature -
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broad-front versus specialised, product versus process and leader 
versus follower, do not take into account the enormous variety 
between firms in sources of technological opportunities, and in the 
rate of their development.82 In particular, the innovative 
opportunities open to a firm are strongly conditioned by a firm’s 
size and by its core business.83
Thus, innovating small firms are typically specialised in their 
technological strategies, concentrating on product innovation in 
specific producer goods, such as scientific instruments, specialised 
chemicals or reagents. The key strategic tasks are finding and 
maintaining a stable product niche, and benefiting systematically 
from user experience.
Large innovating small firms, on the other hand, are typically broad 
front in their technological activities, and divisionalised in their 
organisation. The key technological strengths can be based on 
research and development laboratories, or in the design and 
operation of complex production technology (typically in mass 
production and continuous process industries, and increasingly in 
the design and operations of complex information processing 
technology).
82von Hippel, 1988
83Pavitt et al., 1989
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In research and development based technologies, the key strategic 
opportunities are horizontal diversification into new product 
markets. The key strategic problems are those of mobilising 
complementary assets to enter new product markets, for example, 
obtaining marketing knowledge when a pharmaceutical firm moves 
into pesticides.
In production-based technologies, the key strategic opportunities 
are in the progressive integration of radical technological advances 
into products and production systems, and in diversification 
upstream into potentially magnificent production inputs. The key 
strategic tasks are ensuring diffusion of best practice technology 
within the firm, and choices about the degree of appropriation of 
production technology.
Thus, firms do not have a completely free hand about whether or 
not to be broad front or specialised, product or process oriented. 
Similarly, they do not have a completely free choice about being a 
leader or a follower.
In many areas, especially with nascent technologies, it is not clear 
before the event who is in the race, where the starting and finishing 
lines are, and even what the race is about.
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Even when it is, firms may start out wishing to be a leader, and end 
up being a follower.
Teece (1986) has shown that while there are some advantages in 
being first, particularly when there are strong regimes of property 
rights or cumulative learning, it is sometimes advantageous to be 
second, particularly when product configurations are not fully fixed, 
so that followers can learn from the mistakes of leaders who find 
themselves without the required range of complementary assets.
Given the cumulative nature of technological development, 
technological choices in the firm also depend critically both on the 
time horizons chosen and on management’s abilities to anticipate 
future cumulative paths of technological development, and their 
commercial significance.
3.8 THE DETERMINANTS OF INNOVATIVE
SUCCESS
There has been considerable debate amongst economists over the 
actual significance of advances in science and technology to 
industrial innovation. To an extent this debate parallels that
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concerning the history of science with certain contributors placing 
the emphasis on market forces and others on technology as 
determinants of innovative activity.
Early models of the innovative process emphasised the casual role 
of scientific and technological advance and were generally linear. 
These can be summarised in a simple form in Figure 6 which 
represents the so-called "technology-push" model of innovation. 
According to this model, discoveries in basic science lead 
eventually to industrial technological developments which in turn 
lead to a flow of new products and processes onto the market 
place.
This model implies a more or less passive role for the user, and the 
market place is simply a receptacle for the results of research and 
development, and technological endeavours. Therefore, the basic 
premise underlying the model is that "more R & D" is equivalent to 
"more innovation".
From the mid-sixties onwards the role of market forces as a 
determinant of innovative success began to be emphasised. 
Strong support for the "demand - pull" theory was provided by 
Schmookler’s exhaustive indicator-based study, in which he
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showed that patenting activity has tended to lag behind investment 
activity.84
Subsequent analyses of specific innovation suggested that on 
average, 75% of all successful innovations were primarily due to 
market demand.85 86 87
Such research was interpreted into the linear "need-pull" model of 
innovation, represented in Figure 7. According to this model, 
innovations arise as the result of perceived and often clearly 
articulated needs.
In a critical review of Schmookler’s work and research of specific 
innovation undertaken in other studies, Mowery and Rosenberg 
challenge the case:
The notion that market demand forces ",govern" the 
innovation process is simply not demonstrated by the 
empirical analyses which have claimed to support that 
conclusion.88
The authors highlight the conceptual vagueness surrounding much
of this work and believe a number of methodological biases in such
84Schmookler, 1966
85Langrish et al., 1972
86Baker et al., 1980
87Utterback, 1974
88Mowery and Rosenberg, 1979
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FIGURE 8 SUMMARY OF FINDINGS ON SOURCE OF STIMULATION 
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studies afford such criticism. The authors point out the danger of 
generalising from empirical work which often deals with different 
aspects of the innovation process and different industrial sectors.
In many respects, the debate is a dead one; obviously both market 
and technical opportunities are necessary for success in 
innovation, neither is sufficient. This is confirmed in the research of 
Utterback (1974) who reviewed eight studies of innovation, which 
provided evidence of the sources of stimulation of innovation.
Their results shown in Figure 8, clearly show that both need and 
technology stimulated innovations exist, and that those from market 
mission or production needs dominate. However, as suggested by 
Mowery and Rosenberg (1979) the extent to which they 
predominate is questioned.
It does not follow for example, that because it has been suggested 
that successful innovators tend to have identified needs that 
companies should, or indeed are able to simply ascertain needs at 
the outset of the innovation process in order to ensure that their 
investment will be profitable. First as Langrish et al. (1972) noted in 
their study of 84 successful innovations, innovations often end up 
satisfying needs that are different from those originally intended.
102
Secondly, there is the problem of defining the "need" precisely. For 
instance, a consumer may have a need for a particular product, 
which will be defined in terms of a set of specifications. The 
problem is in eliciting this set of specifications, which of course the 
consumer itself may not be able to do articulately.
Thirdly, the priority that the customer gives to its needs and the 
manner in which these are defined may alter as a result of changed 
macroeconomic conditions, customer’s specific financial 
circumstances, technological innovations and the introduction of 
new products between the formulation of the innovation’s 
specifications and its launch on the market.
Fourthly, the "correct" identification of product specifications is not 
straightforward either. Marketing research techniques will tend to 
focus on securing information on what customers feel they want 
now rather than in the future, with the result that the product 
eventually developed will satisfy what was wanted yesterday.89
A final point, which is extremely important when considering 
innovation through the application of technology, is that technology 
itself can generate demand, for as it develops, the technology can 
open up opportunities for new products that were previously
89Rosenbloom and Abernathy, 1980
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unanticipated. Where the technology is advancing rapidly, as in the 
case of biotechnology, the scope for a thorough ex-ante 
exploration of preferences and specifications may be extremely 
limited.
Under such conditions, instinct, judgement and an empathy with 
the market are suggested as vital ingredients for innovative 
success.90
Such ingredients may be sadly lacking in those firms accustomed 
to administering a large-scale operation selling to the mass market.
In the case of radical innovation employing new technology, where 
the eventual product specifications are likely to be imprecise at the 
outset, traditional marketing research techniques are unlikely to 
supply a meaningful working brief, while the results from many of 
the "management science" techniques are little more than academic 
given the uncertain nature of much of the data that are available.
In the case of the development of new businesses founded on new 
technology and sometimes, although not inevitably so, aimed at 
new types of customers, an adaptive, entrepreneurial approach
90Littler and Sweeting, 1985
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based on close liaison with the market may be more appropriate for 
successful innovation.
Therefore, it should be noted that neither demand nor science and 
technology may be taken as given: both are constantly changing, 
and furthermore, may be directly influenced by the activities of 
innovators themselves through their research and development and 
marketing efforts.91
Furthermore, balance depends on equilibrium, and maintaining this 
equilibrium is a rather delicate process. It should be noted that 
marketing is about satisfying the consumer’s need at a profit, and 
that successful marketing is supplying consumers needs using the 
particular advantages of the company, one of which may be 
technology. As Twiss (1980) explains, the challenge
... is not only one of innovation, but of managing 
technological innovation for profit.
Twiss cites an OECD (1971) study which reviewed several research 
projects on the stimulus for innovation. This states that between 
25% and 33% of the ideas originate within research and 
development, but that their importance may be greater than their
91 Rothwell, 1977
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proportion suggests, since they tend to lead to additional need 
oriented programmes. Thus it should be noted that basic research 
has a role to play, particularly for the "big changes".
An article by James P. Casey (1976) describes a case history of 
high fructose com syrup (isoglucose) and concludes that the 
Japanese benefited most from this innovation because of a lack of 
basic R & D in the USA. He states that "R & D is capable of 
bringing about dramatic and far reaching changes in a mature 
industry", in this case, the food industry. Twiss (1984) reasons that,
. . .a t the more basic research end of the process we have 
the terrible paradox of irrelevance. We really have no clear 
idea about how to decide what subjects of research are not 
irrelevant to what it is we are trying to do ... The most 
important technological changes have come almost always 
out of the wrong line of research and out of the wrong 
technology ... the big changes are by definition, big 
changes, and are not contained in the previously 
understood knowledge.
The point here is that innovation is closely related to creativity and it 
arises by the linking together of previously unconnected lines of 
thought. Hence, a major objection to the application of formal 
planning to research and development is that many of the most 
important technological innovations originate in a random fashion. 
Chance plays an important role and the literature often alludes to
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serendipity, the process of making happy and unexpected 
discoveries by accident.
Creativity does not lend itself to planning. Ideas often seem to 
appear spontaneously or through serendipitous discovery arising 
from the observation of an unplanned event and noting its
significance, as in the discovery of penicillin by Flemming.
Furthermore, creativity is not only required for the original concept 
of an innovation. There is ample scope for the application of 
creativity, although of a lower order, at every stage of development.
It is also argued that the technologist’s spirit of inquiry, particularly 
when he/she is working towards the research end of the R & D 
spectrum, must be given some satisfaction. Provision should be 
made to devote some of the technologist’s effort to working on 
projects which may not appear immediately relevant to the 
company’s needs.
The argument runs that without this freedom to follow certain 
personal interests, the laboratory would become uncreative and it 
would be difficult to attract or retain high calibre technologists. 
Some managers would support provision of personal research on
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these grounds alone, irrespective of the possibility of any 
commercial return. These considerations however, arise mainly in 
large laboratories where applied research forms a high proportion 
of the total activity.92
Furthermore, Twiss (1980) suggests that the existence of 
serendipity and personal research does not destroy the rationale 
for planning if the planning system is sufficiently flexible to accept 
some activities not directed towards clearly identified ends. He 
argues that this can be accommodated by the recognition that a 
company which is investing heavily in technology, relative to other 
business operations, is in reality engages in two businesses which 
include:
* The primary business defined by its corporate objectives 
which is directed towards satisfaction of identified market 
needs.
A secondary technological business which is generating 
technology of a commercial value but often unrelated to the 
corporate objectives. This value will normally be realised 
only by selling the technology itself, although in exceptional 
circumstances it may warrant full development of a product
92Twiss, 1980
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and the establishment of a separate manufacturing and 
marketing operation as a diversification.
Having discussed the concept of technology-push and market-pull, 
and having identified that these two components of innovation are 
closely interlinked and that both should be present of an innovation 
to be successful, a more representative model of the innovation 
process is given by Marquis (1981).
This model recognises that the starting point for successful 
innovations requires the interaction of market demand and the 
technical resources available at a particular time. This model 
suggests that innovation can be regarded as a logically sequential, 
though not necessarily continuous process, that can be divided 
into a series of functionally separate but interacting and 
interdependent stages (see Figure 9).
What is significant about this model is the linking together of the 
firm to the broader scientific and technical community and to the 
market place.
What is crucial, therefore to the eventual success or otherwise of an 
innovation is the action of Schumpeter’s entrepreneurs, who must
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FIGURE 9 MARQUIS '  S INNOVATION PROCESS MODEL ( 1 9 8 1 )
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find ways of "coupling" technological capability to market needs 
and opportunities at the earliest possible stage.
Testimony to the crucial importance of this coupling process was 
provided by the SAPPHO project undertaken in two phases at the 
Science Policy Research Unit.93 It avoided some of the pitfalls of 
earlier innovation studies by investigating pairs of innovations, one 
successful and one failed. Altogether some forty three pairs were 
drawn from the chemical process and scientific instruments 
industries. Project workers measured 122 features of the firms 
involved which led them to identify five main areas of competence 
differentiating the successful from the failed innovators.
These were, better understanding of user needs; more attention 
paid to marketing and publicity; efficient performance of 
development; more use of outside technology and scientific advice 
and greater authority given to the individual within the firm 
responsible for the innovation.94
Such conclusions were upheld in a later review of the literature 
undertaken by Roy Rothwell of the S.P.R.U. team. Furthermore, in
93Rothwell et al., 1974
94Rothwell et al., 1974
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all of the studies covered, emphasis was placed on the role of 
"good communications and effective collaborations" including that 
with external research establishments.95
Empirical work in the field thus attests to the importance of scientific 
and technological knowledge to innovation success. Crucially, it 
also indicates that this knowledge comes both from in-house R & D 
efforts and from the external research infrastructure.
3.9 CHARACTERISTICS OF SUCCESSFUL 
TECHNOLOGICAL INNOVATION IN THE FIRM
Innovation research has come to robust conclusions about the 
factors associated with successful innovations. In addition to the 
quality of technical work, these include strong horizontal linkages 
amongst functional departments, with outside users and with other 
sources of relevant technical expertise; building on existing 
competences and skills; learning from experience; (a) responsible 
manager(s) with expertise in all the functional activities involved; 
accessing complementary non-technological assets.
95Rothwell et al., 1977
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Given the high uncertainties involved in technological innovation, 
trial and error are inevitable in the development and implementation 
of innovation. In fact, the major importance of development, as 
opposed to research activities in industrial laboratories can be 
considered a systematic form of trial and error.
In addition, the ability to learn from experience whether internally 
(learning by doing), or from suppliers, customers and competitors 
(learning by using, learning by failing, reverse engineering is of 
major importance in the management of innovation.96
Individuals’ capacities to learn from their experience depend not 
only on their personalities but on their training. Comparative and 
empirical research has demonstrated the importance of training for 
the effective exploitation of technology.97 98 Particularly in the large 
firm, learning is also a collective activity requiring frequent 
communication amongst specialists and functions.
Since knowledge accumulated through experience is also partly 
tacit, and the tasks to which such knowledge is applied are 
complex and loosely structured, personal contact and discussions
96Pavitt, 1987
97Pratten, 1976
98Prals, 1987
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are the most frequent and effective means of communication and 
learning.
Many authors have argued that technological expertise is a pre­
requisite to the adoption of a technology strategy." 100 101
Approaches to technology strategy focus on the importance of 
accumulated skills within firms. There are advantages for firms 
building on existing competences and skills. While radical changes 
in strategic direction are attainable, they are more likely to be 
successful and more easily realisable if they focus on the 
competences and know-how existing within the firm.102
However, the significance of accumulated technological
competences has been questioned by Hobday (1986). He cites 
the examples of new start-up companies in the semi-conductor 
industry in Europe, and the prevalence of strategic alliances, as 
examples of opportunities provided to firms without established 
technological strength.
"P o rte r, 1983
100Pavitt, 1987
101Maidique and Patch, 1988
102Nelson and Winter, 1982
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The importance of such developments and their potential in more 
than limited market niches has yet to be seen.103
Nonetheless, Hobday’s observations are important. It is not purely 
accumulated technological competences that provide the basis for 
successful diversification, but it is also accumulated management 
skills, market knowledge and the experience within organisations 
which allows the firm meet changing market requirements.
The importance of successful innovation of collaboration and 
interaction amongst the various functions within a firm, particularly 
research and development, production, marketing and finance is 
well known.104 105
Several authors have asserted that technology strategy cannot be 
considered in isolation from the other facets of corporate activity, 
including those mentioned already.
Successful technological innovation, be it in semi-conductors, 
chemicals, foodstuffs or new materials depends on the ability of
103Dodgson, 1989
104Rothwell et al., 1974
105Cooper, 1980
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firms to access non-technological, complementary assets, and to 
use them effectively.106
Senker and Brady (1989) address one particularly important 
complementary asset, the skills of the people developing and using 
the technology. These authors suggest that just as technology 
needs to be considered strategically, so too does human resource 
development.
The complexity and composite nature of technology along with the 
high cost and risk associated with its development has led to 
technological collaboration between firms, and between firms and 
infrastructure scientific organisations.
The ability to access and integrate external sources of knowledge 
helps to overcome the problems cited above. Furthermore, as 
discussed in Section 2.6, it can overcome skill deficiencies and 
provides a potential source of comparative competitive advantage. 
The process of accessing and integrating such externalities 
involves several key functions including considerable management 
skills, identification of skill deficiencies, effective decision making in 
choosing partners and careful monitoring of the effects of such 
collaborations. Obviously, such skills are put to best use in the
106Dodgson, 1989
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pursuit of technology central to a firm’s future direction and 
development, that is collaboration needs to be viewed strategically.
These research results show that further analysis of the processes 
of technological innovation and characteristics of successful 
technological strategies in the firm need to go beyond purely 
political interactions between functional and professional groups, to 
include learning from experience, communication from within and 
amongst firms’ functional elements, and with the outside world of 
suppliers, users and competitors, building on existing competences 
and skills and accessing non-technological complementary assets.
The following section attempts to show that these characteristics 
have major implications for theory and action related to the content 
of technological strategy, to the processes through which they are 
developed and implemented, and to organisational continuity in the 
face of technological discontinuity.
First of all it is necessary to consider corporate strategy of the firm 
as it has implications for technological strategy.
Company structure and company strategy play a major role in the 
formation of technological strategy. Sharp (1987) argues that
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recent initiatives in European technological cooperation in ESPRIT 
have taken off rapidly precisely because they involved chief 
executives rather than solely R & D directors.
However, as outlined in the previous discussion the results of past 
research show that technology strategy cannot be described solely 
in terms of negotiation between professional and functional units in 
the firm. In the market system, the ability to satisfy the user’s needs 
better than the alternatives on offer is the ultimate measure of 
success and profitability, and consequent the allocation of 
resources, power and prestige within the firm.
3.10 SETTING STRATEGY AND DIRECTION FOR 
INNOVATION: THE NEW PRODUCT 
DEVELOPMENT STRATEGY STATEMENT
The new product development strategy statement is essential in 
setting the direction for innovation within the firm. The essential 
elements of this statement are the specification of the product - 
market scope to become involved in, and identification of the basic
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strategies to be used for growing within that product - market 
scope.107 108
In attempting to specify the product - market scope element of the 
new product development strategy the firm should adopt a 
definition of the future business the firm wishes to be involved in. In 
defining future business several important criteria should be 
satisfied.109
(A) Future business should be linked to the present product - 
market scope by a clearly definable common thread.110 
However, Ansoff (1969) clearly argues that the linkage can 
be with product characteristics, distribution capability or 
underlying technology as long as the firm has distinctive 
competency in these areas.
(B) Definition of the product - market scope should be as 
specific as possible to impact on the organisation.
(C) The product - market scope definition should be adapted 
constantly to recognise changing environmental conditions.
107Day, 1988
I 0 8 B o o z , Allen and Hamilton, 1982
109Day, 1988
I I  °Day, 1988
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(D) The firm’s resources and competencies must be compatible 
with the product - market scope definition.
(E) The product - market scope should reflect the exploitation of 
the firm’s strengths and competencies that are not 
possessed as fully by the competition.
At the broad level of a new product development strategy, the 
basic issues are the strategies to be used for growing within the 
chosen product - market scope, and the emphasis on innovation 
versus imitation. There are almost an infinite number of possibilities 
for growth strategies. The basic alternatives are summarised in 
Figure 11.
These strategies are by no means mutually exclusive, indeed 
various combinations can be pursued simultaneously in order to 
realise identified opportunities.
Furthermore, most of the strategies can be pursued either by 
internal development or acquisition and coupled with vertical 
diversification.
An equally crucial basic strategy choice is the degree of emphasis 
on innovation versus imitation. The conscious decision to lead or
119
FIGURE 11 GROWTH STRATEGY ALTERNATIVES
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follow pervades all aspects of the firm. Some of the important 
differences that result can be seen from the various strategic 
orientations to high technology markets discussed by Ansoff and 
Steward (1967).
Briefly, these strategic orientations involve a strategy based on 
strong R & D, technical leadership and risk-taking which attempts 
to be first-to-market with the results of its technology. Secondly, a 
strategy based on strong development resources and the ability to 
act quickly as the market starts its growth phase. "Applications 
Engineering"111 involves a strategy of production modification to 
meet the needs of particular customers in mature markets. Finally, 
"me-too" strategies involve competition through superior 
manufacturing efficiency and cost control.
111 Ansoff and Steward, 1967
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3.11 INNOVATION AND CORPORATE CULTURE
An innovative programme should be carried out in an environment 
conducive to new products and guided by corporate 
objectives.112 113 The final component of an innovation strategy is 
a set of guide-lines that drives the corporate culture required to 
execute the innovation strategy.
Once the type of innovation required to meet the strategic 
objectives have been identified, an environment must be created to 
support the development of such innovation. Environmental 
elements include management style, organisation structure, 
management responsibility and support from top management.
In creating a supportive environment it is crucial that product
opportunities be matched to the elements listed in Figure 12. For
example, generally riskier ventures or those with a longer pay-back
period such as the development and launching of new product
lines, or new-to-the-world, innovative products, require a more
entrepreneurial management approach. A highly creative venture
team, headed by a general manager eager to take substantial risks
and strongly supported by top management, would be appropriate.
112Booz, Allen and Hamilton 1982
113Kuczmarski and Silver, 1982
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FIGURE 12 NEW PRODUCT PROCESS ENVIRONMENT
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Review, July, 1982, p. 40.
It should also be noted that innovation opportunities change over 
time, and companies must change their environments accordingly. 
Companies should periodically and systematically evaluate the 
innovation strategy and the organisational environment to avoid the 
problems that result from a mismatch.
Many authors have suggested that approaches to innovation 
strategy and organisational environment should be tailored to 
support emerging innovation objectives.114
3.12 TECHNOLOGICAL DISCONTINUITIES 
AND INSTITUTIONAL CONTINUITIES
With the present wave of radical technological change in 
microelectronics, information technology and biotechnology, 
considerable emphasis is being placed on management theory and 
practice on the notion of "technological discontinuities", implying a 
radical increase in the rate of technical change, and a marked shift 
in its associated skills and required organisational forms.115
114Booz, Allen and Hamilton 1982 
1 ^u sh m a n  and Anderson, 1987
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It is often argued that technological discontinuities are associated 
with the emergence of new small firms to exploit them, given 
conservatism, obsolescence and bureaucracy in established large 
firms.
However, research has indicated that some of the most 
revolutionary business applications of several technologies 
including semi-conductor, microelectronic and information 
technology, are to be found not only in new technology-based 
firms, but also amongst the longest established, largest and most 
conservative of firms. Two factors may help explain why 
technological discontinuous can co-exist with institutional 
continuities.
First, large established firms normally have specialised and 
professionalised R & D laboratories and other technical functions 
with accumulated skills and experience in orchestrating and 
integrating inputs from a wide variety of scientific and technical 
disciplines. They are therefore experienced in hiring and 
integrating professionals from promising new areas.
Examples from the past included the hiring of computer experts by 
IBM116 whilst today strenuous efforts are being made by the large
116Katz and Philips, 1982
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chemical firms to understand and assimilate biotechnology 
advances.117
The second reason was identified by Schumpeter in his later 
writings.118 Large firms have both considerable resources and 
oligopolistic power. The opportunity to explore the implications of 
technological discontinuities with core competences within the firm, 
through learning and incremental change, before deciding whether 
or not to move into commercialisation. One observable feature of 
innovating firms is precisely that they develop technological 
capabilities beyond those strictly related to their current output.
117Faulkner, 1986
18Schumpeter, 1950
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CHAPTER 4: 
BIOTECHNOLOGY AND 
INNOVATION
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4.1 INTRODUCTION
This section of the present thesis involves a largely descriptive 
outline of the technological context of the present study, that is, 
biotechnology. This outline is presented to provide essential 
background information regarding biotechnology for the reader. It 
starts with a short history of the evolution of biotechnology and 
focuses on current and future perspectives. The global 
biotechnology situation is briefly discussed. Furthermore, specific 
issues related to the development of biotechnology and its 
commercial applications are discussed; including public attitutes 
and acceptance of the technology; finance and patent protection. 
Such a discussion is essential when considering the 
commercialisation of new products or processes through 
biotechnology.
4.2 BIOTECHNOLOGY
Biotechnology is a generic technology, a somewhat formless body 
of knowledge and experience about particular groups of 
production process, with applications in a wide range of different
126
industries. As a consequence of its very nature, available 
definitions of biotechnology tend to be indistinct. The following are 
amongst the most frequently cited; taken together they indicate the 
multidisciplinary nature of the technology:
The application of biological organisms, systems or 
processes to manufacturing and sen/ice industries.119
Any technique that uses living organisms (or parts of 
organisms) to make or modify product, to improve plants or 
animals or to develop microorganisms for specific uses. 20
The integrated use if biochemistry, microbiology and 
engineering sciences in order to achieve industrial 
technological application of the capabilities of 
microorganisms, cultured tissue cells or parts thereof. 21
Thus biotechnology may be taken to refer to the industrial use of 
biological agents, especially microbial, plant or animal cells. 
Unfortunately, the term biotechnology has, at least in popular 
usage, become synonymous with "genetic engineering". This 
usage is misleading in the genetic engineering is only one of the 
techniques involved in the technology. Furthermore it ignores the 
extent of existing industrial capability in biotechnology and the long 
history underlying recent scientific and engineering advances.
119A.C.A.R.D., 1980 
12D
‘ ^  Office of Technology Assessment, 1984 
European Federation of Biotechnology, 1981
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4.3 THE HISTORICAL EVOLUTION OF 
BIOTECHNOLOGY
Biotechnology may be characterised as having three generations 
historically-122 The first generation dates from pre-history to the 
1940s and incorporates the traditional uses of microorganisms by 
fermentation to produce food, drink and energy. This historical 
period of biotechnology is characterised by minimal scientific and 
engineering inputs.
With the discovery of penicillin, and the consequent use of natural 
microorganisms to produce therapeutic or chemical agents, the 
technology entered its second generation of evolution. The 
"second generation" of biotechnology which lasted until the 1970s 
was based on the integrated application of industrial microbiology, 
biochemistry and chemical engineering. This period is 
characterised by the organisation of scientific and engineering 
inputs to industrial scale processes.
The "third generation" of biotechnology had its origins in the 
discovery by Cohen and Boyer in 1973 of restriction enzymes 
which enabled the deoxyribonucleic acid (DNA) chain to be cut,
122A.C.A.R.D., 1980
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inserted and accepted by a foreign host. This period in the 
evolution of the technology is characterised by the production of 
novel genetic combinations and is based on the applications of 
molecular biology and the use of genetic engineering techniques.
During the past years there has been a growing realisation that new 
biotechnology, resulting from developments during the third 
generation of the technology’s evolution, represents the third and 
probably the most dynamic technological revolution of the 20th 
century, preceded only by nuclear energy and information 
technology. Among the fundamental aspects of this revolution are;
a) The development of recombinant DNA technology based on 
the powers of gene cloning and splicing which allow for the 
production of large quantities of DNA and for the expression 
of DNA towards the production of rare proteins.
b) Hybridoma technology allowing for the fusion of specific 
antibody - producing spleen cells with myeloma cells to 
produce large quantities of pure antibodies, and,
c) Instrumentation for the microsequencing of proteins and 
DNA and for the synthesis of oligonucleotides and peptides.
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These and other powerful technologies based on earlier 
fundamental research, carried out during the second generation of 
the technology’s evolution, will have an increasing impact on the 
world’s major problems of disease, malnutrition, energy availability 
and environmental deterioration.
4.4 CURRENT AND FUTURE PERSPECTIVES: 
MAJOR SECTORS OF APPLICATION
The only way to indicate the importance of biotechnology products 
at present and in the future (actual or potential) is by sales or 
production figures. However, precise data on current sales and 
production have until presently been extremely scarce and 
fragmentary.123
In contrast however, global market forecasts for biotechnology 
products have been numerous. It should be noted however that 
the reliability and relevance of such forecasts should be 
considered. Furthermore, factors such as the rate of diffusion of 
biotechnology, including environmental and public acceptance of 
biotechnology products and the future general economic situation
United Nations Centre on Transnational Corporations, 1988
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will effect the development of biotechnology and also determine the 
potential markets for innovative products and processes arising 
from this technology. A further discussion of such factors are 
considered in Section 5.
Nonetheless, global market forecasts for biotechnology continue to 
be performed. Table 1, compares results of eleven reports 
provided by different industries during the 1980-90 period. This 
shows an extremely wide range of forecasts with an order of 
magnitude separating the least optimistic forecast of 9 billion 
dollars for the year 2,000 from the most optimistic which was over 
100 billion dollars.
It has been suggested from these and other OECD (1989) figures 
that the most current commercial applications of biotechnology are 
in the chemical, pharmaceutical and instrumentation/electronic 
sectors, because the technical hurdles have been more rapidly 
overcome.
Commercial applications in food and agriculture will develop more 
slowly until the mid 1990s because significant technical hurdles 
must still be overcome.124
124Senior Advisory Group on Biotechnology, 1990
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TABLE 1: FORECASTS ON SIZE OF WORLDWIDE MARKETS 
FOR BIOTECHNOLOGY DERIVED PRODUCTS 
MN MILLIONS OF DOLLARS!*
Report Year Pharamaceut. 
& Healthcare
Chemicals
Processing
Agriculture 
& Food
Energy Total
Business
Communication
Company
1990 12,300 270 430
*
13,000
Robert S. First 1985 1,400 250 . . -
Company 2000 43,000 8,200 - - -
Genex Corporation 1990 - - - - 10,000
International
Resources
Development
1990 “ “ - 3,000
International
Planning 1990 - - - - 4,500
Information (UK) 2000 - - - - 9,000
Arthur D. 1990 _ _ 4,000 . -
Little 2000 23,000 - - - *
Policy Research
Corporation 
Predicasts, Inc.
2000
1985
1995
10,000
1,120
18,600
-
75,000
6,200
101,000
T.A. Sheets 1990 2,900 5,100 9,400 _
& Company 2000 9,100 10,600 21,300 16,400 69,000
1990 5,000 «. 4,500 _ .
Strategic Inc. 2000 - - 9,500 - -
US Congress
Office of Tech­
nology Assesment/ 
Genex Corp.
2000 14,600
*High Technology Institute, Profits and Outlook: Biotechnology, US Dept, of Commerce, International Trade 
Administration /  Genex Corporation, Washington DC, 1984
4.5 MAJOR SECTORS OF APPLICATION FOR 
BIOTECHNOLOGY
4.5.1 PHARMACEUTICALS (DRUGS AND 
HUMAN HEALTHCARE)
The new biotechnology has clearly had its earliest and greatest 
impact on the pharmaceutical and healthcare industry. Already, 
products of this industry have emerged in the form of insulin, 
produced by bacteria for use in the treatment of diabetes, several 
interferons for the treatment of cancer and leukemia, human growth 
hormone for the treatment of pituitary dwarfs, tissue plasminogen 
activators used for the dissolution of blood cells clots and a 
hepatitis B sub-unit vaccine.
Other important new products are the many (hundreds in fact) of 
diagnostic tests uniquely capable of detecting diseases including 
chimeric, that is humanised, monoclonal antibodies, some of which 
will also be used in therapy.
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The general trend with regard to biotechnology application in the 
pharmaceuticals sector will be towards disease diagnosis 
(immunological tests, gene probes, biosensors etc.) and prevention 
(vaccines) rather than cure, although this will require the continual 
generation of new knowledge related to the etiology and 
pathobiology of disease.125
Acquired Immune Deficiency Syndrome (AIDS) has dramatically 
influenced society and become a problem of sever proportions. 
New biotechnology has already facilitated the understanding of the 
disease, by the generation of monoclonal antibodies, DNA probes 
and genetic structural analysis, thereby enhancing the ability to 
detect the virus. Simultaneously, numerous approaches to dealing 
with the disease have been initiated utilising biotechnology 
products. Vaccines, viral inhibitors and immune modulators are 
being actively pursued and hopefully will provide a solution before 
the end of the century.
The drug industry is suffering badly from the spiralling cost of R & 
D. A drug can cost up to $125 million to bring to the market and 
that figure may have trebled by the end of the century.126 
Meanwhile, the number of prescriptions is not growing and
125OECD, 1989
126Johnson, 1990
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governments are increasingly exerting price pressure to cut their 
public health bills. The outcome is necessarily a reduction in the 
number of new therapeutics that are launched. In this atmosphere, 
pharmaceutical companies are increasingly joining in crucial 
alliances to ensure that expensively developed new drugs are 
launched without any significant competition. They are also turning 
to chirality as the possible solution to their problems.
Many compounds have what are called centres of chirality. Around 
these centres the attached molecules can be arranged in two ways. 
Even though the two versions are the same compound, they can 
have different biochemical effects in the body. The two versions or 
isomers are referred to as dextro (D) or levo (L) depending on the 
direction in which they rotate polarised light.
Usually, only one version exists naturally. Only the D-isomer of 
thalidomide, the anti-morning sickness drug prescribed in the 
1960s, caused the toxic effects seen. The other isomer was not 
toxic, but was an effective therapeutic.
Although only one isomer may be necessary or effective in treating 
a patient, drugs are often a mix of isomers because synthetic 
methods produce both types and separation can be difficult and 
expensive. Many drugs on the market contain this “isomeric
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ballast" which at best, is ineffective and wasteful of manufacturing 
efficiency and, at worst, may be toxic to the patient as seen in the 
case of thalidomide.
While no country is banning racemic (mixture of the two isomer 
forms) drugs, drug companies in Europe and Japan must now 
produce evidence that racemates on the market have advantages 
over the single pure isomers.
In the U.S., the FDA (Food and Drink Administration) looks as if it is 
heading in the same direction. The results of this will be that 
companies will be forced to carry out extensive and very costly 
testing of the different isomers of compounds on the market.
However, the fast spawning separation technology and the 
increasing availability of isomeric intermediaries or chiral pathways 
may, in turn, lead to an increase in drug specificity.
Specificity will lead to a drop in drug volumes according to Dr. 
Balling, director of sales and new product development for DSM 
chemicals,
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There will be fewer billion dollar drugs but these new 
isomers will be very, very marketable, because of their 
specificity and their safety profiled27
Marketing a racemic pharmaceutical already on the market, in its 
isomeric form can also be one way to extend a patent or revamp an 
old drug. Schering has done this with its beta blocker product, 
Labetalol. Schering is now marketing the single isomeric form of 
this product as Dilevalol and claims it significantly reduces postural 
hypertension or dizziness on rising, a side-effect of beta blockers, 
including Lebetalol.128
However, in some racemates the isomers actually potentiate each 
other’s action and this two can be marketed as a bonus.
Hence, biotechnology influences the development of chiral 
intermediates by providing stereo-selective biocatalysts and 
facilitating speedier and more effective separation of racemates. 
Furthermore, it has been predicted that by the year 2000 chiral 
chemistry will be the major element of new intermediates for drugs 
being launched129 and biotechnology has certainly a role to play in 
this development work.
127Johnson, 1990
128lbid, 1990
129Johnson, 1990
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Finally, an entirely new challenge has arisen to deal with the 
delivery of protein/peptide drugs and therapeutics. These large 
molecule drugs cannot be absorbed orally without being degraded, 
and injection of large molecules has also proved problematic and 
occasionally followed by side effects. Delivery problems, including 
for vaccines, have led to delays compared with the expectations of 
a few years ago. Consequently, drug delivery technologies, both 
for humans and for animals have become a major area of interest, 
mobilising already several dozen specialised companies. New and 
novel approaches for drug deliveries will be required and will draw 
heavily upon the advanced, physical, chemical and modern 
biological tools mentioned previously.
Modern technology therefore has the potential to change the 
technology paradigm of healthcare and the pharmaceutical 
industry, to improve cost control of healthcare and to enormously 
enhance the quality of human life.
4.5.2 AGRICULTURE AND FORESTRY
Agriculture is one of the largest economic sectors throughout the 
world and one where the stakes of new biotechnology are very
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great. In the fields of plant and animal agriculture, biotechnology 
may improve food production by increasing the growth rates and 
growth efficiency of animals. Transformation technologies have the 
potential to create plants resistant to diseases, insects, herbicides, 
and plants capable of surviving in environmentally harsh climates. 
Genetically engineered microbial organisms to control plant pests 
and influence nutrient uptake are also under development.
A key area of agriculture is already benefiting from biotechnology- 
generated products is the livestock industry. Field trials have 
indicated that bovine somatotrophin (BST) a naturally occurring 
protein in cows, can be supplemented with biotechnology-derived 
somatotrophin to increase milk production and improve feed 
efficiency leading to more milk for the same amount of feed. New 
and improved vaccines are being produced for foot and mouth 
diseases, scours, shipping fever and other diseases of 
domesticated animals.
The understanding and use of retroviruses for the creation of 
transgenic animals is advancing and may provide a means by 
which animals will be born resistant to various diseases.
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In animal reproduction, sex-specific semen may well enhance the 
business of embryo transfers by producing a greater concentration 
of embryos of the desired sex, although this has also led to 
concerns that sex-specific semen could be used in human 
reproduction. Research focussing on reproductive hormones, 
such as luteinising hormones, folicle-stimulating hormones and 
gonadotrophin-releasing hormones will both benefit animals and 
produce many spin-offs for various aspects of human fertility.
In many of the above described developments, fundamental 
molecular biology, with particular emphasis on receptor biology 
and the regulation of hormone/receptor systems, will be pursued. 
As anticipated for the pharmaceutical industry, this transition will 
ultimately lead to the development of organic molecules that 
replace or augment the first generation of biotechnology-based 
animal products.
Lastly, an area of rapidly developing interest is the use of animals 
as bioreactors to produce rare proteins. For example, the tissue 
plasminogen activator gene has been engineered to create 
transgenic mice that produce and secrete tPA into the mammary 
glands. By simply milking the animal, the product can be isolated 
and purified. Similar studies are being conducted with larger
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mammals. However, the economics of manufacturing rDNA 
products by this means has yet to be established.
4.5.3 FOOD AND FEEDS
Many aspects of the food and feeds industry could benefit from 
biotechnological advances made in plants and animals, as 
described in Section 4.5. Significant quality changes can be 
anticipated in food products derived from these sources.
Biotechnologically-derived and improved enzymes for food 
processing, such as bovine chymosin (rennin) used in milk clotting, 
have already undergone first generation developments. The further 
modification of these enzymes through protein engineering may 
lead to the potential industrial production of foods under conditions 
that are more efficient and cost effective. This area holds great 
potential for the food processing industry.
The genetic modification of food using genetically engineered lactic 
acid bacteria represents yet another area for growth and 
opportunities. These bacteria find utility in the production of
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thickening agents, natural food preservatives and enhancers of 
flavour development. These bacteria also represent a safe 
production host for the manufacture of a variety of food grade 
products such as chymosin for the manufacture of cheese.
Significant advances can be expected in other food grade 
microorganisms, such as yeasts (for example, for low calorie beer), 
bacteria, and fungi. The use of these organisms for the production 
of important food technology enzymes and in various fermentation 
processes will be beneficial.
Clearly, the food products derived from the applications of 
fermentation technology, enzymology, and food microbiology will 
benefit from advances in basic biology and biotechnology.
4.5.4 CHEMICALS - SPECIALITY AND 
COMMODITY
Many important industries are actively using fermentation to 
produce industrial chemicals. They range from gluconates, lactic
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acid, citric acid, antibiotics, steroids, amino acids to a wide variety 
of enzymes.
Amino acids will be among those products benefiting most from 
advances in genetic engineering, host strain modification and 
improvements in the bioengineering sciences, such as 
fermentation, reactor design etc.
The major trend in those instances will be the application of 
fundamental genetic engineering to cost reduction in the 
production of a variety of amino acids, such as phenylalanine, 
aspartic acid and lysine.
Biotransformation, which may include fermentation but is somewhat 
more specific and sophisticated may find increasing use in the 
modification of modules. Biotransformation is the modification of 
organic substrates using enzymes and other biological systems. It 
is likely that chemists will use enzymes for synthesis instead of 
classical organic reagents.
Advantages of such approaches would include reduction of side 
products, thereby minimising pollution problems and maximising 
yields. It should be noted that enzymes used in organic reactions
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will help the chemist in the laboratory and may well see commercial 
application in more sophisticated and high value products.
Protein engineering will provide a major tool for the improvement 
and development of industrial enzymes, an opportunity which is 
already actively pursued by industry. Examples will include 
enzymes with greater stability, unique physical properties and novel 
applications.
Regarding feedstocks for biotechnology applications, it is likely that 
sucrose, starch, methanol, paraffins and lignocellulose will be 
potential replacements for the commodity chemicals currently 
produced from petroleum. However with current oil prices, one 
should not expect a significant impact of biotechnology on 
commodity chemicals in the next decade.130
4.5.5 ENVIRONMENT
While much has been written about the environmental uses of 
biotechnology, including about biofilters which play an increasingly
130OECD, 1989
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beneficial role in waste-treatment plants, many commercial 
developments for pollution control and waste-treatment will be slow 
in the next decade.131
Important future applications for biotechnology in the environment 
will include the area of waste water purification, groundwater 
contamination and the recycling of important chemical materials 
such as sulphur. Progressing this area will be economically 
influenced by the coupling of reactor design and chemical 
engineering principles with the genetic modification of appropriate 
microbes.
Bacteria will be engineered to enhance the metabolism of 
sequester-specific toxic wastes. While naturally occurring bacteria 
have abilities to degrade a variety of specific chemical agents, 
modern genetic engineering and selection tools will be able to 
enhance the abilities of these microbes to be more efficient and 
cost effective.132
131 OECD, 1989
132OECD, 1989
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4.6 GLOBAL BIOTECHNOLOGY
Developing and marketing contemporary technology are essentially 
international activities. The new pervasive technologies, information 
technology, new materials and biotechnology are world-wide 
phenomena. There are numerous examples of public policies and 
private firms’ strategies reflecting recognition of comparative 
technological advantages on a global scale. In recognition of the 
economic importance of biotechnology many nations of the world 
are becoming increasingly involved in the new era of technology.
This section of the present report examines the level of international 
involvement in biotechnology, considering such issues as 
development origin, public policies and the major industrial sectors 
involved in biotechnology in individual countries. The discussion 
focuses on these issues relating to the US, Japan and Europe.
The centre of commercial biotechnology activity as measured by 
small enterprise creation and corporate investment is clearly the 
United States (see Section 4.6.1). US commercial biotechnology is 
a result of the country’s strong climate support for biotechnology 
and the fact that American investment culture and incentive
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schemes remain innately more attractive for risk capital, especially 
start-up venture capital.
Furthermore, the United States has been the principal beneficiary of 
recent commercial investment in biotechnology, both start-ups and 
major investments. It is interesting that European investors 
represent a significant share of biotechnology investment in the US. 
Furthermore, virtually all US-source start-up investment in 1989 
remained in the US. Japanese investment patterns reflect a 
strategy of global technology sourcing with regard to 
biotechnology, (see Table 2).
Intellectual property rights, and particularly patents, are a direct 
indicator of effective research and development activity. Even more 
important they secure the future economic benefits of R & D and 
commercial investments (see also Section 4.7.3 for a further 
discussion on intellectual property rights). It is interesting that far 
fewer biotechnology patents are being granted around the world to 
European inventors than to American or Japanese inventors, 19% 
versus 41% and 36% respectively of patents recently documented 
(see Table 3). Furthermore, European-owned patents account for 
far less of total biotechnology patents granted in each competing 
region than the US and Japanese-owned patents, that is,
146
TABLE 2 COMMERCIAL BIOTECHNOLOGY INVESTMENTS IN 1989
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1 9 9 0 ,  SAGB. B r u s s e l s .
irrespective of the features of the local patent environment (see 
Table 3).
Europe falls behind America and Japan in securing proprietary 
rights for biotechnology for a number of reasons, but primarily due 
to the fact that unlike the US and Japan, Europe remains 
ambivalent about patents for biotechnology;
(1) Europe has not yet reconciled its traditional system of Plant 
Variety Rights with the need for strong biotechnology patent 
law.
(2) European law currently excludes patents for plant and 
animal varieties.
(3) The ethical acceptability of patenting living organisms has 
yet to be resolved in Europe via open political debate and 
resolution.
(4) Biotechnology inventors are seeking patents first where the 
entrepreneurial opportunities are perceived to be greatest, 
that is, in Japan and the United States.
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TABLE3
ACQUISITION OF INTELLECTUAL PROPERTY RIGHTS - 
RECENT BIOTECHNOLOGY PATENTS GRANTED
Patent issued 
in
Origin of Patent Holder
E u rope U S A Japan Totalissued
EUROPE 123 215 92 430
(EPO) * 
(1985) 
U )
(29%) (50%) (21%) (12 mths.)
USA
(1988) 500 950 420 1,870
(2 ) (26%) (51%) (23%) (6 mths.)estimate
3,700
(12 mths.)
JAPAN 239 454 1,599 2,292
(1988) (10%) (20%) (70%) (12 mths.)
TOTALS 862 1, 619 2,111 4,592
* E P O  =  E U R O P E A N  P A T E N T  O F F I C E
SOURCES: (l)BREVETTI, PULAZZINI, BIOTEC; JUNE 1988
(2)BIOTECHNOLOGY BACKLOG OF PATENT APPLICATIONS, 
(US GENERAL ACCOUNTING OFFICE, APRIL 1989)
(3) WORLD PATENT INDEX, DERWENT PUBLICATIONS
Public support for biotechnology research obviously influences a 
country’s development with regard to this new technology. Public 
support of basic scientific research is a catalyst of growing 
importance for cycles of technology-driven economic growth. In 
competitive terms, the political and financial weight of governments 
in pre-competitive scientific research is an increasingly decisive 
factor in strategic commercial development by the public sector.
Furthermore, for these reasons an analysis of public support for 
biotechnology is required. Public funding of biotechnology within 
the European community in 1989 was 79% of the total US funding, 
representing a shortfall of half a billion ECU.
Furthermore, federal government biotechnology funding in the US 
represented 95% of total US funding of 2,379 billion ECU.
European Community level support in 1989 amounted to 50 million 
ECU, 2.6% of total European public support of 1, 857 billion ECU.
Japanese public funding of biotechnology R & D appears low at 
283 million ECU in 1989, however it must be noted that R & D 
investment in Japan is undertaken largely by the private sector. But 
virtually all of this effort is organised and co-ordinated by M.I.T.I. at 
the pre-competitive stage (see Section 4.6).
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Table 4 summarises public support for biotechnology research and 
development spending and its impact in terms of related spin-off 
research and development.
It is recognised that European Community member states have 
world class centres for expertise in biotechnology. Nevertheless, 
public funding for biotechnology research within the community is 
fragmented amongst member states and for this reason is likely to 
be less efficient than federal support and co-ordination in the US 
and Japan.
The following section considers the level of international support 
and involvement in biotechnology, considering such issues as 
development origin, public policies and major industrial sectors 
involved in biotechnology in the following countries.
* United States
* Japan
* Europe (Great Britain, West Germany France, The
Netherlands and Ireland)
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TABLE 4
PUBLIC SUPPORT FOR BIOTECHNOLOGY RESEARCH 
R  & D SPENDING AND IMPACT
(ALL FIGURES IN BILLION ECU)
RELATED SPIN-OFF R & D
D irect publicy 
funded
biotechnology
Instrum ents Databases C om puter
hard/soft
ware
Reagents
EUROPEAN
COMMUNITY
EEC
0. 050 
('89)
MEMBER STATES 
TOTAL
1.807
(*89)
1. 857 
(•89)
0. 041 0. 004 0 . 060 0 .0 0 1
USA 2 , 250 0.205 0.010 0. 190 0.010
FEDERAL
STATES
('88) 
0. 129
TOTAL 2, 379
JAPAN 0. 283 
('89)
0 . 122 0 .0 0 1 0.300 0.060
AUSTRALIA 0. 070 
( ' 8 9 )
NA NA NA NA
CANADA 0 . 160 
('8 8)
NA NA NA NA
SOURCES: E U R O P E A N  C O M M I S S I O N ,  D G  XII
C H E M I C A L  E N G I N E E R I N G  - P R O G R E S S ,  D E C .  '89
P.27-32
C O M L I N E  C O M P U T E R S ,  A U G .  '89
C O M L I N E  B I O T E C H N O L O G Y  &  M E D I C I N E ,  F E B .  '89
4.6.1 UNITED STATES OF AMERICA
The US is world leader in genetic engineering, immunology and 
molecular biology. Its superiority is founded upon its research 
institutes and universities and the intellectual base therein (including 
some eminent scientists attracted from abroad). In fact, the new 
era of biotechnology has its roots in the pioneering work of two 
prominent American scientists, Dr. Stanley Cohen of Stanford and 
Dr. Herbert Boyer of the University of California. These scientists 
were responsible for the new enabling technique of recombinant 
DNA technology.
Historically, the US has maintained a technological advantage in 
biotechnology projects compared to Japanese and European 
efforts. This lead has been a result of many factors. In relation to 
Japanese efforts, the superiority of American developments in 
biotechnology is partly based on the late entry of Japan to the field. 
Furthermore, during the 1970s, genetic engineering was fraught 
with ethical and philosophical controversies, even though there 
were no commercial applications for recombinant DNA. As a result, 
the US banned genetic engineering research from 1976 - 1978 until 
the National Institute for Health formulated specific guide-lines.
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However, the ban in Japan lasted far longer which delayed their 
entry into the field until 1980.
At the national level, the US indicated its support for technology- 
government ties through such legislation as the Stevenson-Wydier 
Technology Act of 1980133 This legislation served to stimulate 
technology transfer between industries.134
Furthermore, a major influence on the US biotechnology industry’s 
development has been the level of state funding of research. For 
example, in 1982, this support accounted for about $380 million in 
health, $35 million in agriculture, $52 million in science and $36 
million in energy/biomass research, thus the total government 
spending for this period amounted to some $510 million.135
The US succeeded in translating its intellectual base into 
commercial practices. Since the early 1970s more than 300 small 
companies have been founded to work with the new technologies 
of genetic engineering, monoclonal antibody production and 
protein engineering. In addition many major corporations in the US 
have sought entry into biotechnology. Hundreds of new
133Dutton, 1989
US congress, 1985
135O.T.A., 1984, p309
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companies have been founded to interact with the biotechnology 
firms, supplying reagents, equipment and serving a variety of other 
ancillary functions.136
Braun suggests that the boom of specialist biotechnology 
companies was to a large extent fostered by
a) the cultural entrepreneurial spirit of open market 
competition,
b) the availability of venture capital, and,
c) tax laws which encouraged personal investment through tax
write-offs.
An interesting aspect of the development origins and evolution of 
biotechnology in the US is the shift in founders of biotechnology 
companies. Dibner (1987) reports that there has been a shift in 
founders of biotechnology companies from academic backgrounds 
from 52% to 18.5%, while those of industrial background have risen 
from 25% to 66% during the period 1982-1987. This shift is 
attributed to the following factors:
136Braun, 1987
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(1) The movement from basic research to product development, 
manufacturing and marketing.
(2) The awakening of non-academic entrepreneurs to the 
potential of biotechnology, and,
(3) More involvement of established industries in biotechnology 
as indicated in Table 5 by the level of R & D investments in 
biotechnology. (It should be noted that more recent 
information on R & D biotechnology budgets of US 
companies is not available, probably due to the increased 
secrecy of these companies).
There is a definite bias in the US towards pharmaceutical and 
agriculture biotechnology as reflected by the proportion of 
American biotechnology firms engaged in different areas of 
research; 62% pharmaceutical and 28% animal and 24% plant 
culture.137 This bias may be partially due to the perception of 
biotechnology as a cheap route to pharmaceuticals, and may also 
be a reflection of the federal funding directed towards these 
research areas as outlined earlier.
137OTA, 1984
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R & D BIOTECHNOLOGY BUDGETS FROM LEADING U.S. COM-
TABLE5
COMPANY $M
SCHERING PLOUGH (pharmaceuticals) 60
ELI-LILLY (pharmaceuticals) 60
MONSANTO (chemicals) 62
D U PON T (chemicals) 120
GENENTECH (New Biotech Co.) 32
CETUS (New Biotech Co.) 26
GENEX (New Biotech Co.) 8.3
BIOGEN (New Biotech Co.) 8.7
HYBRITECH (New Biotech Co.) 6.0
SOURCE: OFFICE OF TECHNOLOGY REPORT, 1984 
"GENETIC TECHNOLOGY: A  NEW FRONTIER 
WESTVIEW PRESS / CROOM HELM, P.74
However, American firms involved in biotechnology research are 
predominantly small companies which market one or two products, 
in the hope that profits will finance further research and new 
products. Of the 300 companies involved in biotechnology, only a 
few have accomplished the goal of independent, profitable 
operation.
One of the main difficulties with bringing a biotechnology product to 
market is extremely high development costs. While it costs only 
$10,000 to develop a new monoclonal antibody, it costs millions to 
test and market the product.138
In 1985, the Food and Drug Administration first approved a 
biotechnology product which synthesized a human growth 
hormone. Sales of $90 million of the drug by the company 
Genentech produced 1987 earnings of $5 million139
With this commercial success, Genentech and other biotechnology 
firms were extremely successful in raising capital to finance long­
term projects. As recently as 1987, raising money beyond the start­
up phase was not difficult, particularly in the stock market. As a 
result of the popularity of biotechnology stock in the mid 80s,
138Lunzer, 1988
Hamilton, 1988
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several US firms grew large enough and were profitable enough to 
finance growth internally.
Unfortunately, because of high risk, biotechnology stocks are more 
volatile than most others. One analyst summed up biotechnology’s 
position very simply:
Biotech stocks exaggerate market conditions,140
Continuing investor pessimism has effectively closed the public 
equity markets for initial and secondary stock offerings to finance 
operations beyond their venture capital or private funding 
beginnings.
As a result of investors’ pessimism in biotechnology stocks, joint 
ventures and biotechnology alliances have suddenly become 
popular for US companies suffering from cash shortages. Cash- 
rich limited partners who invest in biotechnology R & D hope to 
receive a high rate of return in royalties when the products finally 
get to the market. However, recent tax law changes have dictated 
an important qualification for R & D partnerships to be profitable; 
the biotech firm must be close to bringing a product to market.
140Lunzer, 1988
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Therefore, limited partnerships are realistic only for the larger 
biotech companies who have already finished most of the testing 
on the product.
For small firms in the early development stages, there are currently 
two common ways of financing operations:
(A) Performing contract R & D for larger companies.
**
(B) Making marketing agreements with large pharmaceutical or 
biotechnology houses giving away some or all rights to 
products.
These strategic linkages serve to strengthen the position of the 
leading firms in biotechnology and makes it very difficult for small 
firms to realise supernormal profits. Thus in the US, the 
competition for finance will continue to favour the large 
biotechnology houses.141
141Lunzer, 1988
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4.6.2 JAPAN
Biotechnology is one of the fields, along with microelectronics and 
superconductivity in which Japan’s rapid transition from a major 
purchaser of technology to a major developer of it can be seen 
most clearly.
In the case of biotechnology, all the necessary factors are there for 
Japan to excel. Both the government and the corporate sector are 
flush with cash and are looking aggressively for new industrial 
developments which will sustain the momentum of the country’s 
strong economic growth.
Most leading industrial companies are now internationally 
competitive in their fields and can no longer hope to improve their 
positions by buying technologies from abroad. Thus they are 
willing to invest heavily in research and development of new 
products on their own.
In some cases, they also appear to be acquiring foreign companies 
with a view to speeding the process. The purchase in 1989 by 
Yamanouchi Pharmaceutical of the US health products group 
Shaklee for $395 million is thought to have been made in part to
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improve the Japanese groups position in biotechnology 
research.142
By nature, the Japanese are also willing to take a long view, an 
approach which coincides perfectly with the profile of 
biotechnology where successful commercial applications are not 
expected to be numerous for at least another decade.
Perhaps most importantly, the Japanese people are embarrassed 
about their image as copiers and are eager to shed it. Tt has been 
said that there is something approaching a national campaign in 
Japan at the moment to promote creativity and innovation, and 
investment in biotechnology research is one of the main 
beneficiaries.143
In terms of commercial production, the earliest developments in 
Japan were in pharmaceuticals. Competition emerged about two 
years ago among companies to commercialise hepatitis B vaccines 
to treat the disease hepatitis B, a disease which is more common in 
Japan than elsewhere.
142Rodger, 1989
1 ^ R o d g e r, 1989
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More recently, the focus of biotechnological product development 
has switched to agriculture with new companies bringing out new 
type of flowers and vegetables applying tissue culture. A couple of 
years ago a lot of publicity as generated around the development 
of seedless watermelons and something called a pomato, but now 
more serious products are emerging!
For example in April 1989 Sapporo Breweries set up a joint venture 
in Peking that will use a clone proliferation technique to raise 
masses of low priced orchid seedlings for import and sale to 
Japanese horticulturalists.
Similarly, Japan Tobacco, the dominant tobacco industry in Japan, 
paid $6 million for an 8.7% stake in Plant Genetic Systems, a 
Belgian company active in the genetic engineering of plants. It 
claims to have pioneered field research in making plants resistant 
to specific insect predators.144
The following section of this discussion on Japanese developments 
in biotechnology will focus on specific public policies and private 
sector involvement with regard to biotechnology, to illuminate the 
environment in which this nascent technology has and is 
developing.
1 ^ R o d g e r, 1989
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The patenting of recombinant DNA procedures by US scientists in 
1980 led to immediate interest in Japan, particularly since its ban in 
genetic engineering had just expired. Japan’s biotechnology 
interest is consistent with its overall goals in science and 
technology. Given Japan’s limited natural resource base and its 
dependence on other countries or food, energy and raw materials, 
the Japanese government viewed biotechnology as a means of 
strengthening its economic position during the 1980s, if progress 
could be made quickly.145
The research development corporation of Japan (J.R.D.C.), 
established in 1961, has been actively working on the development 
of technology with a gradual shift in focus from production 
processes and large scale efficiency to prevention of pollution, 
technology for social gains, energy-conserving technologies and 
high technology.
Another agency which fosters biotechnology is the Science and 
Technology Agency. Its involvement began in 1981 with a $25 
million grant for recombinant DNA research'146 Its research team 
composed of Seiko, Fuji, Hitachi, Toyo Soda and Mitsui Knowledge 
Industry, developed the first biorobot to automate the task of
145Rodger, 1989
146Tatsuno, 1986
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analysing DNA cultures. This has led to much faster progress in 
deciphering genetic data than in the US. In fact, it has been stated 
that,
There is no question that the Japanese are ahead in
automating DNA sequencing.147
The advent of commercial biotechnology in 1980 nearly coincided 
with the creation of a new organisation called the Exploratory 
Research for Advanced Technology program (E.R.A.T.O.). Its 
purpose is to promote basic research in leading techniques 
through a unique structure. The program features key individuals 
who are named as project leaders or directors and are usually 
young researchers from varied technical backgrounds. According 
to the president of the J.R.C.S., Nobuhisa Akabane, the E.R.A.T.O. 
program has proven far more successful that expectations, and is 
one of the world’s most advanced pure research programs.148
Progress in biotechnology was spearheaded by Japan’s Ministry of 
International Trade and Industry (M.I.T.I.), along with thirteen other 
industries targeted for basic research and product development, in 
1981.
147Wall Street Journal, 1987
148Akabane, 1986
161
In 1981, M.I.T.I. budgeted $150 million to Japan’s first 
biotechnology project-149 Over the next two years, M.I.T.I. 
organised fourteen companies to carry out research in recombinant 
DNA and bioreactors for industrial and medical applications.
One year later, M.I.T.I. formed the Office of Biotechnology to fund 
and provide information for the 150 companies which were then 
involved in biotechnology research.
Continuing to support biotechnology at the national level, the 
M.I.T.I. established a "Key Technology Centre" in biotechnology in 
1985. The centres allow two or more Japanese countries to set up 
joint venture companies whereby 70% of R & D is funded by the 
centre.
Japan’s real strength however, lies in its company sector. 
Significant numbers of Japanese companies have shown 
awareness and involvement in biotechnological activities. A survey 
by M.I.T.I. in 1982 which involved 200 corporations revealed that 
157 had a R & D programme involving biotechnology. 
Furthermore, certain companies were devoting significant 
resources in this area. For example, the managing director of 
Mitsubishi Chemical Industries Ltd. reports that 40% of the
149Tatsuno, 1986
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company’s $233 million R & D budget is devoted to 
biotechnology.150
Like most of Japan’s large corporations, Mitsubishi can afford to 
spend large amounts of cash from profitable divisions to develop 
biotechnology products which have payback projections far in the 
future.
It appears that Japanese companies are well-positioned in the 
certain and long term biotechnology market. One indication of this 
is that Japanese biotechnology firms have not been as adversely 
affected as US firms in the aftermath of the downturn of financial 
markets in October, 1987.151
Hence the pattern of development of biotechnology in Japan differs 
considerably to that witnessed in the US. In Japan, the technology 
is developed and exploited by the largest corporations with the 
integration of government support. In the US open market, 
competition has driven development resulting in a rash of 
entrepreneurial "start-up" companies involved in biotechnology 
research. These new biotechnology companies have served as
150Wall Street Journal, 1987
151 Dutton, 1989
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research bases for established larger companies to become 
involved in the technology.
Japan’s forte with regard to biotechnology is in the area of 
fermentation. This strength combined with industrial foresight has 
given Japan the lead in the world amino acid market and 
considerable strengths in other fine chemical and enzyme areas.
Japan’s commitment to biotechnology is expected to yield 
dividends and compensate richly for the country’s lack of natural 
resources.
Biotechnology trade associations in Japan expect biotechnology to 
account for 11% of the country’s G.N.P. by the year 2.000.152
4.6.3 EUROPE
As a whole, Europe’s intellectual base for biotechnology is quite 
strong. The major disadvantages facing Europe are those of 
internal language and trade barriers, which at present contribute to
152Smith 1988
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the fragmentation to the industry. However, the advent of the 
Single European Act may help contribute to the development of 
science research and technological development, including 
biotechnology, through the eliminating of trade barriers and the 
dissemination and optimisation of the results of activities in 
community research and development. This aspect of 
biotechnology development will be discussed further in this section.
At this stage it is considered appropriate to consider the industrial 
production and trade impacts of biotechnology on European 
Sectors in which the future commercial impacts of biotechnology 
will be most significant.
Estimates based on European Community/GATT statistics suggest 
that with regard to industrial production sections in which the future 
commercial impacts of biotechnology will be most significant 
(agriculture/food, pharmaceuticals/healthcare and chemicals), 
today account for over 21 % of total European Community industrial 
production in these five sectors, higher than in the US or Japan153 
(see Table 6).
153SAGB Report, 1990
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TABLEÓ
INDUSTRIAL O UTPUT  
EU R O PEA N  COM M UNITY INDUSTRIAL PRO DUCTIO N IN  
SEVERAL SECTORS (AS% OF EC TOTAL)
Agriculture Chemicals Pharms. Health Food
Total
5
Sectors
% o f  
EC t o ­
t a l
4 .5% 6% 3% NA 8% 2 1 . 5
ECU
( bn)
1 5 7 . 5 2 1 0 1 0 5
—
2 8 0 7 5 2 . 5
SOURCE: SAGB R eport, 1990
SAGB Estim ates based  on E uropean  Com m unity/ 
G A T T  Statistics
To add to this the market sectors most affected by biotechnology 
developments account for almost 30% of community exports with 
the rest of the world (see Table 7).
Although the organisation which provides such estimates is 
reputable, these estimates must be created with caution. 
Nonetheless, they attempt to set the context with regard to 
biotechnology and European industrial sectors in which the future 
impacts of the technology will be most significant.
The European Community has adopted several initiatives in 
biotechnology designed to achieve a cohesive European market. 
In 1978, the European Federation of Biotechnology (EFB) was 
formed. Furthermore in 1981, the Concentration Unit for 
Biotechnology in Europe (CUBE) began a relationship with the 
EFB, to effectively monitor and co-ordinate European 
biotechnology activities.
The European Commission put together a community strategy for 
biotechnology in 1983 partly as a result of the FAST program 
(Forecasting and Assessment of Science and Technology) and 
also various contributions which the EFB and CUBE made.
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TABLE 7
EUROPEAN TRADE 
EUROPEAN COMMUNITY EXPORTS WITH THE REST OF THE 
WORLD, IN SEVERAL SECTORS
(AS PERCENTAGE OF TOTAL EC EXPORTS)
Agriculture Chemicals Pharms. Health Food
Total
5
Sectors
% o f  
EC t o ­
t a l
3% 14% 1.5% NA 11% 2 9 . 5
ECU
( bn)
13 . 5 63 6 . 7 5 — 4 9 . 5 1 3 2 . 7 5
SOURCE: SAGB Report, 1990
SAGB Estimates based on European Community/ 
GATT Statistics
The 1983 European Community Strategy for Biotechnology is 
outlined in Figure 13.
Training was certainly seen as a major part of the 1983 community 
strategy. As a result, training and research programmes in 
biotechnology have continued and are expanding.
Since 1983, CUBE have focussed on development and 
demonstration projects which has led to the establishment of such 
programs as FLAIR, which focuses on food technologies, and 
ECLAIR regarding agro-industrial technologies. There has certainly 
been an expansion of the research programs in biotechnology 
throughout Europe.
The library of the Royal Netherlands Academy of Arts and Sciences 
recently prepared a permanent inventory of publicly funded 
biotechnology research projects in the European communities, as 
part of a BIOREP database.
During the period 1981-89 data was collected on the number of 
projects and institutes involved in publicly funded biotechnology 
research projects of each member state. The data obtained were 
tested against the selection guide-lines employed or inclusion of 
scientific papers and patents in Derwent Biotechnology abstracts,
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FIGURE 13 THE 1 9 8 3  COMMUNITY STRATEGY FOR
BIOTECHNOLOGY IN EUROPE
T h e  1983 C o m m u n ity  S tra te g y  fo r  B io te c h n o lo g y  in  E u ro p e
1. R E S E A R C H  A N D  T R A I N I N G
- “CONTEXTUAL” BIO-INFORMATICS
CULTURE COLLECTIONS 
• BASIC BIOTECHNOLOGY 16 AREAS
2. C O N C E R T A T I O N  O F  A C T I O N S  A N D  P O L I C I E S  ( C U B E )
3. F E E D S T O C K  P R I C E S
- SUGAR, STARCH REGIMES
4. R E G U L A T O R Y  R E G I M E S
- FOOD, FEED, CHEMICALS, PHARMACEUTICALS, ENVIRONMENT, rDNA
5. I N T E L L E C T U A L  P R O P E R T Y  R I G H T S
- PATENTS, PLANT VARIETY, TECHNOLOGY TRANSFER
6. D E M O N S T R A T I O N  P R O J E C T S
- AGRO-INDUSTRIAL
S o u r c e :  C a n t l e y ,  M . F . , ( 1 9 8 9 ) ,  "M anpow er  & T r a i n i n g
N e e d s  f o r  B i o t e c h n o l g v  i n  Eurngf t  in  t h e
1 9 9 0 s " ,  R e p o r t  o f  a  W o r k i n g  P a r t y  M e e t i n g  a t  
D e l f t  U n i v e r s i t y  o f  T e c h n o l o g y ,  N e t h e r l a n d s , 
1 9 8 9 .
Derwent Publications Ltd., and against the following definition of 
biotechnology:
Biotechnology comprises the integrated use of 
biochemistry, molecular genetics, microbiology and process 
technology to arrive at practical application at the 
possibilities of microorganisms, cell cultures or part thereof.
It is important to note that in the BIOREP database, classic 
biotechnology, for example, brewing, as well as fundamental 
research, mostly molecular sciences research relevant for 
biotechnology, has been included.
The number of projects and institutes in each member state is 
tabulated in Table 8. The number of records in the BIOREP 
database does not give any indication on the coverage because of 
the level of aggregation of the information values. For example, the 
506 German records which are generally taken up in the database 
as themes with often very extensive abstracts describing the 
various projects, from the information and coverage points of view 
may be regarded to be equivalent to the 2180 British records.
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TABLE 8
THE NUM BER OF PROJECTS A N D  INSTITUTES INVOLVED IN  
BIOTECHNOLOGY RESEARCH IN EACH EURO PEAN  
COMMUNITY MEMBER STATE
M E M B E R  S T A T E  P R O J E C T S  I N S T I T U T E S
l-'.V
BELGIUM 374 127
DENMARK 168 77
BRITAIN 2,108 521
GERMANY 506 286
SPAIN 33 20
FRANCE *
GREECE **
IRELAND 261 43
ITALY 225 151
LUXEMBOURG 1 1
NETHERLANDS 407 184
PORTUGAL 70 40
■ •• • • . '■ ; ' - • •' :
CEC (BAP)*** 245 213
:: :■ *■ ■: -V   :■TOTAL 4,480 1,663
■ : X ■: . . ■: • : «:
■ . : « . V , . .  . .........
'  .
' ; iW .. ' : v: ->r:^
V. \< :• \ . ^  •: : ' / ' ; -
■. , . A  >¿3-. v •> ■ . . . • ■* ■< : ■ NV\ '
* Involved in 46 BAP projects
** Involved in 5 BAP projects
*** BAP:Biotechnology R esearch Program m e
SOURCE: B I O R E P  D A T A B A S E ;  L I B R A R Y  O F  T H E  R O Y A L  A C A D E M Y  O F  
A R T S  A N D  S C I E N C E S ,  ( J A N U A R Y ,  1990)
All data in 1989/1990 are now available on line on the host ECHO. 
Additionally a printed directory is also available.154 Plans to 
develop the starting databases have been formulated and set down 
in a proposal for the Commission of the European Communities 
(period 1991 -93). Such plans include attempts to complete the 
technical and organisational infrastructure and to improve it, where 
necessary. Routines will be developed to guarantee completeness 
of the data and the user-friendliness of the on-line directory will be 
raised. Furthermore, preparations for a new program are being 
made, part of which will include examination for the possibilities for 
extension of the information in order to raise its attractiveness for 
management and biocommerce.155
For a starting database the use of BIOREP is satisfactory and 
makes a significant contribution to bioinformatics for the following 
reasons;
(1) The data have a high intrinsic value. This is indicated by the 
fact the BIOREP, although still far from being up-to-date and 
complete, provided keys for collaboration in formulating 
proposals in the framework of the new BRIDGE
154BIOREP-Permanent Inventory of Biotechnology Research Projects In the 
European Community (Library of the Royal Netherlands Academy of Arts and 
Sciences) (1989)
55Personal communication, confidential source
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biotechnology program of DG XII; people did in fact find 
research which was unknown to them.156
(2) Because biotechnology is multidisciplinary and has
applications in many fields, the potential number of users is
high.
(3) It serves as a welcome addition to the already available 
commercial systems such as BioCommerce Data, BIKE 
(Biotechnology Information Knot for Europe), and a key 
player in the future biotechnology information infrastructure 
for which a strategy has to be developed.
With regard to the gradual awakening of the significance of 
biotechnology by many areas of the European commission, the 
organigram outlined in Figure 14 emphasises the large and
growing number of services that are becoming involved in
biotechnology.
The Single European Act, 1987, has also happened since FAST 
and the 1983 Community Strategy for Biotechnology in Europe. It 
is of major interest to the scientific community. It spells out in very 
"hard-nosed" terms that research is given much more attention in
156Lalieu, 1990
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order to strengthen the scientific basis of Europe’s international 
industrial competitiveness. Article 130F, paragraph 3, expresses 
the connection between R & D effort, the implementation of the 
common market and all other common policies, thus providing 
horizontal cross-linkage (see Figure 15).
Further to these developments with regard to European 
biotechnology, the European Biotechnology Co-Ordination Group 
(EBCG) was created in 1985. It now has about seven national and 
eight sectoral associations. The Senior Advisory Group for 
Biotechnology was since created in June 1989.
The Senior Advisory Group for Biotechnology (SAGB) includes 
members of the European Chemical Industry Federation (ECFI) 
and several of the large multinational companies in Europe, 
including ICI pic, Unilever pic, Sandoz Pharma Ltd., Ferruzi Group, 
Rhone Poulac, Hoechst AG and Monsanto Europe S.A.
The SAGB provides a senior industrial forum for debating policy 
issues affecting biotechnology in the European Community in an 
effort to promote a supportive climate for biotechnology in Europe.
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As with any new and advancing technology, biotechnology raises 
important issues for a broad range of interest groups. Of concern 
to all is protection of humankind and its environment. Secondly, 
the rapid development and spreading use of biotechnology 
inevitably creates important economic and industrial policy issues 
for Europe. The nature of biotechnology is such that social and 
ethical issues also need to be addressed.
The SAGB recognises that the intrinsic nature of the biotechnology 
issue must determine how community policy making is conducted. 
The SAGB outlines priorities and actions for each of the issues 
discussed above.157 It should be noted that the SAGB explicitly 
excludes the modification of the human germ line from its meaning 
of "biotechnology", and confirms that none of its member countries 
is working in that area. The proposals as to how the European 
Community should deal with biotechnology policy issues, 
suggested by the SAGB are discussed as follows:
(1) PROTECTION OF HUMANKIND AND ITS ENVIRONMENT
According to the SAGB this issue requires a community regulatory 
system based on the three scientific criteria of safety, quality and
157SAGB Report, 1990
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efficacy, and objective assessment of the highest possible 
standard. It believes that political involvement must comprise:
* The legislation necessary to establish the appropriate
community-level regulating processes;
* On-going community level review and surveillance to ensure 
effective functioning of these processes.
12) ECONOMIC AND INDUSTRIAL POLICY ISSUES RAISED BY
BIOTECHNOLOGY
The SAGB believes that where these issues are community-wide in 
scope, they must be addressed by the political processes by which 
community citizens decide what is in their common interest, subject 
always to the judicial processes by which the individual’s 
community rights are protected.
(3) SOCIAL AND ETHICAL ISSUES
The SAGB believes that such issues are equally contentious and 
feel that Europe’s processes and institutions are therefore the 
proper venue for debate and resolution.
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According to SAGB members the most immediate European 
Biotechnology policy priority is to ensure that the community’s 
regulatory framework for human and environmental safety is 
science-based, co-ordinated, and not overlapping or contradictory 
and that community regulation does not compromise long term 
European biotechnology competitiveness.
Finally the SAGB promotes broad community-wide debate on 
social and ethical issues relating to biotechnology. Furthermore, its 
members fully encourage broad understanding of scientific 
principles, practices and goals as a basis for responsible choice. 
The SAGB also endorses the decision of member states’ research 
ministers taken in December 1989 to mandate a process of 
continuing debate and reporting on ethical aspects of the 
community-funded program for research on the human genome. 
This may provide an appropriate venue for other issues as well.
More recently a series of Irish initiatives designed to promote 
European Biotechnology research were announced by the Minister 
of State for Science at an international conference on 
biotechnology (Ahlstrom, 1990). These initiatives will be put to the 
Council of Science Ministers in Luxembourg in late 1990. Initiatives 
such as these have resulted from increased recognition of the 
danger of losing key scientists and researchers because of the
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strongly restricted controls being placed on the development of 
biotechnology in Europe.
It has also been suggested that such restrictions also put European 
industry at a competitive disadvantage compared to the US or 
Japanese companies.158
It has been suggested that future European tax revenues derived 
from competitive biotechnology will rise in direct proportion to the 
European added value contained in future products and processes 
of biotechnology. The SAGB indicates that the key generator of tax 
revenue will nevertheless be the downstream industrial and 
commercial activity following on from research and development, 
because R & D is generally accorded tax incentives, precisely to 
encourage the downstream activity in nearby locations.159
Finally, a great deal of European public money in the form of R & D 
support and R & D tax incentives, has and will continue to be 
invested in biotechnology R & D. The only way Europe can 
ultimately reap the future tax dividend from this public investment is 
to develop taxable, downstream industry. Otherwise this public
158Ahlstrom, 1990
159SAGB Report, 1990
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investment will produce no public wealth. The European 
Community objectives for biotechnology in Europe in the 1990s is 
summarised In Figure 16.
The following part of this discussion will focus on the development 
of biotechnology in several European Community member states 
and reflects the on-going commitment, both by governments and 
individual firms to the new technology, despite European 
opposition from several quarters. The countries considered 
include:
* Great Britain
* West Germany
* France
* The Netherlands
* Ireland
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FIGURE 16 BIOTECHNOLOGY I N EUROPE IN THE 1 9 9 0 s
"EUROPEAN COMMUNITY OBJECTIVES
B IO TEC H N O LO G Y  IN  E U R O P E  IN  T H E  1990s: 
COM M UNITY O B JE C T IV E S
O v era ll, c o n tin u in g , lo n g -te rm  goal:
■ THE BENEFICIAL APPLICATION OF BIOTECHNOLOGY TO THE MAINTENANCE 
AND IMPROVEMENT OF HEALTH AND WELLBEING, LOCAL ENVIRONMENTS, 
AND THE GLOBAL ECOSYSTEM
M ajo r p o lic ie s  w ith  sp e c if ic  im p lic a tio n  fo r  b io tech n o lo g y :
■ COMPETITIVENESS AND INNOVATION IN THE BIO-INDUSTRIES, WITH 
PARTICULAR REFERENCE TO THE FORMATION AND GROWTH OF SMALL AND 
MEDIUM-SIZED ENTERPRISES
■ HARMONISED INTERNAL MARKET (REGULATIONS, PATENTS, STANDARDS), 
TAKING INTERNATIONAL DIMENSIONS INTO ACCOUNT
■ R E S E A R C H  (BASIC, PRE-COM PETITIVE AND INFRASTRUCTURE), 
DEVELOPMENT AND TRAINING
■ INTERNATIONAL COLLABORATION (SCIENTIFIC, TECHNOLOGICAL AND 
INDUSTRIAL)
O th e r  c u r r e n t  p r io r i t ie s  fo r  b io tech n o lo g y :
■ E U R O P E A N  B I O T E C H N O L O G Y  I N F O R M A T I O N  P O L I C Y  (FOR 
INFRASTRUCTURE AND COMPETITIVENESS)
■ COMMUNICATION : PUBLIC, CONSUMERS, POLITICAL LEADERS AND 
LEGISLATORS
S o u r c e :  E u r o p e a n  C o m m i s s i o n ,  B r u s s e l s  ( 1 9 9 0 ) .
4.6.4 GREAT BRITAIN
Despite cuts in fundamental research, applied research is receiving 
support from biotechnology programs of several British ministries.
In 1980, A.C.A.R.D., The Advisory Council for Applied Research and 
Development commissioned a report on biotechnology, more 
commonly known as the Spinks Report. The results of this report 
led to the allocation of extra funding toward research facilities and 
the encouragement of collaborative research.
A surprising outcome of this report was the establishment of a 
public sector biotechnology company, Celltech (since privatised). 
This company built up a program based on contract research, 
licensing and product development and is profitable as the world’s 
largest monoclonal antibody producer.
In the early 1980s, the Science and Engineering Research Council 
established a Biotechnology Directorate for the purpose of 
establishing links between academia and industry. It has 
encouraged the cross fertilisation of ideas through a series of 
workshops where groups of companies co-operate in developing 
research of mutual interest by using the skills and expertise of
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researchers in universities or the public sector. Because more than 
one company is involved in each workshop, the research is 
necessarily pre-competitive.
Many of the larger multinational firms have major research facilities 
involved in biotechnology and as a result of British strengths span 
pharmaceuticals (Glaxo, BP, ICI), single cell protein (Shell, BP, ICI) 
and the agrifood field (Shell, Unilever, Rank Hovis, Mac Dougall).
There is also an increasingly strong small firm sector in the UK. 
Celltech is the only British company equivalent in scale and style to 
the more publicised American NBFs. Celltech’s research capability 
is of undoubted weight. The quality of its research team ranks with 
the top one or two scientific institutions in the UK and in the area of 
hybridoma technology at least, with its leading US competitors.160
Monotech IRI, although a subsidiary company, has its origins in the 
initiatives of a group of academic scientists based at British 
universities, to raise industrial money for collaborative research in a 
specific area of hybridoma technology.161
160Fishlock, 1989
1 1  Faulkner, 1986
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The development of UK biotechnology has seen the emergence of 
a number of specialist supply companies to care for the needs of 
the biotechnology firm, just as in the US case.
4.6.5 WEST GERMANY
The federal Republic of Germany has had major public 
expenditures on biotechnology since 1970 by both central and 
regional governments. The intellectual base for biotechnology is 
very strong, with the main centre for research, the Gessellschaft fur 
Biotechnologische Forshung (GBF), renowned for its fermentation 
development and general process technology including
bioreactors.
Government funded agencies such as GBF have helped to 
stimulate early industrial involvement in biotechnology not least by 
their policies of financially supporting products and encouraging 
collaborative research with universities and specialist institutes.
Large corporations such as Hoechst and Bayer have invested 
heavily in biotechnology in the areas of yeast expression systems 
and single cell protein, and waste treatment. Such investment has
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put them in the same league as American corporations Du Pont 
and Monsanto.
However, European opposition to biotechnology is strongest in 
West Germany, where the Green Party seems to view the 
technology with the same reservations as it has towards nuclear 
power. Opponents persuaded the European parliament to impose 
a ban on growth stimulants for beef cattle without even considering 
the evidence of a scientific committee that Euro MPs had 
commissioned.
Furthermore, in Brussels, the European Commissioner for research 
and development blocked a planned £10 million European 
Community participation in the international human genome 
program, in response to the lobbying of West German Green Party 
lobbyists.162
New developments in biotechnology have seen venture capital 
opening up in West Germany, and a number of new small firms 
enter the field. However, restrictive legislation, enacted as a result
162Fishlock, 1989
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of the Green Movement, means that some companies may look 
elsewhere for new R & D activity.163
4.6.6 FRANCE
In 1982, the French socialist government spurred industry Into the 
biotechnology field with its ten year "mobilisation plan". The 
program sought to mobilise both research and commercialisation 
around centres of development and to build on France’s traditional 
strengths i.e. food production and agriculture.
Core teams of institutes and universities were focussed on different 
areas of biotechnology research. For example, the core team to 
research on genetic engineering involved the Pasteur Institute, 
I.N.R.A. Strasbourg based agronomics institute and Inserm, the 
institute for health and medical research.
The programme sought commercialisation to be led by a group of 
core firms and at its inception, the government proposed to invest 
considerable financial support hoping that industry would match 
the investment. Political changes at government level, and cut
163Script, 1988
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backs in public expenditure have caused a reduction in the financial 
input of the program but the strategy remains.
France now has a number of nationalised large firms, such as the 
government-owned oil company Elf-Aquitane and its subsidiary, 
Sarofi, which are now spearheading government efforts in the 
company sector with their interest in biomass energy and 
pharmaceuticals.
4.6.7 THE NETHERLANDS
Although it is a relatively small country, Holland is host to several 
multinationals (Unilever, Phillips, Akzo, Gist - Brocades) and as a 
result, biotechnology revenue comprises 7% of the world’s total.164
National skills include the development of enzymes, yeast and dairy 
product and protein engineering.
In 1983, the M.I.P. Equity fund, a $500 m state funded but privately 
operated venture capital pool was established. This fund has the
1 ^S im pson, 1988
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dual purpose of fostering innovation in areas such as 
biotechnology and making a profit.
Another source of venture capital is provided by Robobank, a 
banking co-operative which has pursued a national biotechnology 
policy which has the dual purpose of making a profit and 
strengthening Dutch agriculture to meet the high technology 
challenges of the next century.
A further asset to Holland’s biotechnology strategy has been its 
Innovation Orientation Program for Biotechnology (IOP-B) which 
brings together Industry initiative, university know-how and 
government subsidies.
However, recent developments have seen Holland’s progress in the 
area of genetic engineering retarded by regulations relating to 
experiments using recombinant DNA (rDNA) techniques.
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4.6.8 IRELAND
An Irish National Biotechnology Programme as initiated in 1983 by 
the then National Board for Science and Technology (now EOLAS) 
and the Industrial Development Authority. The programme’s 
objective is to promote and assist the application of biotechnology 
in Irish Industry, agriculture and other areas of social and economic 
development.
The major areas of application in Ireland are in food & drink and in 
the healthcare / pharmaceutical industries.165
The healthcare and pharmaceutical sector is also important for 
Ireland and has undergone considerable growth in recent years.
As in many other countries, much of Ireland’s expertise in
biotechnology is located in universities and other higher education
colleges and research institutes. Areas of biotechnology expertise
in Ireland include, genetic engineering, diagnostic technology,
speciality chemicals and pharmaceuticals, biopharmacology,
mammalian reproductive technology and plant biotechnology.166
165BioResearch Ireland, 1990;
personal communication 
BioResearch Ireland, 1990 
Personal Communication
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These areas of biotechnology expertise are discussed in this 
section, however, discussion of the biotechnology infrastructure in 
Ireland can be found in Section 6.10.
i l l  GENETIC E N G IN E E R IN G
Research on genetic engineering is conducted in 6 Irish colleges 
but particularly in Trinity College, Dublin and the University Colleges 
of Cork and Galway.
Microbial genetics is the main area of interest at the Department of 
Genetics, Trinity College Dublin, where the research teams has 
performed work for many companies. This group of researchers 
has recently signed a research agreement with the Agricultural 
University of Beijing to jointly clone the gene for Porcine Growth 
Hormone.
Another interesting area in Trinity College Dublin is in vaccines at 
the department of microbiology. Among other projects is one with 
the objective of developing a vaccine for mastitis.
In animal genetics, research is in progress at University College 
Galway, in collaboration with the Agricultural Institute to develop
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transgenic animals including fish. This work is funded by the EEC 
in association with French researchers.
The Dairy Microbiology Department at University College Cork, and 
the Agricultural Institute in Cork, have developed considerable 
expertise in the genetics of dairy starter culture organisms. Strains 
of bacteriophage resistant bacteria developed by this group are 
now used to produce almost all of the 50,000 tonnes of Cheddar 
cheese produced in Ireland. Further work on the genetic 
manipulation of important dairy microorganisms is currently 
underway.
(2) DIAGNOSTIC TECHNOLOGY
Ireland has much expertise in the area of diagnostic technology. 
The close contacts between the biological and clinical scientists in 
Ireland has been an important factor in the development of this 
area of biotechnology.
The major centre for research on diagnostics is ‘«University College 
Galway, where work is ongoing on solid phase immuno-diagnostic 
technology, and on the development of kits for various human and 
animal hormone indicators.
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Veterinary diagnostics is an area of particular interest in Ireland 
because of the country’s large livestock population. Work at 
University College Galway has resulted in the first animal 
progesterone assay to be put on the market.
Ireland has also a very important thoroughbred horse industry. 
Research on behalf of this sector is conducted by the Irish Equine 
Centre, a privately funded organisation, in association with 
university researchers.
This centre is currently researching indicators of stress, for 
example, travel stress, in performance horses with a view to 
developing diagnostic kits for equine health. Diagnostic kits are 
also in preparation in other centres for Epstein Barr Virus, 
Chlamydia and others.
(3) BIOPHARMACOLOGY
Ireland has a large pharmaceutical and healthcare industry. To 
service the needs of the industry, both for technical services and for 
trained staff, Irish colleges ave developed centres of expertise in 
several relevant areas. Of particular interest are development of in- 
vitro tests for pharmaceutical screening and for toxic effects. 
Among the projects in process at the moment are in-vitro assays
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for detection of drug-related specific neural tube defects, for 
example, spina bifida (which has a high incidence in the Irish 
population) and also an assay for assessing efficiency and toxic 
effects of cancer chemotherapeutic drugs.
The developments of novel drug delivery methods employing 
biotechnology techniques are also ongoing in Irish research 
institutes and universities.
(4) MAMMALIAN REPRODUCTIVE PHYSIOLOGY
Ireland is one of the major milk and meat exporting countries in the 
world, and the breeding of sheep and cattle is therefore of great 
importance. Both the universities and the Agricultural Institute 
perform research on many topics of relevance to the breeding and 
production of cattle and other livestock. A topic which is of 
relevance to biotechnology is the area of mammalian reproductive 
physiology.
The research group at University College Dublin was among the 
pioneers of embryo transplantation.
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Work by the UCD group and the associated roup at the Agricultural 
Institute continues on areas such as immunological control of 
reproduction, embryo sex determination, oestrous control and in- 
vitro fertilisation.
(5) PLANT BIOTECHNOLOGY
The major crops of interest to Irish biotechnologists are potato, 
cereals and ornamentals. Ireland has a large seed potato industry 
based on exports to Mediterranean and North African countries. 
The majority of these exports are two varieties which were bred, 
employing biotechnological techniques, at the Agricultural Institute. 
Forestry research focuses on the use of mycorrhizae to assist the 
reafforestation of Ireland’s marginal lands at UCD.
4.7 SPECIFIC ISSUES RELATED TO 
BIOTECHNOLOGY
This section examines a number of issues that arise when one 
considers biotechnology as a means towards innovation.
189
Issues such as public attitudes and acceptance of biotechnology, 
the financing of biotechnology research and development and the 
protection of intellectual property arising from biotechnology 
developments (especially patenting and trade secret law), have 
proven to be significant in the overall development of the global 
biotechnology industry.
Each of the above issues is discussed separately in the following 
subsections.
4.7.1 PUBLIC ATTITUDES AND ACCEPTANCE 
OF BIOTECHNOLOGY
Section 5.2 indicates that the successful diffusion of new 
technologies is conditioned by a number of factors, amongst which 
are societal and environmental acceptability. The microelectronics 
based information revolution satisfied the criteria of societal and 
environmental acceptability, whereas nuclear power encountered 
increasing difficulties, which largely explains why its diffusion has 
come to a halt in many countries. Public acceptance of new 
biotechnology, or public confidence in it, has emerged as a central 
factor in the diffusion of this technology.
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IThe human and social Impacts of biotechnology are pervasive and 
in this sense biotechnology is clearly not comparable with 
microelectronics, for example, which has few direct environmental 
or health impacts. Furthermore, just as the pressure of public 
opinion has reduced nuclear power developments, one might 
question whether certain applications of biotechnology will not 
encounter similar obstacles.
If biotechnology, as a broad generic technology, is not comparable 
to microelectronics, it is even less comparable to nuclear power, 
and it is important to understand why. Three main characteristics 
separate biotechnology from the controversial new energy 
technology, nuclear power.
* Nuclear power consists of a small number of core 
technologies (reactor, fuel, waste disposal), these core 
technologies are closely linked so that the failure of non- 
acceptibility of any of them could lead to the abandonment 
of the entire industry. Compared to nuclear power, 
biotechnology has a great versatility, covering a wide range 
of technologies derived from and relevant to every form of 
life, from microorganisms to wo/man. Thus, holding up one 
development of this multidisciplinary technology does not 
necessarily put a stop to "biotechnology" on the whole. On
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the contrary it has been suggested that such a delay of 
progress in certain areas may accelerate other 
developments. For example, temporary difficulties with the 
introduction of genetically modified microorganisms into the 
environment are said to have accelerated plant research, 
and may help explain a recent increase in the number of 
plants submitted to regulatory authorities for approval.167
* In the context of nuclear power generation technologies, the 
terms "health impacts" or "environment impacts" have clearly 
negative connotations. Societal acceptance of such 
technologies became more difficult when it appeared that 
they would have undesirable health and environmental 
impacts. In contrast, biotechnologies have the potential to 
address hitherto unsolvable health and environmental 
problems and to replace other, potentially harmful 
technologies. Thus, even if the concerns about possibly 
detrimental side-effects of some biotechnologies are 
justified, and whether they are is not discussed in the scope 
of this study, it has never been denied that numerous 
biotechnology developments will effectively reduce risks and 
have beneficial health and environmental impacts.
167OECD, 1989
192
* A third feature of biotechnology, which could be decisive for 
its ultimate acceptance by society, is that the discussion on 
the risks and benefits associated with the technology, began 
earlier than in the case of any other 20th century technology 
and before new products or processes existed. 
Contrary to what occurred in nuclear, information and other 
industries, this debate, focussing mainly on the new genetic 
engineering methods, has helped to shape the direction and 
rate of scientific and technical change from the very 
beginning, and before the first large industrial investments 
were made.168 Table 9 selects a number of key events in 
the US where the main safety and regulatory discussions as 
well as many of the scientific and technical successes have 
occurred. It should be noted that the events listed in the two 
columns of Table 9 bear little or no relations to one another, 
but the lists show that, in the early stages, safety and 
regulation considerations have preceded scientific and 
technical developments by several years.
The discussions on safety risks and benefits, and public 
acceptance have lasted fifteen years. For the sake of greater 
clarity, it has been proposed to distinguish between issues related
168OECD, 1989
193
Table 9: A Selection of Key Events in Biotechnology
Research and Innovation Safety and Regulations
1977: First successful genetic ma­
nipulation (Cohen-Boyer)
1978: First successful Expression of 
Insulin in rDNA Microorganisms 
(US)
1982: First production of Human 
Insulin by Microorganisms (US)
1982: First Gene Transfer in Mam­
mals ("Supermouse") (US)
1982: First, unsuccessful Gene 
Tra»sfer in Man (Italy, Israel)
1986: First Release of rDNA plants 
(US)
1987: First Release of rDNA mi- 
cro-organisms into the environ­
ment (US)
1973: Letter of Prof. Paul Berg to 
National Academy of Sciences 
warning of rDNA risks (US)
1974: Asilomar Science Conference
I decides Moratorium for rDNA 
experiments (US)
1975: Asilomar Science Conference
II lifts Moratorium (US)
1976: First rDNA Safetey Regula­
tions / Guidelines (NIH, US)
1985: Columbia District Court 
prohibits release of microorganisms 
into the Environment (US)
1986: US Court of Appeal over­
turns Columbia District Court
decision (US)
1986: First inetmational Guidelines 
on rDNA Safety considerations, 
Paris, OECD, adopted by the 
OECD council.
Source: OECD, 1989 "Biotechnology - Economic and Wider Inpacts"; OECD Report, 
Paris, 1989
to the "acceptability", and those related to the "acceptance" of 
biotechnology.169
Acceptability derives from rational, scientific evaluation of 
biotechnology, mainly rDNA safety issues which, however, does not 
exclude rational dispute when different weight is given to external 
social or economic criteria.
Acceptance is the reaction of the public rooted in a large number of 
motifs, including emotional ones. In cases where the public has 
shown concern about a technology, scientific acceptability is a 
necessary, but not sufficient condition of acceptance. Furthermore 
it has been suggested that when a gap between acceptability and 
acceptance appears, it will be a goal of public policies to attempt to 
close it.170
Both acceptability and acceptance affect the diffusion of
biotechnology. For example, a biotechnology company developed
a new diagnostic test to detect the virus for cervical cancer but
feared that the relevant drug authorities would not approve it.171
This meant that the company anticipated a problem with the
acceptability of the innovation.
169Heusler, 1986
170OECD, 1989
171 OECD, 1989
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A major food company developed a new rDNA based yogurt that 
was not only economical, but satisfied ail its country’s safety and 
health criteria, yet decided not to market it out of concern that 
journalists might quote this innovation in a misleading headline172.
This company foresaw problems with the public acceptance of its 
products.
Experts believe that more research is necessary to develop risk 
assessment in biotechnology, particularly to analyse both the 
probability and scale of conjectural accidents in comparison to 
other technologies. Thus, expert discussions on risks, safety and 
acceptability will probably continue as long as techniques relevant 
to biotechnology advance and multiply. However, the fact that 
these discussions began comparatively early has already had three 
major effects:
1) Biotechnology laboratories and industry have been 
encouraged to choose low-risk microorganisms.
2) A public institutional framework to review and if necessary 
supervise new biotechnology processes and/or products
172OECD, 1989
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has been put in place in most, if not all, OECD countries with 
biotechnology laboratories and industries.
3) A strong movement towards international harmonisation of 
rDNA-safety criteria has begun within and beyond the OECD 
area, guided by OECD work. This harmonisation will 
facilitate the international diffusion of a technology which 
depends so heavily on global markets.
Fears about the potential impact on the environment should novel 
"man-made" organisms be released or accidentally escape has led 
to calls for higher controls on the technology within the European 
community.
In 1988, three organisations decided to make their own start on 
involving the general European public in a debate on 
biotechnology. The organisations involved included ERICA 
(European Research into Consumer Affairs) an independent 
research organisation set up to study consumer questions in the 
European Community; The European Foundation for the 
Improvement of Living and Working Conditions, a research 
foundation of the EC located in Dublin; and CUBE (Concentration
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Unit for biotechnology in Europe), a team in the Directorate General 
XII, Science, Research and Development of the EC Commission.
The above organisations held a workshop in Brussels (1989), the 
first of its kind in relation to the subject of biotechnology. The 
workshop entitled "Consumers and Biotechnology" involved 
participants of all the EC member states, except Luxembourg and 
Greece, and included scientists, industrialist, trade unionists, press 
, radio, tv journalists and leading members of consumer and 
environmental organisations.
The EC Commission, after studying the laws of all its member 
states, has made proposals for several directives related to the 
regulation of biotechnology. Three of these directives related to the 
use of genetically engineered organisms and silage additives, have 
been approved by the Council of Ministers of the 12 member states 
(1990). The status of all proposed EC directives relating to the 
regulation of biotechnology are shown in Table 10.
The community under the Irish presidency in 1990, introduced two 
new directives setting strict controls on biotechnology in European 
industry. At present there are moves to add a "fourth criterion" to
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Table 10: Status o f EC Directives on Biotechnology 
Regulation (July 1990)
EC Directive / Regulation D.G. Status
* Intellectual Property Protection Ill Draft
* Food Labelling III Draft
* Harmonisation III Draft
*New Foods IV Draft
* Protection of Workers V Draft
* Plant Breeder's Rights VI Draft
* Plant Protection VI Draft
* Marketing Ornamental Plants VI Draft
* Marketing Transgenic Plants VI Draft
* Marketing Transgenic Animals VI Draft
* Silage Additives VI Approved
* BST (Bovinesomatotrophin) VI Draft
* Productivity Enhancers VI Draft
* Transport of Biological Materials VII Draft
* Contained Use of GMO's IX Approved
* Deliberate Release of GMO's IX Approved
(GMO=Genetically Modified Organisms)
Source: EC Commission (1990), Brussels.
Personal Communication
the existing regulatory criteria of safety, efficacy and quality, that of 
socio-economic need.173
Many researchers believe the "fourth criterion" to the existing 
regulatory criteria would bring an end to much biotechnology 
research and industrial projects it generates. It is also suggested 
that this fourth regulatory criterion would add a new and complex 
subjectivity to the development of science.
The pro-biotechnology argument raised by many researchers in the 
field is that biotechnology has, in fact, the potential to improve the 
environment through, for example reducing pesticide use by 
developing pest-resistant plants.
Furthermore, powerful industrial groups investing in biotechnology 
research in the US, Europe and Japan object to any restraints on 
the introduction of biotechnology products including the Senior 
Advisory Group on Biotechnology in Europe (SAGB).
These groups employ the simple logic that there will be no market 
for dubious products, and so, manufacturers will not bother 
supplying them.174 However, this logic does not consider whether
173Ahlstrom, 1990b
174Ahlstrom, 1990b
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or not the ultimate consumer is capable of deciding what is and 
what is not a "dubious product". Thus effective safeguards to 
protect humankind and its environment, including restraints on the 
introduction of biotechnology products, where required, are 
essential for the protection of both humankind, and its environment.
The current situation with regard to biotechnology regulation in 
Ireland is discussed in greater detail in Section 6.10.4.
4.7.1.1 PUBLIC CONCERN
Public concern and confidence in biotechnology products and 
processes can have a significant impact on commercialisation. 
There are real fears, particularly in West Germany (see Section 
4.6.5), Scandinavia and The Netherlands, that biotechnology is 
likely to open up a "Pandora’s Box" of mutant strains onto the 
environment. At the other extreme, there seems to be a cultural 
acceptance of biotechnology and its products in Japan with 
colours, enzymes and various additives produced from 
biotechnology finding use in for example, foodstuffs, for example, a 
biotechnology wine called "Fusion Bio A".175
175Smith, 1988
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Compared to the scientific "acceptability" of biotechnology, it is 
much more difficult to assess and summarise "acceptance", 
because the public has understood the term biotechnology in 
various ways, and also because there are large international 
differences in public acceptance as discussed above.
These differences in public acceptance are deeply rooted in 
national traditions related to food, medicine, and health, which 
explains why they are changing only very slowly and why different 
countries do not seem to strongly influence each other.
In contrast to the scientific assessment of rDNA Safety, there has 
been little or no international convergence of public attitudes 
towards biotechnology, neither in a favourable or unfavourable 
direction. An opinion survey conducted in 1979 indicated wide 
variations between popular attitudes in European countries towards 
genetic research and R & D on synthetic food.176 For example, 
61% of the interviewed people in Denmark thought genetic 
research to be "unacceptably risky" while the corresponding figure 
for Italy was 22%.
Not enough is known about the wide and diverse social and 
cultural roots of attitudes towards biotechnologies, and why they
1760ffice of Technology Assessment (OTA), 1984
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vary so widely. Understanding public attitudes is important for 
policy formulation and perhaps even for predicting future trends. In 
fact, Denmark has subsequently (1988) been in the forefront of 
legislative initiatives constraining genetic engineering, while of all 
EC countries, Italy has given least effect to the 1982 EEC Council 
Recommendation on the registration of rDNA research.
Unfortunately, surveys of public attitudes are infrequent and often 
not comparable between countries. Regular and internationally 
comparable surveys of professional quality would be very helpful to 
policy makers and to industry.
4.7.1.2 PUBLIC ATTITUDES TO 
BIOTECHNOLOGY IN IRELAND
In recognition of the importance in understanding public attitudes 
to biotechnology for policy formulation and predicting future trends, 
research is currently being carried out in Ireland. Bioresearch 
Ireland, a contract research organisation set up under the National 
Biotechnology Programme for Ireland (see also Section 6.10) has
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Icommissioned opinion surveys on public attitudes to biotechnology 
in Ireland.177
From preliminary opinion surveys, as part of this research, it is 
revealed, that in general Irish adults have a very limited 
spontaneous understanding of biotechnology. Interestingly, men 
tend to have a slightly greater knowledge of the topic than do 
women. The extent of knowledge is also slightly higher among 25- 
34 year olds. Furthermore, levels of awareness concerning 
biotechnology vary depending on social-class, with those from 
upper-middle-class backgrounds being most informed about the 
technology. With regard to attitudes to biotechnology, overall 
public opinion tends to be more positive than negative, with 
younger people expressing the most positive attitude.
Although this research must be treated with caution in generalising 
public opinion to Biotechnology in Ireland, it is a progressive step in 
assessing the level of awareness and public opinions of the 
technology in Ireland and hopefully further research in this area will 
illuminate the issue further and probably serve as useful information 
for companies developing biotechnology products and the Irish 
government in formulating policies with regard to the technology.
177Bioresearch Ireland, 1989 (Personnel Communication)
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TABLE 11
PUBLIC ATTITUDES TO BIOTECHNOLOGY IN  IRELAND  
N  =  1401 (AGED 15+)
/'I'l Understanding the term "biotechnology" is very limited amongst Irish 
adults: only one in four have any spontaneous knowledge of the topic.
(2) Over half of all adults have never heard of biotechnology. A  further 
third have heard of it but know nothing about it. Only one in ten Irish 
adults feel they know anything about biotechnology, when asked about 
the extent of their knowledge regarding the area.
The chemical industry is most commonly associate with biotechnology, 
mentioned by one in six adults. Agriculture and biology achieved the 
next highest levels of association.
(4) Overall public opinion regarding biotechnology in Ireland at present
tends to be more positive than negative. It would appear that the more 
knowledgeable the people are about the area, the more positive their 
outlook. To a limited extent, the public recognise that biotechnology 
will play a more important role in the future in Ireland than it does at 
present.
(5) Agriculture and health are seen to be the areas on which biotechnology 
will impact most in the future, with agriculture being the most 
prominently mentioned.
SOURCE: "Attitudes to Biotechnology", Decem ber 1989.
Study prepared for Bioresearch Ireland Ltd 
by Landsdowne Market Research Ltd., 
Dublin
The principle findings of a preliminary opinion survey on public 
attitudes to biotechnology in Ireland are listed in Table 11.
4.7.1.3 GOVERNMENT AND INDUSTRY 
RESPONSES TO PUBLIC ATTITUDES TO 
BIOTECHNOLOGY
While national differences may be difficult to interpret, it has in 
general not been too difficult to understand what the public’s main 
concerns are with regard to biotechnology. The following are most 
often mentioned;178
* Ethical concerns about genetic modifications in general or
more particularly in humans;
* Safety concerns about health, and about the introduction of
modified organisms into the environment;
* Concerns about the alleged, radical novelty of
biotechnology, or about its alleged unpredictability or
irreversibility;
178OECD, 1989
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* Concerns about negative employment impacts.
However, these concerns are often found mixed up with issues of 
health and life which have no direct link with biotechnology, such as 
in-vitro fertilisation.179
Governments, parliaments and in some countries, industry have 
paid exceptional attention to public acceptance, and public fears. 
Some reviews of public opinion have been conducted, as indicated 
in Section 4.7.1.1, and numerous, often extensive debates have 
taken place in national parliaments.
The single most persistent response of governments to cope with 
the confusion between biotechnology and medical ethics in the 
public’s mind, has been to keep debates and committees on 
human genetics or medical ethics strictly separate from those 
which review gene technologies for scientific and commercial 
applications.
Apart from this it can be said that public authorities and industry 
have shown a remarkable degree of innovation developing a wide 
range of responses to address public concerns.
179OECD, 1989
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Amongst the main responses, some of which have also been used 
in combination, are the use of communication techniques 
(information campaigns’180, books, industry visits, poster 
campaigns) to demystify biotechnology by improving information 
for the public. Public participation in safety assessment such as the 
UK’s Advisory Committee for Genetic Manipulation (ACGM) where 
trade union representatives and members of the public sit side by 
side with industry and government representatives.
However, what people need is more trust in biotechnology risk- 
management, in the credibility of those who inform them, and in the 
willingness of governments and industry to abandon projects when 
risks become more important than benefits.
4.7.2 FINANCE
The use of biotechnology as a tool towards new product
development can present extra problems in terms of financing. As
with all innovation, the financial questions of profitability, level of
uncertainty and cash flow are raised.
1 fin
Including the current Biotechnology Information Campaign in Schools in 
Ireland, conducted by BioResearch Ireland in conjunction with the Department 
of Education.
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Biotechnology research and development presents additional risks 
in that it is research-intensive high technology, and many projects 
may be long term. Cash flow problems can present themselves if 
the firm is small, the extreme case being an innovative start-up, and 
the level of investment required is proportionally large in relation to 
the total resources of the firm or entrepreneur.
Figure 17 presents a model of cumulative cash-flow of the typical 
firm in the course of innovation.181 The costs of the various 
development stages vary. The product development stage 
represents a critical point because of the escalation in level of 
investment required. The investment of both time and money 
increases proportionally with the technical complexity of the new 
product or process. Quinn (1985) however, has shown that in spite 
of spiralling investment costs, many of the large innovative 
companies have parallel prototype programmes, so that if one 
prototype proves to be inappropriate another can be invoked.
The duration from the R & D through to commercialisation can vary 
significantly depending on the area of research. Monoclonal 
antibodies have opened up a whole new field of diagnostic testing 
and because of less regulation provide good opportunities for cash
181Twiss, 1980
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flow while therapeutic products with inherent regulation delays 
require long term investments.
Financing is central to the growth and commercial reality of 
biotechnology. According to Burrill (1986), the maxim that a 
company’s business strategy dictates its financing strategy does 
not hold for biotechnology in the US. Instead, the financial strategy 
adopted by a firm drives the business strategy and in turn the kind 
of products it produces, determining the length of time a product 
could remain in development and thus the ultimate profitability of 
the product.
Various methods of financing are discussed addressing this issue.
In the case of Public Financing the public company must project 
steady earnings, growth and consistently improved results to 
support shareholder confidence and thus safeguard the public 
market as a source of future finance. Therefore, the biotechnology 
company seeking public financing through the equity markets will 
require a number of short term relatively uncomplicated products 
that can be quickly commercialised, generate profits and initiate a 
history of stable growth. However, the corollary to a short 
development time is usually a short product life, and smaller profits.
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Generally, an early stage financing source is Private Financing. 
Private equity investors are prepared for the high risk investment, 
anticipating and understanding the fluctuations of developing 
companies. In the case of biotechnology, private financing is ideal 
for the development of major therapeutic products. The rewards of 
long term projects are exemplified by the American company 
Genentech’s tissue plasminogen product. Activasetm which, when 
it finally made it through F.D.A. regulations to the marketplace, 
generated $58 million in revenues in its first 45 day of sales.182
Debt Financing is not usually feasible for startups since credit­
worthiness is based upon tangible assets and not on the long term 
potential of the firm. Furthermore, it is not recommended for 
companies still in the R & D phases because the loan must be 
serviced immediately, detracting from funds that would otherwise 
be available for research and development.
Like a public company, the firm must develop products it can bring 
to the market quickly or it must have established products that can 
provide servicing the debt.
The source of the Venture Capital firm’s funds will dictate whether it 
is suitable for a biotechnology company’s needs.
182Burill, 1988
208
Limited partnerships have fixed lives and as such are only 
interested in companies exhibiting potential for growth in the short 
term. Because management surrenders large portions of equity in 
return for a venture capital infusion, owners of biotechnology 
companies should be sure that the venture investor shares the 
same goals.
More long term investments are also made by venture capitalists 
and this form may be suitable for biotechnology startups, or those 
working on products which are long term to market. The 
development of the Irish venture capital industry in Ireland is 
discussed further in Section 6.1.1.
In a symbiotic Corporate Partnership the smaller company usually 
benefits through access to corporate capital resources and sales 
and marketing channels which the larger company benefits by 
tapping into the new and evolving technologies. Prior to such 
alliances, the smaller high technology company should seek an 
agreement on product development goals, otherwise corporate 
purse strings will dictate which direction it goes.
Furthermore, if a biotechnology company can wait and prove the 
value of its product under development before entering a strategic 
agreement, then it can dictate more favourable terms for itself, from
209
the commercialisation of a product. Such a tactic would be 
beneficial if delays in the R & D costs could blunt a company’s 
competitive edge. Either way, Burill (1988) has stated that,
... strategic linkages are emerging as one o f the most 
important financing tools biotechnology companies can use.
4.7.3 INTELLECTUAL PROPERTY PROTECTION
COMMERCIAL ASPECTS OF THE PATENT SYSTEM
Intellectual property generally encompasses patent, trade marks, 
designs, copyright, and know-how. The term "industrial" property is 
also used but it is not as appropriate. One cannot over-emphasise 
the importance of intellectual property.
Patents are monopolies for the protection of inventions, that is 
original processes and products. The monopoly is granted by the 
state, in return for the disclosure of the invention. Designs relate to 
the aesthetic appearance of the articles while copyright, so far as it 
affects scientists and engineers in their industrial applications 
relates to the protection from copying drawings.
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Know-how is industrially useful knowledge which is available to 
allow a process to be performed or products to be produced. It is 
often referred to as "Trade Secrets". Trade marks are words or 
logos used to identify one trader’s product from another trader’s 
and thus to protect business good will.
This discussion focuses on intellectual property as it relates to 
biotechnology and therefore focuses on patenting and trade secret 
protection.
Standard patenting gives its owner the right to take legal action 
against others exploiting his/her invention without consent. In 
return for such protection, a patentee is legally bound to provide full 
technical details of the novel product or process. The full technical 
details are then published , or otherwise made publicly available by 
each of the patenting authorities to which applications have been 
made for protection.
The stage at which publication occurs varies with the country. It 
should be noted that in granting a patent, society allows the 
inventor to control the commercial exploitation of the invention for a 
limited time only. In most industrialised countries, the patent term 
provided by law ranges from sixteen to twenty years. The patent 
term allows time for product development and a subsequent sales
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period during which the costs of research and development can be 
recovered.
Payne (1988) defines trade secrets as
commercially valuable information that is not widely known to competitors, thereby giving it owners a competitive advantage.
In the event of misuse by a former employee or competitor the 
owner of the proprietary information may be entitled to an 
immediate injunction, compensation damages and reimbursement 
for legal fees.
Trade secret law offers protection to innovators during the R & D 
stage prior to patent application, pending patent approval or in the 
event of a patent application being rejected.
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4.7.3.1 PATENT PROTECTION IN 
BIOTECHNOLOGY
Modern biotechnology has depended, from its beginning, upon an 
appropriate legal framework. This is the first case in history where 
the law has come to play a dominant role in the very emergence of 
a new technology. Among various legal issues, those relating to 
patenting have remained a reason of concern for governments and 
industry alike.
The "Chakrabarty Decision" of 1980, when the United States’ 
Supreme Court ruled that a man-made, oil-eating micro-organism 
developed for industry was patentable under US law, has freed the 
discussion on patent protection in biotechnology from doubts, as 
far as microorganisms are concerned. The principle of patenting 
industrially useful microorganisms is now widely accepted 
throughout the OECD area.
The crucial importance of this and other court decisions to grant 
patents to new biotechnology inventions was, in its time, hailed as a 
breakthrough in the history of modern biotechnology. In many 
countries, law-makers and judges have recognised that the new 
biotechnology, often derived from genetic modification,
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represented a great novelty due to human Ingenuity, and a 
departure from past practice, and hence deserved a change or 
reinterpretation of law or legal practice, which is not easily granted.
Thus while the need to reassure a worried public has led policy 
makers to emphasise the old roots and safe traditions of 
biotechnology (see Section 4.7.1.1 )r the need to improve patent 
protection has also led to greater emphasis on the scientific and 
technical novelty of the new inventions.
Biotechnology is a particularly good example of the patent 
questions raised by rapid scientific and technological change. 
Change leads to problems of legal adaptation, particularly when the 
law is embedded in international treaties which can be changed 
only with the approval of a large majority of its signatories. The 
latest important international legal conventions relevant to 
biotechnology, (International Convention for the Protection of New 
Varieties of Plants, 1961; Strasbourg Convention, 1963; European 
Patent Convention, 1973) were discussed and ratified before the 
spread of the new biotechnology innovations, especially those of 
genetic engineering and therefore do not take them into account.
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Three is no technology where patent laws vary so widely, and on so 
many points as they do in biotechnology. New technical and 
ethical questions are raised by the fact that biotechnology uses 
living organisms as production tools. Contrary to all other 
inventions, public disclosure of a new organism may defy 
description by scientific formulae and words. It is also important to 
remember that both government and industry serve as major 
sources of funding or biotechnology research carried out at public 
institutions. The patent system makes it possible to establish a 
proprietary position for the results of this research without 
unnecessarily delaying the researcher’s transmission of these 
results to the research community as a whole. Once the position is 
established, a company can invest time and money in turning the 
innovation into a product, and the license fees paid by industry on 
the resulting products provide the public institutions with support 
for further research. Failure to provide adequate unambiguous 
patent protection will have a significant impact on both the future of 
biotechnology research as well as the resultant diversity of 
products coming from the private sector.
As stated in Section 4.6 national patent laws differ, however, the US 
law and Japanese law, are on the whole, more open and flexible to 
new developments in biotechnology, than are the laws of other 
OECD countries. It is worth mentioning three critical differences in
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terms of patent protection relating to biotechnology because of the
detrimental effects of European law:
(1) Grace periods exist in the national laws of the US, Japan and 
Canada. These grace periods allow scientists to submit, 
within a certain time limit, a patent claim on invention, even if 
they have already disclosed it in scientific publications or n 
any other way that would contravene the "novelty" 
requirement of patent law. These make patent law more 
compatible with the habits of the academic scientists, whose 
impulse is to publish their findings without forfeiting patent 
rights.
There is a widespread conviction in industry and universities 
that the importance of the academic contribution to the 
development of biotechnology will make the introduction of 
an internationally recognised grace period of six months , if 
not a year, more and more necessary. However, this 
proposal has met with strong opposition because, amongst 
other reasons, it would require a modification of the 
European Patent Convention (EPC).
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(2) The European Patent Convention places an absolute ban on 
patenting new plant and animal varieties, and also new 
breeding methods. In contrast, the US patent law provides 
for the patenting of new plant varieties, however the law for 
the protection of higher organisms has yet to be decided in 
the courts, although it does allow for the protection of animal 
breeding processes.
(3) The practice of depositing microorganisms in culture 
collections for the purpose of patent application is now 
widely established to fulfil the needs of public disclosure. 
However the European system involves the re-release of 
deposited microorganisms to the public with the first 
publication of the patent application, that is, before the 
depositor knows whether the patent claim will be accepted. 
This may lead to the "unfair" situation where the "public" 
could commercially exploit a deposited microorganism until 
a patent is granted, which could take several years 
depending on the country. In contrast, however, the US and 
Japanese systems release the microorganisms only when 
the patent is granted.
According to Coleman (1988), should the less favourable European 
system encourage European firms to file for patents under US
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patent laws, then they might be in for a shock. The US Patent and 
Trademark Office will award a patent to the first inventor, but in 
doing so it will consider only "invention activity" that takes place in 
the US.
This problem potentially affects every US patent sought by 
biotechnology companies performing research abroad and is most 
acute in those areas where many competitors are simultaneously 
conducting novel, "state of the art" research. This problem could 
possibly help explain the lack of investment of American 
biotechnology companies in Europe (see Table 2).
There are other components of patent protection particular to 
biotechnology which have been found unsatisfactory. The lifetime 
or term of patents is one such component. This patent term/period 
may not be long enough for innovative companies to recover their 
investment in R & D, as most companies are compelled to apply for 
parent protection as soon as research results confirm that the 
invention is successful. After this a significant time period is 
required for further testing and approval before the innovative 
company is in a position to recover R & D investments. Also, 
protracted patenting procedures for biotechnology innovations 
further erode the normal 16-20 years life-span of patents.
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It would seem appropriate therefore for legislators to establish a 
more market effective patent life in fields such as biotechnology, 
where product development and registration approval take up such 
a large part of the patent life.
The rising wave of oppositions, as in the case of Wellcomes’s 
successful challenging of a patent granted to the US biotechnology 
company Genentech, relating to techniques of tissue plasminogen 
activator (tPA) production, a therapeutic substance for heart attack 
victims, will no doubt eventually lead to clearer guidance on the 
nature and extent of biotechnology products.183184
4.7.3.2 TRADE SECRET LAW IN 
BIOTECHNOLOGY
Trade secret law is beginning to emerge as a vital aspect of 
biotechnology development. As stated already in Section 4.7.3, 
trade secrets are commercially valuable information that is not 
widely known by competitors, thereby giving its owner a 
competitive advantage.
183Fishlock, 1988
184Marsh, 1987
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Trade secret law offers protection to innovators in biotechnology 
during R & D stage prior to patent application, pending patent 
approval or in the event of a patent application being rejected.
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CHAPTER 5: 
ECONOMIC IMPACTS 
OF BIOTECHNOLOGY
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5.1 INTRODUCTION
This section of the present thesis discusses the future diffusion of 
biotechnology through the economy, in particular, the probable 
time-scales and consequences. Parallels are drawn with the 
diffusion of the electronic computer and of electric power. This 
section also discusses biotechnology as a "techno-economic 
paradigm" (referred to in Section 2) accompanied by many 
potential changes, including structural adjustments in the sectors 
affected by the technology. Finally, the section reviews prospective 
employment impacts of biotechnology.
5.2 DIFFUSION OF BIOTECHNOLOGY 
THROUGH THE ECONOMY: THE TIME SCALE
It has been shown that modern biotechnology is opening up 
innumerable exciting new possibilities which may dramatically affect 
society over the next century, (see section 4.5).
Some of these developments are already finding commercial 
exploitation, especially in the fields of healthcare and agriculture.
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But the results of previous research185 coupled with the results of 
interviews with Irish companies operating in biotechnology (as part 
of present study), suggest that we are still only in the early stages 
of the full scale application of this revolutionary new technology. 
This section discusses the problems of diffusion of the technology 
through the economy as a whole and considers the probable time- 
scale of this diffusion process and the resulting consequences.
Comparisons are made with other pervasive technologies which 
have had very widespread economic consequences in the past, 
such as the introduction of electric power and more recently 
computer technology and micro-electronics. In making such 
comparisons it is extremely important to take into account of the 
differences as well as the similarities between the various generic 
technologies which have impacted on industrial society.
However, although the unique features of modern biotechnology 
and its distinct areas of application must always be kept in mind, 
there are useful lessons which can be learnt from earlier 
technological change which had very widespread economic and 
social consequences.
185OECD, 1989
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It is evident, for example, that a transformation of the technologies 
in use in many sectors of the economy must lead on the one hand 
to large-scale investment in new types of plant and equipment and 
on the other hand to a change in the skill profile of the labour force.
From the past experience of the introduction and diffusion of such 
revolutionary new technologies it is still clear that the changes they 
exert are realised over decades rather than years or months. The 
recognition of the relatively long time scale involved in diffusion is 
extremely important as it can avert two dangers which might 
otherwise have adverse policy consequences both at Government 
and industrial levels.
First is the danger of "technological super optimism", which tends 
to ignore the hard economic realities of relative costs, profitability 
and size and consumer acceptance of entirely new products. 
Second is the danger of "technological conservatism" which fails to 
recognise the enormous long-term potential of generic 
technologies for the ultimate development of an entirely new range 
of products or services. The first can lead to serious under­
estimation of the time-scale involved in diffusion processes, the 
second to equally serious errors of under-estimation of the potential 
of long term transformation186.
186OECD, 1989
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5.3 THE ANALOGY OF THE ELECTRONIC 
COMPUTER
The example of electronic computer technology illustrates the 
general problem scale and timing of a new technology. This 
example is cited because (at least until the advent of 
biotechnology) it is probably the best known example of a 
pervasive technology in the second half of the 20th Century. 
Moreover, it is one which is well documented and which is generally 
agreed to be of extraordinary importance for all OECD Member 
countries187.
With the first application of the electronic computer during and just 
after the Second World War it was realised that this new technology 
had an enormous potential for transforming industrial processes, 
office systems and records and communication systems. However, 
opinions differed sharply on the probable time scale and the extent 
of these developments.
Some scientists and engineers anticipated very rapid and large- 
scale applications with immense social consequences, (including 
large scale unemployment), already in the 1950s and 1960s. On
187OECD, 1989
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the other hand, it was well established that such a well-informed 
leader as Thomas J. Watson (Senior) did not believe, even in the 
early 1950s that there would be any big commercial market for 
electronic computers:
He felt that the one SSEC machine which was on display at 
IBM’s New York offices could solve all the scientific 
problems in the world involving scientific calculations. He 
saw no commercial possibilities. This view, moreover, 
persisted even though some of private firms that were 
potential users of computers - the major life insurance 
companies, telecommunications providers, aircraft 
manufacturers and others were reasonably informed about 
the emergina technology. A broad business need was not 
apparent. Q*
It was not until the Korean war that IBM was persuaded to 
undertake production of a small batch of electronic computers and 
even then it was only with a change of management that they 
entered the commercial market. As against this conservative view 
of a very limited market for computers, imaginative scientists like 
Norbert Weiner (1949) envisaged a huge scale of applications and 
forecast large scale unemployment as a result.
A much more balanced view of the probable time-scale and social 
consequences of the diffusion of the electronic computer was taken 
up by one of the most imaginative and authoritative consultants in 
this field, John Diebold. In his book "Automation: The Advent of the
188Katz and Phillips, 1982
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Automatic Factory"189, the author showed remarkable foresight and 
depth of understanding of the problems involved.
While recognising the enormous potential of the electronic 
computer for the transformation of all industrial and office 
processes, he saw quite clearly that this would be a matter of 
several decades and not a few years. Indeed, most of the "factory 
automation" which is today described as "FMS" (Flexible 
Manufacturing Systems) or "CIM" (Computer Integrated 
Manufacturing) did not show a really rapid take-off until the 1980s 
event though most of the technical innovations which come under 
this heading were clearly seen by Diebold in 1952. The 
"automation" of the 1950s was really a kind of advanced 
mechanisation, mainly in the automobile industry, rather than 
computerisation.190
Diebold stressed several reasons for believing the diffusion process 
would be much slower than many computer enthusiasts imagined 
at the time. The most important of these were as follows:
(1) True computerised "automation" would involve the redesign 
of all industrial processes and products. It would be quite
189Diebold, 1952
190OECD, 1989
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impossible to achieve this in a short period. The simple 
availability of computers was only the first step. An 
enormous amount of R + D, design and new investment in 
machinery and instruments would be needed in every 
branch of industry.
(2) Such a process of redesign would affect both products and 
processes. Diebold gave examples to show that this could 
only occur if there was a change in the structure and 
organisation of firms, as well as in the attitude of 
management. This change would involve much closer 
integration of R & D, design, production engineering and 
marketing - a horizontal rather than a vertical flow of 
information and communication within firms.
(3) Not only would computer-based automation change the 
configuration and organisation of every factory, it would also 
involve a big change in the skill composition of the 
workforce. Diebold rejected the idea of mass unemployment 
arising from automation and also the idea of "deskilling" the 
workforce. On the contrary, he stressed the new skills that 
would be required, especially in design and maintenance, 
and saw automation as a means of overcoming the 
fragmentation and dehumanisation of work. But he also
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realised that it would take a long time before the skills were 
available and people were retrained.
(4) Diebold recognised the importance of the economic aspects 
of diffusion. Computers would diffuse not only because they 
were technically advantageous, they had also to be cheap. 
It was only in the 1960s with the advent of micro-electronics 
and in the early 1970s with the advent of the micro­
processor, that computerisation took off in small and 
medium-sized firms, as well as in large firms, and in batch 
production as well in flow process industries such as 
chemicals. Moreover, and this is the most important point 
when we are looking at economy-wide effects, computer 
technology could only realise its potential outside a few 
"leading-edge" industries when computerised systems 
became relatively cheap and accessible.
Events since 1952 have fully confirmed Diebold’s analysis. Even 
though the computer industry itself was growing at an extremely 
rapid rate for the next thirty years, it took a whole series of 
complementary radical and incremental innovations such as 
Computer Aided Design (CAD), Computer Numerical Control 
(CNC), Large Scale Integration (LSI) and big developments in 
software engineering and process instrumentation before
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computer-based automation could diffuse to most industrial and 
service sectors. In fact, even now, the economic advantages are 
by no means always clear cut and there are often considerable 
teething problems when firms attempt to introduce FMS or other 
forms of automation191.
5.4 THE ANALOGY WITH ELECTRIC POWER
A similarly long time scale was necessary for the diffusion of electric 
power and its innumerable applications, from the time of its first 
appearance in the 1880s. Not only did it take two or three decades 
before generating and transmission systems made the new energy 
source universally available in the industrialised countries; it took 
even longer to redesign machinery and equipment in other 
industries to take advantage of electricity, and to make the 
necessary skills available.
An illuminating account of the debates which took place at the end 
of the 19th Century and the early part of this century on the 
implications of electric power for the future of factory processes is 
given by Warren Devine:
191 OECD, 1989
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Replacing a steam engine with one or more electric motors, 
leaving the power distribution system unchanged, appears 
to have been the usual juxtaposition of a new technology 
upon the framework of an old one. Shaft and belt power 
distribution systems were in place, and manufacturers were 
familiar with their problems. Turning line shafts with motors 
was an improvement that required modifying only the front 
end of the system. v4s long as the electric motors were 
simply used in place of steam engines to turn long line 
shafts, the shortcomings of mechanical power distribution 
systems remained.192
It was not until after 1900 that manufacturers generally began to 
realise that the indirect benefits of using unit electric drivers were far 
greater than the direct energy saving benefits. Unit drive gave far 
greater flexibility in factory layout, as machines were no longer 
placed in line with shafts, making possible big capital savings in 
floor space. For example, the US Government Printing Office was 
able to add 40 presses in the same floor space193.
Unit drive meant that trolleys and overhead cranes could be used
on a large scale, unobstructed by shafts, countershafts and belts.
Portable power tools increased even further the flexibility and
adaptability of production systems. Factories could be made much
cleaner and brighter, which was very important in industries and
printing, both for working conditions and for product quality and
process efficiency. Production capacity could be expanded much
more easily.
192Devine, 1983
193Devine, 1983
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The full expansionary benefits of electric power to the economy 
depended, therefore, not only on a few key innovations in the 
1880s, but on the development of a new "paradi9m" or production 
and design philosophy194. This involved the redesign of machine 
tools and much other production equipment. It also involved the 
relocation of plants and industries, based on the new freedom 
conferred by electric power transmission and local generating 
capacity.
Finally, the revolution affected not only capital goods but a whole 
range of consumer goods, as a series of radical innovations led to 
the universal availability of a wide range of electric domestic 
appliances going far beyond the original domestic lighting systems 
of the 1880s. Ultimately, therefore, the impetus to economic 
development from electric power affected almost the entire range of 
goods and services.
But this complex diffusion process took about half a century and it 
was not until the 1920s that electricity overtook steam as the main 
source of industrial power in the United States. It was not until the 
1950s and 1960s that widespread ownership of electric durables 
became the norm in Europe and Japan.
194OECD, 1989
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From these historical analogies it is evident that there is a major 
difference in the diffusion process for a single product and the 
diffusion process for a generic technology with numerous potential 
applications in a variety of different industrial sectors. Once it is on 
the market in an acceptable form, a single product may be adopted 
by more than half the potential adopters within a decade. This 
accounted, for example, in many OECD countries for a variety of 
consumer durables such as television in the 1950s and 1960s195.
Mansfield’s studies also showed that this rate of adoption, occurred 
for some types of industrial and transport equipment, such as the 
diesel locomotive and the continuous stripmill. However, there are 
cases of both agricultural and industrial innovations such as 
Metcalfe’s 1970 study of the diffusion of the sizebox in the cotton 
industry196. Such studies show many "laggards" and non-adopters 
even when the economic and technical advantages are clear. 
When one considers whole clusters of related innovations with new 
generations of products, such as biotechnologies, a much longer 
timescale is involved.
195Mansfield, 1961
196Metcalfe, 1970
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5.5 NEW BIOTECHNOLOGY AS A CHANGE OF 
TECHNOLOGY SYSTEM
Most diffusion research in the post-war period has concentrated on 
the diffusion of individual products and processes, and on 
incremental types of innovation. Schumpeter was almost alone 
among leading 20th Century economists in looking at "creative 
waves of destruction" - the effect of major new technologies as they 
pervade the economic system197.
More recently a number of economists have made further 
contributions to this Schumpeterian approach. Nelson and Winter 
(1987) used the expression "generalised naturalised trajectories" to 
describe cumulative clusters of innovations, as for example, those 
associated with electric power.
Dosi (1982) used the expression "technological paradigm" by 
analogy with Kuhn’s (1982) scientific paradigms. In these terms 
"incremental innovations" within an established paradigm may be 
compared with Kuhn’s "normal science". Carlota Perez (1983) has 
developed the concept of the "techno-economic paradigms" to 
describe those changes in technology which pervade the entire
197Schumpeter, 1939
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economy and provide the new "common sense" for a whole 
generation of engineers and managers.
Clearly, biotechnology is already a new paradigm in Dosi’s sense 
and a new "natural trajectory" in Nelson and Winter’s sense for the 
development of products and processes. Whether it is such an 
important trajectory that it will ultimately come to affect 
management decision-making in most branches of the economy 
remains an open question. The new biotechnology has 
undoubtedly led to enormous excitement in the US research 
community and many new companies were established with 
venture capital to pursue R & D, (see Sections 4.6.1).
This "research explosion" was indeed unique. However, the 
pervasiveness of a new technology system depends on the range 
of profitable opportunities for exploitation. Until recently, despite its 
undoubted importance for the future, biotechnology has led to 
profitable innovations in only a relatively small number of 
applications in a few sectors and in a few countries198.
In Schumpeter’s model, the profits realised by innovators are the 
decisive impulse to surges of growth, acting as a signal to imitators. 
But this "swarming" behaviour, generating a great deal of new
198OECD, 1989
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investment and employment depends on falling costs of adoption 
and very clear-cut advantages and/or competitive pressures. Later 
on, of course, after a period of profitable fast growth, profitability 
may decline.
Schumpeter stressed that changing profit expectations during the 
growth of an industry are a major determinant for the sigmoidal 
pattern of growth199. As new capacity is expanded, at some point, 
varying with the industries in question, growth will slow down. 
Exceptionally, this process of maturation may take only a few years 
but more typically it will take several decades and sometimes still 
longer.
Biotechnology is a very long way from this mature stage and the 
main interest is in when it will enter the "swarming" phase and on 
what scale200.
For a new technological system to have major effects on the 
economy as a whole it should satisfy the following conditions201:
(1) A new range of products accompanied bv an improvement
in the technical characteristics of many products and
1 "Schum peter, 1939
200OECD, 1989
201 OECD, 1989
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processes, in terms of improved reliability, new properties, 
better quality, accuracy, speed or other performance 
characteristics. This leads to the opening up of many new 
markets, with high and rapid growth potential and the rise of 
new industries based on these products.
(2) A reduction in costs of many products and services. In 
some areas this may be an order of magnitude reduction; in 
others, much less. But it provides another essential 
condition for Schumpeterian "swarming", that is, widespread 
perceived opportunities for new profitable investment. The 
major revolutions such as electric power and computing, 
were both labour-saving and capital-saving, but also offered 
a reduction in the cost of other major inputs, such as energy.
(3) Social and Political Acceptability. Whereas the first two 
advantages are fairly quickly perceived there may be long 
delays in social acceptance of revolutionary new 
technologies, especially in areas far removed from the initial 
introduction. Legislative, educational and regulatory 
changes may be involved, as well as changes in 
management and labour attitudes and procedures.
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Changes in taste, especially in sensitive areas such as food 
and drink, are often unpredictable.
(4) Environmental Acceptability. This may be regarded as a 
subset of (3) above but especially in recent times, it has 
become important in its own right. It finds expression in the 
development of a regulatory framework of safety legislation, 
and procedural patterns which accompany the diffusion of 
any major technology.
(5) Pervasive Effects throughout the Economic System. Some 
new technologies, as for example, the float-glass process, 
have revolutionary effects and are socially acceptable, but 
are confined in their range of applications to one or a very 
few branches of the economy. However, for a new 
technology to be capable of affecting the behaviour of the 
economy as a whole, in the Perez sense202, it must clearly 
have effects on technical change and investment decisions 
in many or all important sectors.
Using these five criteria it is relatively easy to see why nuclear 
technology, for example, does not qualify as a change of "techno- 
economic paradigm" since it fails on almost every one of them. By
202Perez, 1983
237
contrast, however, electric power or the microelectronic computer- 
based information technology satisfy all five criteria.
5.6 NEW BIOTECHNOLOGY AS A TECHNO- 
ECONOMIC PARADIGM
From the evidence in Sections 4.4 of this report, the new 
biotechnology is likely to satisfy the first of the five criteria, outlined 
by the OECD (1989), necessary for a new technological system to 
have major effects on the economy. It is beginning to give rise to a 
range of new products and processes in healthcare, in medical 
diagnostics, in veterinary applications, in the food and drink 
industry and in agriculture and forestry. The future potential is even 
greater, extending to a broad range of chemical and food products 
and processes and perhaps ultimately to an even wider spectrum. 
If the hopes of "bio-chips" are realised they could extend to the 
whole range of micro-electronics.
With regard to the second criterion; a reduction in the cost of many 
products and services; the application of new biotechnology is less 
clear-cut. Perhaps the best analogy is with the first two generations 
of electronic computers before the advent of the integrated circuit
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and the microprocessor. At this stage, in the early 1950s, 
computers certainly found cost-reducing applications in such areas 
as pay-roll and invoicing, but the cost of computers was still 
relatively high so that the range of adoption was limited.
In the case of new biotechnology there are indications that rDNA 
derived and other processes will be less costly than traditional 
manufacturing processes in certain Healthcare and Agricultural 
sectors (see Section 4.5.2), but it is also evident that in other 
important areas, such as animal feeding stuffs (see Section 4.5.3), 
the lack of cost competitiveness has slowed down or prevented 
more widespread applications. This is an important limitation on 
the speed of diffusion in key industrial sectors. However, these 
limitations may be overcome as a result of further research and 
development, or as a result of rising costs and diminishing supplies 
of non-renewable materials, or both.
In his analysis of the "Economic Potential of Biotechnologies", Rehm 
(1982), pointed out that future research and development was 
needed not only in the area of chemical feedstocks but also in 
relation to biomass and oil-recovery. Relative prices and estimates 
of probable profitability have not yet led to a major expansion of 
these fields of R & D.
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In the NAS Report on "New Frontiers in Biotechnology" Cooney 
(1984) pointed out that:
Products from the biochemical process industry take 
advantage of the same economies of scale experienced in 
commodity chemicals production. Most biochemicals are 
made using inexpensive raw materials, such as sugar, and 
they offer good potential value added. The profit margins 
depend on the efficiency in transforming these raw materials 
into products. It is this biochemical problem that needs to 
be translated into a biochemical process. At this point one 
begins to see the need for integrating improved conversion 
yields, better metabolic pathways and new reactor 
mechanisms. This requires integrating biochemistry, 
microbiology and chemical process technology.
However, this integration of disciplines and skills is by no means 
easy to achieve as it requires new forms of organisation and 
structure in both firms and universities. It is a problem comparable 
to that identified by Diebold in the case of factory automation203. 
Diebold realised that there was an enormous amount of design and 
development work necessary for each specific application of 
computers to industrial processes and that the skills were not often 
available for this work. Nor were firms organised to achieve results. 
In the case of biotechnology similar points are valid but the extent 
of "re-design" may be far less reaching204. Postgate may be right 
when he says that one major disadvantage of biotechnological 
processes need not prevent them from becoming cost effective,
203Diebold, 1952
204OECD, 1989
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that is, that the product usually has to be concentrated from 
relatively dilute solutions205. However, the experience so far with 
the scaling up of biotechnological processes to meet the 
requirements for large scale production of bulk commodities has 
not been encouraging in relation to comparative costs. Costs 
remain high and it is an open question whether biotechnological 
processes will replace the present processes for bulk chemicals in 
the next twenty years.
Applications in the copper industry appear more promising206.
Links upstream to more fundamental research have been a central 
feature of the new biotechnology and exceptionally important for 
chemical and drug firms207. This will continue to be extremely 
important in relation to most new products. At present, the 
dependence of biotechnology on information technology is 
considerable. Advanced information systems are essential for 
advanced research, development and design work in molecular 
biology.
The discussion so far has concentrated mainly on the problems of
process technology in relation to the potential large scale future
205Postgate, 1984
206Warhurst, 1986
07Faulkner, 1986
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applications of biotechnology outside the present rather limited 
area. This is because the economy wide effects of the new 
biotechnology depend on the resolution of these problems. It is 
already clear that biotechnology is having an effect in the 
pharmaceutical industry, medical care and agriculture (see Section 
4). Whether these effects extend to the whole of the chemical 
industry, oil recovery, energy industries, the food industry and 
ultimately an even wider range of manufacturing and service 
industries depend upon the progress of research, development 
and design over the next 10-20 years.
This in turn relates to social and organisational problems in the 
"national system of innovation", the management and scale of 
R & D, the interfaces between different parts of the system, the 
availability of skills, the encouragement of experimental application 
to new processes and so on. Finally, the incentives to conduct 
research and development and to introduce new processes 
depend on the development of relative costs in alternative 
processes.
Whether or not the new biotechnology becomes a "techno- 
economic paradigm" dominating future economic development in 
the next century depends also whether it satisfies other criteria. So
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far, the first two criteria relating to technical and economic 
performance have been discussed. The third and fourth criteria of 
social, political and environmental acceptability are dealt with more 
comprehensively in Section 4.7.1.
This speculative discussion serves to illustrate the type and 
magnitude of the structural changes and the social and institutional 
adjustments which may occur as biotechnology begins to have 
really widespread effects.
Big changes in the internal structure of agricultural production 
within each country are also probable. One small example of this 
may illustrate the point. The UK is now exporting date palms on a 
significant scale to the Middle East. This business has been 
pioneered by what was once a small horticultural enterprise on 
traditional lines but is now a medium-sized firm with R & D facilities 
and hundreds of employees208.
Classical and neo-classical trade theory would probably have 
considered the idea of the UK being an exporter of date palms as 
absurd on grounds of comparative advantage. But new
208OECD, 1989
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technologies change many parameters and this certainly applies to 
biotechnology.
The following discussion focuses on the fifth and final criterion 
outlined by the OECD in assessing the macro-economic 
consequences of a new technological system: the pervasiveness of 
the new technology.
The new biotechnology is clearly more pervasive than more 
narrowly focussed technologies, such as nuclear power. It has 
already found applications in primary industries (agriculture, 
forestry and mining), secondary industries (chemicals, drugs and 
food) and tertiary industries (healthcare, education, research and 
advisory services).
However the actual range of applications is still far narrower than 
the potential applications if one compares the information 
presented in Sections 4.4.
In fact, biotechnology has often been compared to information 
technology, whose influence can be felt in all economic sectors209. 
However, it is necessary to emphasise some fundamental
209OECD, 1989
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differences. Firstly, the fact that biotechnology operates through 
living organisms, or parts thereof, limits the field of activity to 
materials that can be biologically manipulated. Numerous industrial 
sectors would then be excluded from the direct influence of 
biotechnology such as the steel industry, telecommunications and 
so on, although an indirect or mediated influence cannot be 
excluded. On the other hand, information technology, operated 
through substitution or change of a given production factor, labour, 
has been able to penetrate almost all products and processes of 
human activity.
From this feature derives the functional pervasiveness of 
information technology: informatics and telecommunications are 
employed not only by technical personnel (production, R & D, 
engineering), but also by non-technical personnel (administration, 
financing, marketing, sales). This does not presently hold true for 
biotechnology. However, in the longer term, a linking of biological 
and information technologies might materialise in specific devices 
such as biorobotics and neurocomputers, endowed with much 
higher capacities for storage and processing. The merging of 
information technology with the power of the new biotechnology 
would give the latter all the pervasiveness-aspects of information 
technologies and would influence human activity in ways which are 
difficult to imagine at present.
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Three possible scenarios have been illustrated for the future path of 
diffusion of new biotechnology (Figure 18). For the purposes of 
comparative discussion the two extreme cases Scenario 1 and 4 
will be discussed first.
Scenario 1 would represent an accelerated diffusion of the new 
biotechnology into many industrial sectors and applications, 
including the rapid development of many new industrial processes 
as well as products. It would represent a more rapid advance than 
that which occurred historically with earlier waves of new 
technology. For reasons which have been discussed, time and 
scale of R & D, education/training, capital investment, social and 
structural change, this scenario seems highly improbable. Only 
rapid changes in relative costs, prices and profitability might induce 
such a development.
Scenario 4 would represent a much slower rate of diffusion than 
now seems likely from the identifiable potential of the technology. It 
suggests that many of the potential applications of biotechnology in 
the chemical, food, agricultural, medical, energy and other 
industries remain still in the far future even after another 20 years of 
R & D.
246
FIGURE 18 A SIMPLIFIED ILLUSTRATIVE REPRESENTATION OF 
THE DIFFUSION OF “MEGA-TECHNOLOGIES"
S o u r c e :  F r e e m a n , C .  T e c h n o l o g y  P o l i c y  an d  E c o n o m ic
P e r f o r m a n c e  : L e s s o n s  f r o m  J a p a n ,  F r a n c e s
P i n t e r ,  L o n d o n ,  1987 .
This scenario also seems a rather unlikely scenario in the light of 
information based upon the current pace of R & D activity and the 
technological potential.
Something between Scenario 2 and Scenario 3 is therefore the 
most probable, with biotechnology beginning to be a major basis 
for new investment and the growth of the economy in the second or 
third decade of the next century210. It should be noted however 
that the level of aggregation of this scenario is very high. A more 
precise analysis would require that biotechnology be broken down 
into various fields of application in order to asses both promoting 
and retarding diffusion factors in each of them.
It has been recognised that diffusion rates vary greatly between 
sectors211. Health applications of biotechnology are likely to 
diffuse much faster than agricultural applications, and within the 
health sector, diagnostic products are diffusing faster than 
therapeutic products, mainly as a result of regulatory influences 
(see Section 4.5.1).
Past experience in agriculture indicates that new technologies often 
take 10-20 years before they are adopted, but these rules may not
210OECD, 1989
211 OECD, 1989
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always apply to the innovations coming from biotechnology (see 
Section 4.5.2).
The fact that the new biotechnology is not likely to become the 
predominant technology for most industries and services, to which 
it can be applied, in this century should be no cause for surprise. 
Nor does it mean that it is unimportant for economic growth and 
international competitiveness. On the contrary, it is clear that 
already it will be at the heart of a rapidly growing cluster of new 
industries and an essential element of survival in an increasing 
number of established industries.
Moreover, one reason for the intense research interest is that the 
unexpected can always happen in such a fast-moving area.
5.7 THE NEED FOR STRUCTURAL CHANGE
Section 5.2 discussed the complex problems related to the 
diffusion of new biotechnology, and mentioned that structural 
changes and system transformation are prerequisites of a 
pervasive diffusion throughout the economy. This section focuses
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on some of these changes, particularly emphasising those in the 
healthcare and agricultural sectors, as they are the first sectors 
affected by the new technology. It should be noted that assessing 
structural changes inevitably implies an element of speculation as 
biotechnology is still in its infancy in terms of new commercial 
products and processes.
5.8 IMPACTS ON PRODUCTS AND PROCESSES
A number of biotechnology developments will have a profound 
impact(s) on products and processes. Structural changes in the 
economy and society are likely to follow from these technical 
changes. Some of them are already detectable in the progress of 
biotechnology and are briefly discussed in the following sections: a 
new emphasis on diagnosis and prevention; an increase in the 
specificity and effectiveness of new products; a reduction in the 
intensity of use of energy and materials which has been called 
"dematerialisation"; and increasing compatibility of technology with 
the environment and with natural resources.
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5.9 A NEW EMPHASIS ON DIAGNOSIS AND 
PREVENTION
A recent OECD report indicates that new biotechnological methods 
of diagnosis and prevention are expected to multiply in the fields of 
health, agriculture and the environment212. Already some of the 
greatest successes of new biotechnology are tied to the 
commercial introduction of the growing number of 
immunodiagnostic tests based on monoclonal antibodies, 
biosensors and gene probes213 214 Empirical data resulting from 
the present study also indicates that this is the case in the 
biotechnological activities of Irish companies (see Section 8). 
These new devices will allow for an extension of hitherto limited 
physical and chemical measurements, to a wide number or organic 
molecules, as well as for potential control and regulation of complex 
systems in the human body, in animals, plants, the environment 
and in industrial processes.
The new tests are rapid and highly specific. The range of 
applications could be extremely wide: clinical controls and online 
monitoring of patients; in vitro and in vivo diagnostics of humans
212OECD, 1989
213Dodet, 1987
214Schmid, 1988
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and animals; monitoring of the effectiveness of drugs; quality 
control of food, air, water and soil through detection of pollution 
agents; criminal investigation and industrial purifications systems.
In another field of healthcare, new vaccines for humans and 
animals presently under study will significantly increase the number 
of diseases which can be dealt with through effective preventive 
measures rather than with more costly therapeutic treatment215.
The situation outlined as above for healthcare is valid also in other 
sectors. For example, the mass productions of clones with desired 
characteristics and the transfer of new traits to plants using the 
techniques of recombinant DNA has resulted in the production of 
superior plants with qualities fitting the need of the eventual user, or 
the production of plants highly resistant to disease, climatic and 
environmental conditions, (see Section 4).
215Bona, 1987
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5.10 DEMATERIALISATION
Several authors have shown that in industrialised societies, new 
materials and energy inputs into the economy tend to diminish at 
least in relative terms; this can be measured at the macroeconomic 
level for most OECD countries with the reduction of intensity of use 
of raw materials and energy (expressed as the relationship between 
energy or raw materials demand and the GDP, in kcal / $ or kg raw 
materials / $)216 217. It has been suggested by these authors that 
such reductions are linked with the displacement of the production 
mix towards "light" industry and services, which in general are low 
hardware-intensive sectors and with the impact of modern 
technology, which acts towards the efficiency in use of resources, 
optimisation processes, increasing effectiveness, specificity of 
materials, waste reduction and utilisation.
It has been suggested that new biotechnology operates in the
same direction, and will contribute to reduce energy and raw
materials needs per unit of GDP, thus accelerating the movement of
industrialised societies "beyond the era of materials"218 219.
Examples of this include, production of chemicals through
216Malenbaufri, 1978
Larson etal., 1986
218Larson et al., 1986
219OECD, 1989
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enhanced fermentation, enzymatic processes, tissue culture, the 
insertion of a pest resistance function into the genome of plants to 
reduce the use of pesticides and the substitution of sugar by new 
compounds with dramatically superior sweetening properties. For 
example, studies of sweeteners and flavour enhancers have 
involved the cloning of genes for thaumatin, a protein isolated from 
the fruits of a West African shrub: 1 gram of thaumatin is equivalent 
to 2 kilograms of sugar.
Dematerialisation may also have structural aspects. One is a shift 
in the utilisation of natural resources from rare to more abundant 
raw materials. Modern technology allows humankind to generate 
new materials and energies from easily available and cheap 
sources. It is possible, for example, to produce electricity without 
high-energy content fossil fuels, but by solar energy, the least 
expensive and most abundant energy source.
Biotechnology contributes in very similar ways to dematerialisation. 
For example, the first practical results of genetic engineering have 
been obtained by using modified microorganisms to mass produce 
already known pharmaceuticals which, up to now, have been 
obtainable only in small quantities (such as growth hormones).
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Quantitative and structural dematerialisation of economic activities 
induced by biotechnology may lead to better environmental 
capability of new products and processes, as the amount of 
materials to be mobilised decreases and rare resources are 
preserved.
5.11 "RATIONALISATION" OF THE INNOVATION
PROCESS
It should be noted that the potential of biotechnology relies on 
sound and rigourous scientific knowledge in numerous areas. The 
methodologies employed in the development of new products and 
processes increase rationality, while the contribution of pure 
empiricism is diminishing. This phenomenon is fully apparent in the 
radical change which has occurred in the last decade in the 
approach to the development of new drugs. The method of 
screening of large number of molecules (that is serendipity) has 
been to a great extent abandoned in favour of a large number of 
research projects aimed at understanding the mechanism of 
various diseases.
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With this knowledge it becomes possible to target a suitable 
molecule to act upon those mechanisms. The change in the 
"paradigm" of pharmacological research has simplified the process 
of innovation and has made it more rational. This change, made 
possible by biotechnological research instruments and products, 
has profoundly affected the pharmaceutical industry.
A similar evolution towards rationalisation of the innovation process 
in industry is expected to emerge on other sectors where 
biotechnology may apply, from agrochemical to food industries220.
5.12 THE HEALTHCARE SYSTEM
Advances in biotechnology offer the possibility to collect more 
precisely, and on a wider scale information about biological and 
biochemical aspects of a particular organism, and about the 
mechanism of action of drugs, in order to arrive at a more specific 
drug design, with fewer secondary effects (side effects). An 
example of this can be seen in the possibilities offered by the 
identification, isolation and production of new factors; for example, 
proteins with different functions in the human organism, which can
^ O E C D , 1989
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be used as drugs themselves (tissue plasminogen activator as a 
thrombolitic agent). Also, monoclonal antibodies can be used as 
ultraspecific drug reactors against specific tissue antigens 
(targeting). These advances involve complex research and the time 
and cost factors associated with new drug developments (up to 12 
years and $125 million) are high; hence new problems of risk 
assessment and experimentation continually arise.
The slowness with which new therapeutic drugs become available 
suggests that structural change in medical practice is not imminent 
and not immediately required as a result of "therapeutic innovation". 
However, this may change in the future with the introduction of 
medicines specific to individual patients, such as personalised 
cancer therapy (LAK therapy), anti-idiotype monoclonals for auto­
immune diseases, and others.
However, economic, social and institutional changes deriving from 
the wave of immunodiagnostic tests based on the monoclonal 
antibodies and gene probes may be faster and deeper. These 
tests arrive on the market at regular intervals, as their development 
requires relatively minor costs, time and risks, at least compared to 
therapeutic drugs.
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The diagnostics revolution will cover a broad spectrum, including 
prenatal diagnosis, early diagnosis of the onset of diseases, and 
the monitoring of degenerative diseases. The new tests have many 
interesting characteristics: rapidity, specificity, facility of use, a wide 
spectrum of applications and great sensitivity to small quantities of 
material needed (urine, blood, cells etc..). A recent example of 
such developments is a pre-natal diagnostic test, developed by a 
team of Australian doctors, which examines foetal genetic material 
for the presence of genetic defects, replacing earlier techniques 
such as amniocentesis221.
The availability of a large number of simple diagnostic kits will also 
favour the diffusion of tests performed at home or by the doctor. 
The best known example is the home pregnancy test. Here also, 
the change is important because the possibility of self-control of 
infective diseases or of biological parameters becomes available at 
the patient level.
It should also be mentioned that technological progress which 
substitutes laboratory by home tests, corresponds to an apparently 
growing social demand for self-diagnosis and self-therapy which
221 Sunday Business Post, 1990
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opinion surveys have recently detected in industrialised 
countries222.
The transfer of technology from the laboratory to the doctor 
(doctor’s test) or to the private individual (home test) represents a 
great organisational and functional innovation. Since this breaks 
with traditional practice, obstacles from the health care sector, from 
conservative bureaucracies and from professional categories which 
have a vested interest in the existing system are predictable.
The pharmaceutical industry has been for some time in a state of 
change: from product supplier (principally drugs) it is becoming an 
"industry of function" or a healthcare industry, that is a supplier of a 
wide range of therapeutic products, diagnostics, auxiliary materials, 
equipment, machines and biomedical systems. The scientific basis 
is more and more interdisciplinary, relying not only on chemistry, 
biology and medicine, but also on physics, electronics, computers, 
lasers etc.. These transformations have already brought with them 
problems of internal reorganisation.223
In the future, the massive diffusion of diagnostic will probably move 
the current process of transformation further towards an extended
222OECD, 1989
223OECD, 1989
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multidisciplinary base. The diffusion of mass health screening 
through the population carries with it not only biological tests, but 
also the parallel development of automated equipment and 
software for data processing. This trend is, therefore, towards 
more integration of biotechnology, microelectronics and 
telecommunications. In fact, in the area of medical technology, it 
has been suggested that the traditional pharmaceutical industries 
may find themselves competing with the electronic industries.
This is a new challenge to the innovativeness of the pharmaceutical 
industry; it may be noted in this context that the first development 
of new diagnostic tools arose from small biotechnological start-up 
companies and not the pharmaceutical industry. The critical 
success factor in this new challenge may be the ability to further 
integrate different functional departments during the innovation 
process rather than biotechnological knowledge itself.
The organisation and institutional implications of this evolution are 
far-reaching. Such developments offer private enterprises the 
possibility of extending their activity to services, directly running 
diagnostic centres, for example and in this way substituting part of 
the public health system. It has been suggested that this emerging 
trend could spread, above all in countries where the public health
259
sector has great difficulty in adapting to technological change, 
suggesting that Governments would be obliged to turn to the 
organisational support of private industry224.
5.13 THE AGRO-INDUSTRIAL SYSTEM
In the agricultural sector, the new biotechnological techniques may 
have a very dynamic power extending beyond agriculture itself, to 
ancillary activities, such as fertilisers, agrochemical, machinery, as 
well as to other downstream activities concerned with food, 
biomass and the transformation of agricultural products. A 
discussion of changes in agribusiness related to new 
biotechnology necessarily involves the complex question of 
biomass utilisation (that is the constituent material of vegetable and 
animal organisms) as agricultural surplus-production in many 
OECD countries is causing great concern.
The diffusion-time of agricultural innovations may become shorter 
as a result of the strong industrial involvement in agricultural 
biotechnologies225 (see also Section 4.5.2).
224OECD, 1989
225OECD, 1989
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There certainly are agricultural commodities where quantitative 
production increases would be much appreciated. For example, 
countries which have a trade deficit in soya or in lumber may 
welcome the potential of new biotechnology to increase the 
production of both.
However, the introduction of new biotechnology know-how will 
bring about a further increase in agricultural production on a broad 
front because productivity will grow and by-products may find new 
applications. The example of whey utilisation, a by-product of 
cheese making, to produce alcohol for use in many commercial 
applications supports this claim.
The OECD has suggested that while increased efficiency of 
agricultural production and reduction of resource inputs must be 
encouraged, the net effect of the new know-how could be to 
exacerbate the problems of excess agricultural production in the 
OECD countries as long as there is no fundamental change in the 
latter’s agricultural policies and systems.
Furthermore, it has been suggested that the surplus problem will 
be overcome by finding new solutions which do not rely on 
subsidies that place too great a burden on governments; for 
instance, the fermentation of large amounts of biomass to produce
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ethanol for use as gasoline additive, would arouse opposition 
because it requires at present oil prices, conspicuous government 
subsidies.
Resistance to the introduction of new biotechnology into agriculture 
has been fuelled by concern about the quantity impacts of the new 
technology. It is therefore increasingly evident that agricultural 
biotechnology should be directed more towards qualitative goals 
than quantitative production increases, and more towards the 
development of novel industrial uses of biomass. Quality has 
several facets. First, there are market demands, at least in wealthy 
countries, for food with better taste and aroma etc. Such quality 
areas are those which the traditional food industry has often 
neglected, although it has applied high quality standards to 
manufacturing processes and safety. In the future, new 
biotechnology could open up larger markets for the food industry 
by focussing on their quality aspects. Marketing studies in wealthy 
OECD countries have indicated that consumers are ready to pay 
up to 30 per cent more for quality increases of this type, which 
could increase food sales in OECD countries by the year 2000 by 
up to $30 billion226. However such predictions based on future 
intentions must be treated with caution as several factors, including
226OECD, 1989
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economic conditions and consumer attitudes, will obviously change 
during the next decade.
A second quality aspect relates to safer food and food with fewer 
chemical residues from pesticides and other agrochemicals and 
also synthetic colours and flavours.
In a third and more general sense, quality means greater 
specialisation and diversification of products in order to respond to 
specific demands. Products derived from agriculture may, in many 
cases, better respond to differentiated needs than synthetic or 
inorganic needs (see Section 4.5.2).
In food companies, the biggest opportunities are presently 
expected to arise from improved processes through the use of 
enzymes, for example227.
The applications of new biotechnology are more controversial in the 
agricultural sector than in any other. As mentioned previously in 
this section, the potential of new biotechnology to increase 
productivity growth in agriculture, entails the danger of increasing 
food surpluses, in a survey of 94 industrial companies in 17 OECD, 
including Ireland, the opinions of industrial firms with regard to
227OECD, 1989
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biotechnology was investigated228. With regard to agro-industrial 
applications of biotechnology, bovine growth hormone (BGH), also 
known as bovine somatotrophin (BST), was cited as the most 
important example of a new biotechnology mistake. The 
administration of BST in lactating dairy cows supplements the 
natural level of BST in the blood stream. It has been claimed that 
with the quota system in operation in Europe, BST will enable 
farmers to produce the same amount of milk more efficiently and 
cheaply in terms of land and resources229
Although at least five companies continue to work on BST, 
including the parent of an Irish subsidiary, others have stopped 
development. The possible consequences of a product that could 
increase milk and meat production on the one hand, and reduce 
agricultural employment on the other, has made a number of 
potential manufacturers uncertain230 and might lead to more 
comprehensive technology assessment methods in industry, 
whereby R & D and marketing costs will be confronted with market 
perception and acceptance.
Interestingly, independent economists predict that BGH / BST will
have little overall impact on the dairy industry. They expect that
228OECD, 1989
29Elanco, 1987
230Fishlock, 1989
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BST will gradually be taken up by farmers, and used only on a 
percentage of cows for a selective period of time. BST requires no 
capital outlay and can be used to increase productivity on any farm, 
large or small. Farmers may reduce cow numbers to remain within 
quota, but the number of farms should be largely unaffected by the 
introduction of BST231. At present, the development of bovine 
growth hormone by industrial companies operating in Ireland is 
banned by the Government unless milk used in the development 
work is dumped. Such a restriction is not acceptable to 
industrialists and hence development by the Irish subsidary of a 
multinational involved in BST development is not carried out 
here232.
The development of new, economically viable uses of agricultural 
products, particularly for industry, is a critical challenge of our time, 
and biotechnology greatly adds to the currently available chemical 
and physical processes to transform otherwise useless biomass. 
However this is a very complex task. It includes the development of 
new products to absorb not only excess cereals, typical of 
temperate climates, but also other types of products from different 
climatic and geographic conditions. This strategy could also help 
countries to find new uses for marginal lands, hills and mountains,
231NOAH, 1988
232Personal Communication; confidential source
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which are being abandoned whenever governments consider this 
to be an ecological or other risk.
Such measures will take time, and they cannot under any 
circumstances solve the present surplus problems of many OECD 
countries. Also, they should not be expected to greatly affect the 
historic downward trend in agricultural employment of OECD 
countries. However, while the development of industrial uses for 
agricultural products is unlikely to reverse this downward trend, it 
might, in some instances, slow it down.
The proposed shift of emphasis in agriculture from quantity to 
quality, and from food surpluses to new industrial products, calls 
for structural transformations in agribusiness, and for changes in 
the interaction between agriculture and industry. Trends are 
already emerging towards a closer integration between agricultural, 
input industries and user sectors. For example, the transfer of the 
crop protection function from pesticides to biotechnological 
modified seeds has structural implications for the concerned 
players, as can be seen in the large-scale acquisition of seed 
companies by the agrichemical industry233. The trend is towards 
an integration of input and output industries, which would operate
233Financial Times, 1989
266
as a global service to agriculture. The farmer would, in turn, 
change his/her activity almost into that of an industrial 
entrepreneur; delegating several functions to specialists whenever 
growing technological complexity requires specialised competence.
Although the most dynamic actor in the transformation of 
agriculture is likely to be the industrial enterprise, governments 
farmer lobbies and the ultimate consumer are likely to play equally 
critical roles.
5.14 PROSPECTIVE IMPACTS ON 
EMPLOYMENT
A large and growing literature discusses the impacts of technology 
on employment, particularly the question of whether and how new 
technologies have affected jobs in industrialised countries since the 
Second World War. In the late 1970s the beginning of the 
"microelectronics revolution" coupled with the economic downturn 
fuelled concern that widespread use of microelectronics would 
have labour-saving bias and thus lead to a period of "jobless 
growth".
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Studies indicate that global employment levels in the OECD area in 
recent years have not been significantly increased or influenced by 
technological progress, and that macroeconomic factors, 
particularly growth rates, shifts in demand patterns and 
international competition have been much more important234.
Employment impacts have varied considerably between economic 
sectors. Technological progress has contributed to job losses in 
manufacturing sectors, although employment in high-technology 
industries has increased in a few countries without, however, 
changing the negative net balance. In the service sector, for 
example, technological progress has been accompanied by the 
creation of new jobs, particularly in business, financial and 
communication services. The sum of these new jobs more than 
compensates for the technology-induced losses incurred by the 
manufacturing sector235.
Hence, the major effect of technological progress has been felt less 
in total employment levels, than in changes in the structure of 
employment and in higher skill requirements.
234Brainard and Fullgrable, 1986
235Brainard and Fullgrable, 1986
268
TABLE 12
EMPLOYMENT IN SECTORS W HICH WILL BE AFFECTED BY
NEW  BIOTECHNOLOGY  
( A S A  P E R C E N T A G E  O F  C I V I L I A N  E M P L O Y M E N T ;  1983 U N L E S S  D A T E D
O T H E R W I S E )
COUNTRY Agriculture Health Chemical
Industries
Food
Industries
Total
AUSTRALIA 6.6 7.0
AUSTRIA 8.6 5.4 (1982) 2.0 2.1 -
BELGIUM 3.0 4.6 (1981) 2.7 3.1 -
CANADA 5.5 4.9 (1981) - - -
DENMARK 7.4 4.8 (1980) 1.5 3.1 -
FINLAND 12.7 5.8 - - -
FRANCE 7.9 6.2 2.6 2.9 19.6
GERMANY 5.6 2.5 3.5 1.8 13.4
GREECE 29.9 2.0 (1981) - - -
ICELAND 10.7 6.9 (1979) 1.0 12.3 -
IRELAND 17.1 5.2 - - -
ITALY 12.4 3.0 1.8 1.1 18.3
JAPAN 9.3 3.1 (1981) 3.7 (1979) 2.2 (1980) -
LUXEMBOURG 4.7 3.8 (1981) - - -
NETHERLANDS 5.0 6.5 2.4 2.7 16.6
NEW ZEALAND 11.2 6.0 1.9 5.9 25.0
NORWAY 7.5 6.7 1.4 2.8 18.4
PORTUGAL 23.6 2.4 1.5 (1980) 2.2 (1980) -
SPAIN 18.6 3.3 2.1 3.2 27.2
SWEDEN 5.4 7.9 1.6 1.6 16.5
SWITZERLAND 6.7 5.5 2.9 (1980) 3.8 (1980) -
TURKEY 58.9 - - - -
UNITED KINGDOM 2.7 5.3 2.9 3.2 (1978) -
UNITED STATES 3.5 5.8 1.7 1.5 12.5
TOTAL code 9.5 1.3* 1.3* 1.2*
* Refers only to countries for which 1983 data are available
SOURCES: Labour force statistics 1964-1983, O E C D ,  Paris, 1986
Historical Statistics 1960-85, O E C D ,  Paris, 1987 (Agriculture) 
Measuring Healthcare, O E C D ,  Paris, 1985, (Health)
O E C D  Database Sector ISIS, in segment ISIC (Industry)
With regard to biotechnology, industry and governments have not 
linked their support for biotechnology to hopes that its 
development could create many new jobs. In fact, the few surveys 
conducted in the 1970s shed doubts on the labour-creating 
potential of the new biotechnologies at least during the first years of 
development236. Persistent manpower shortages have, since 1987, 
led to a somewhat more optimistic assessment of the labour- 
creating potential of biotechnology, both in the short and long-term, 
at least for well trained/qualified people.
In view of the economic size of the sectors which will be affected by 
biotechnology, particularly their importance for jobs, the 
employment question is a legitimate one. Even excluding the 
possible impacts on sectors which biotechnology might penetrate 
at a later stage, such as energy, the number of jobs the sectors 
which could be affected are large.
Table 12 gives employment in the OECD area, as a percentage of 
total employment, in the sectors which will be first and most 
affected by the new biotechnologies; agriculture, public health, and 
the food and chemicals industries (including pharmaceuticals).
236Bull et al„ 1982
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Large international variations can be found reflecting mainly the 
variations in agricultural employment between OECD countries. 
However, even in the most industrialised countries, employment in 
all sectors together exceeds 10 per cent of total employment, in at 
least nine countries (Finland, France, Spain, Italy, New Zealand, 
Norway, Switzerland, Iceland, Japan) it is approximately a quarter 
or fifth of all employment, and in three countries (Greece, Portugal, 
Turkey) it is much higher due to the large size of their population 
still active in agriculture.
It is more difficult to find data on employment in biotechnological 
activities or industry directly. Estimates in the 1970s indicate that in 
the United Kingdom and the Netherlands, between 20 and 25 per 
cent of the production of food and beverage industries comprises 
fermented products. If it is assumed that manpower percentages in 
this sector do not deviate from production percentages, then 
relatively large numbers of people are employed in classical 
biotechnological manufacturing.
In the pharmaceutical industries, an estimated 25 per cent of all 
products go through a fermentation process, including antibiotics 
and some vitamins (mostly modern biotechnology), but it would be 
hazardous to take this as a basis for a manpower breakdown in the 
drug sector.
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The numbers employed in genetic engineering companies in the 
United States are better known; trade associations published 
figures of more than 30,000 employees working in these companies 
in 1982-3, and of approximately 40,000 in 1987237. This figure is 
probably an underestimate as it does not include the manpower of 
some large corporations working on new biotechnology projects.
According to many experts however, it is the qualitative 
employment impacts which in time will be most important and their 
direction is already more clearly visible than that of quantitative 
impacts.
Qualitative impacts will result from the responses to current training 
and manpower needs in biotechnology, which continue to be a 
source of concern for governments and industry alike and which 
have, therefore, been scrutinised in various countries.238 239
There is agreement that a high qualification profile is a predominant 
feature of the manpower needs in biotechnology. The Irish 
government’s approach to the manpower needs of biotechnology 
is discussed in Section 6.10.3).
237Biotechnology News 1983; 1987
238OECD, 1986
239OECD, 1988
271
The diffusion of biotechnology through the economy, and the 
productivity increases this will bring about, will have larger 
employment effects than those which can be expected in the bio­
industries themselves. New biotechnology products and market 
will lead to demand widening which could be felt across the 
economy.
Of the numerous possible employment effects of biotechnology, 
those which are expected to be most critical, both politically and 
economically, are in the area of agriculture. They are the only 
prospective employment effects of biotechnology which have 
already provoked counterveiling forces.
Agriculture has, in the last years, adopted biotechnology more 
slowly than would have been technically possible because a 
perceived threat to employment has acted as a barrier to diffusion. 
Still notorious is the 1979 decision of the EEC to impose a quota 
system on isoglucose, a biotechnology derived sugar substitute, to 
protect the European Community’s 300,000 or more sugar beet 
farmers.
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TABLE 13
GROW TH OF OUTPUT, PRODUCTIVITY AND EMPLOYMENT 
IN  AGRICULTURE, 1950 - 1978
(ANNUAL AVERAGE COMPOUND GROWTH RATES)
Growth of Output
1950-73 1973-78
France 2.0 0.1
Germany 2.3 1.0
Japan 3.2 -1.0
Netherlands 3.1 3.2
United Kingdom 2.6 0.9
United States 1.9 0.9
Average 2.5 0.9
Growth og Output per Person Employed
1950-73 1973-78
France 5.6 5.4
Germany 6.3 5.0
Japan 7.3 -1.2
Netherlands 5.5 4.9
United Kingdom 4.7 2.8
United States 5.5 1.2
Average 5.8 3.4
Growth of Employment
1950-73 1973-78
France -3.5 -4.2
Germany -3.7 -3.8
Tapan -3.8 -2.1
Netherlands -2.3 -1.7
United Kingdom -2.0 -1.9
United States -3.5 -0.3
Average -3.1 -2.3
Source: Angus Maddison, Phases of Capital Development, Oxford., N.Y. 1982, p ll7 .
TABLE 14
EMPLOYMENT IN AGRICULTURE 
(AS A  PERCENTAGE OF CIVILIAN EMPLOYMENT 1978 AND 1985)
COUNTRY 1978 1985
AUSTRALIA 6.41 6.17
AUSTRIA 9.63 8.15
BELGIUM 3 .19 2.91
CANADA 5.75 5.22
DENMARK 7. 85 6.70
FINLAND 14.43 11.54
FRANCE 9.19 7.56
GERMANY 6 .1 0 5.44
GREECE 32 . 02 23.90
ICELAND 12 . 87 10. 34
IRELAND 20. 64 15.86
ITALY 15.45 1 1 .2 0
JAPAN 11.70 8.77
LUXEMBOURG 6.41 4 .38
NETHERLANDS 5.38 4.93
NEW ZEALAND 11.24 11. 14
NORWAY 8 . 68 7.30
PORTUGAL 31.26 23 .15
SPAIN 20.64 18.24
SWEDEN 6 .1 0 4.45
SWITZERLAND 7.30 6 . 62
TURKEY 60. 69 57.06
UNITED KINGDOM 2.75 2.55
UNITED STATES 3 . 70 3 .12
TOTAL OCDE 1 0. 62 8 .8 8
SOURCES: Labour Force Statistics 1964-1983, OECD, Paris, 1986
Historical Statistics 1960-1985, OECD, Paris, 1987 (Agriculture)
The European consumer still pays approximately twice the 1987 
world market price for sugar and this price has in part been 
maintained by lack of availability of the cheaper sugar substitute.240
Present difficulties with bovine growth hormone in Europe have 
various explanations, one of them being the agricultural labour- 
saving potential of a product which could increase milk production 
considerably (see also Section 5.1.3).
However, with regard to fears of job-reducing effects of 
biotechnology in the agriculture of OECD countries, one can argue 
that taking a historical perspectives, many OECD countries have 
their biggest agricultural adjustments behind them. Table 13 shows 
in the case of six countries that these adjustments, characterised by 
a dramatic growth of output per person, and by large annual job 
losses have mainly taken place in the 1950s and 1960s and that 
already in the 1970s, annual job losses tended to become smaller 
in some countries.241
Table 14, which compares agricultural employment as a 
percentage of civilian employment between 1978 and 1985, tends 
to confirm this general trend. In some countries with still large
240OECD, 1989
241 OECD, 1989
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agricultural employment, including Ireland, Greece, Finland, Italy, 
Portugal in the 1970s substantial reductions of agricultural 
employment (up to a third in relative terms) have taken place in the 
seven years between 1978 and 1985, before new biotechnology 
could have had a significant impact.242 Agricultural productivity will 
keep rising, employment will decline further and agricultural 
adjustment will thus remain a continuous long-term process, with or 
without biotechnology.
Obviously, biotechnology could facilitate agricultural adjustment if it 
were to concentrate its efforts more on quality improvements and 
the development of new, industrially useful crops (see Section 
4.5.2) rather than on further agricultural production increases. 
However, even if biotechnology does increase quantities as well, it 
will do so in the context of other, parallel technological advances 
which act together.
Junne’s examination of the possible impacts of bovine growth 
hormones in Europe is an interesting case study because the 
figures are perhaps more widely significant for the relative weight of 
biotechnology impacts, particularly in the employment context243
242OECD, 1989
243Junne, 1987
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The dairy sector is the most important subsector of European 
agriculture, accounting in 1986 for almost 19% of the total value of 
agricultural output in the EEC area. It has been calculated that the 
combined effect of continuous upgrading of breeding, improved 
feed conversions, progress in veterinary sciences and the use of 
growth and other hormones, will add up to tremendous productivity 
increases. If total production volume is not allowed to increase, 
approximately 33% of the current livestock would have to be taken 
out of production by the year 2000. Even if growth hormones were 
completely banned in Europe, the necessary reduction in cattle 
numbers will still be 22%, and many cattle farmers will have to leave 
the sector.244
Thus the prohibition even of one of the most important new 
agricultural products, could delay but not stop an apparently 
inevitable evolution, because of the ongoing synergistic effect of 
other innovations on productivity.
Agricultural employment effects of biotechnology will also depend 
upon a country’s international trade in agricultural products. A 
leadership position in agricultural biotechnology innovation 
translated into increased exports, may create jobs. Imports of 
biotechnology products may lead to loss of jobs.
244OECD, 1989
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Technological progress leads to productivity increases, reduced 
production costs and hence to higher profits or wages, or to lower 
prices. This will increase real income and demand which is likely to 
be translated into higher employment in the economy in general. 
Thus employment reductions in one sector, if they are due to 
general factor saving effects and not compensated for by increased 
capital costs, will after a time-lag, theoretically result in higher 
employment in other sectors.
In conditions of competition, productivity increases and factor- 
saving effects will find their way into price reductions. In 
monopolistic and oligopolistic conditions, productivity increases will 
find expression in higher profits and/or wages.
This discussion has mentioned the production costs of 
biotechnology as they have important implications for a number of 
economic issues, including economic pervasiveness and structural 
changes in industry. Looking at costs from a third economic 
perspective, that of employment consequences, one must consider 
long-term factor-saving effects. Discussing the economics of 
biotechnology, Hacking refers both to current uncertainties in 
assessing costs, particularly of fermentation, and to the potential for 
further cost-reducing improvements.245
245Hacking, 1986
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However, there are already more than a few examples of factor- 
saving effects of biotechnology which go beyond labour. Many 
result from the "dematerialisation" trend (see Section 5.10) whereby 
traditional raw materials are replaced by rDNA derived products 
and processes.
The perhaps extreme example of thymus hormone can be given. 
Thymus hormone is produced from calf thymus glands. The global 
supply of calf thymus glands is limited to approximately 50 tons per 
year, which is much less than would be necessary for world-wide 
therapeutic treatment.
The production costs of the necessary therapeutic dosage per 
person, amounts to $1000 (1985). However, with the help of rDNA 
technology, the same product could be manufactured without any 
raw material supply limitations and calculations indicate that 
production costs could come down from $1000 to less than $1 for 
one therapeutic dosage, during the 1990s.246
Other examples include the production of insulin, human growth 
hormone or interferons 247
246Hacking, 1986
47Fishlock, 1989
277
To summarise the net result of so many possibble trends cannot be 
precisely evaluated. In the short and medium terms, biotechnology 
might add somewhat to the unemployment problem, particularly In 
countries with large agricultural sectors, such as Ireland, although it 
is impossible to separate biotechnology from other job-reducing 
effects of technology. In the long term, after fundamental advances 
in many, including health-related sectors and with an increasing 
number of new products, biotechnology could well become a net 
creator of jobs.
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CHAPTER 6: 
INDUSTRIAL 
INNOVATION IN 
IRELAND
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6.1 INTRODUCTION
This section of the present thesis focuses on government 
innovation policies, the promotion of innovation and the creation of 
an environment for innovation. The importance of exploiting local 
resources for innovation is highlighting the impact of technology 
transfer and the role of the university / research centres for 
innovation are considered.
The evolution of Irish Science and technology policy is discussed to 
illuminate the environment in which technology-based Irish industry 
operates.
The discussion then turns to the specific government policy and 
state-support framework for innovation through biotechnology in 
Ireland. Finally, the role of the Irish Venture Capital Industry in 
assisting the development of indigenous Irish industry is briefly 
discussed.
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6.2 IRELAND AND INNOVATION
Ireland has experienced unprecedented levels of growth 
since the early 1960s and has undergone major change in 
all areas of economic, social and cultural activity. Ireland 
now displays the features of both a developed and an 
underdeveloped economy and is characterised as a society 
in transition in which both traditional and modern values and 
attitudes co-exist. Against this background of a society in 
transition, the transformation of work occurring in the 
industrialised countries of the world presents both 
opportunities and challenges.
Over the past forty years many studies have been carried out to 
identify the sources and determinants of economic growth. These 
studies have indicated that technological change is one of the most 
important factors related to economic growth.
A recent OECD report highlights the need for Ireland to get 
involved in three key future technologies which it identifies as 
microelectronics, new materials and biotechnology.249
The application of these new technologies is seen as a means 
towards revitalising existing products and services, improving 
manufacturing processes and the exploitation of natural resources.
2480 ’Connor, 1989
249OECD, 1987
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6.3 GOVERNMENT INNOVATION POLICIES
Government policy towards science and technology is not new. 
Governments have long since followed policies designed to 
encourage innovation on the assumption that technical change will 
ultimately lead to the improvement of living standards. For 
instance, one of the earlier measures to encourage inventive activity 
and spirit were the patent Acts, which in essence rewarded 
inventors for their discoveries.
Throughout the industrialised world these numerous measures 
were later followed by a large number of institutional steps to 
enable industry to make use of developing technology.
For example, in the UK, the Department of Scientific and Industrial 
Research (DSIR) was established in 1917, aimed at making science 
and technology contribute to the benefit of society. In the 
Netherlands, a similar body - the Organisation for Applied Scientific 
Research - was set up in 1932. Similar organisations were 
established in many more countries including Ireland. The 
evolution of science and technology policy in Ireland is discussed in 
detail in Section 6.9.
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Today, therefore, almost all industrialised countries take at least 
some steps to help the innovative capacity of industry. There are a 
number of different approaches with respect to innovation policy 
that a government can adopt, both in the economy and in industrial 
development generally.
Here, two kinds of state intervention with regard to planning and 
industrial policy can be discerned.250 In some countries state 
intervention is seen as a major process of indicative planning. This 
is the case in such countries as France and Italy where industrial 
policy is used as an important instrument for economic policy and 
where the objectives of that policy are formulated within a 
framework of economic and social development plans, which are 
indicative for the private sector. Industrial innovation policy is then 
formulated through consultative an co-ordinate procedures by 
institutions within government and between government and 
industry.251
In other countries, industrial policy is seen as part of general 
economic policy aiming to create a favourable climate for industrial 
development. Although these countries, such as the Netherlands, 
Denmark and the German Federal Republic use industrial policy
250Rothwell and Zegveld, 1982
251 Condon, 1986
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instruments or even sectoral policies, these policies are not 
formulated within the framework of a national plan, nor are they 
used as selective policies in an intensive or systematic way.
Regarding state assistance aimed at small industry, Kennedy 
(1985) also distinguishes between two different contrasting patterns 
of state intervention, what he describes as "active neutrality" and 
"positive discrimination".
Active neutrality consists of state intervention designed to remove 
disadvantages facing small and medium sized firms, found 
wherever free market forces are allowed to operate. Such 
"disadvantages" usually arrive from legal, institutional or 
administrative factors or as is more usual, from imperfections in the 
marketplace itself.252
On the other hand, positive discrimination involves the provision of 
facilities and incentives to small firms which are not offered to large 
firms. The generally accepted basis for this approach is that the 
market is sufficiently imperfect in relation to small firms that only 
positive discrimination can place such small firms in a competitive 
position with their larger counterparts.
252Condon, 1985
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Kennedy (1985) believes that the balance between either approach 
being adopted by different countries is primarily determined by 
political philosophy and by economic environment. For instance, 
the US and Japan are examples of countries that employ positive 
discrimination in favour of small firms operating within their 
economies.
However, it has been suggested that the policies followed by these 
two governments are far from protecting the small firm sector from 
the strenuous forces operating within the free market economy.253
In the US, for example, small firms are expected to create more 
competition in an environment that already is among one of the 
most competitive in the world. The Japanese government, for 
instance, places stronger emphasis on flexibility and adaptation 
and small firms are expected to co-operate with each other, as well 
as with larger firms, in achieving these goals.
Traditionally, most western governments have tended towards a 
more general policy of active neutrality, although in recent years 
there has been a substantial increase in the scope of policies and 
institutions aimed at helping small industry in many countries. The 
impetus for this change has come from a number of different
253Condon, 1985
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sources. Firstly, the increase in unemployment In many countries, 
especially over the last decade, has forced policy makers to look at 
small firms as sources for new jobs. Also, the technological 
"backwardness" of so many small firms plus the innovative potential 
of some, have also helped to improve the technological services 
offered to small firms.
A valid case can therefore be put forward for the provision of 
special assistance for small firms, not alone here in Ireland, but 
throughout the industrialised world. However, specifically 
regarding Ireland, a number of clear-cut factors are generally put 
forward in justifying the assistance provided for small and medium 
sized firms by a large number of state sponsored agencies.254
(i) Ireland has a sizeable proportion of its workforce employed 
in the small and medium firm sector. Almost 60% of this 
country’s manufacturing workforce is employed in 
establishments employing less than 200 people.255 It is also 
estimated that small firms employing less than 50 people, 
represent 80% of all Irish owned manufacturing firms.256 
The small firm sector is therefore of crucial importance to the
254Condon, 1985
255Kennedy, 1985
Kennedy, 1985
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national economy. While many of these firms may never 
become large, the most important consideration of 
employment creation and indeed employment preservation, 
requires the state to provide the assistance needed to help 
improve the general efficiency of such firms.
(ii) Small firms are now thought to be an integral part of regional 
policy, and the trend of Irish industrial policy has been to 
disperse manufacturing industry throughout the country. 
Regional development has long been an important factor in 
this country’s industrial development and small firms have an 
important role in this area.
There has been a remarkable tradition of public intervention by 
successive governments, in the Irish economy. The Irish approach 
to public intervention as dealt with matters according to their 
practical significance or immediate importance, promoting 
economic development by certain kinds of activity which were 
unlikely to be generated by the private sector, and which therefore 
required public support.
By far the most popular mechanism for state intervention in the Irish 
economy has been the "state-sponsored body". The Irish semi­
state sector is usually divided into two parts. On the one hand
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there are those bodies which receive most of their income from the 
sale of their products; they trade openly on the market, offering 
products and services to the consumer, and counterparts of such 
bodies in other countries. Examples of such bodies are An Bord 
Bainne and Aer Lingus.
On the other hand, there are those bodies whose income comes 
totally or mainly in the form of government grants and whose 
function is the implementation of certain aspects of public policy. 
The state support framework for innovation in Irish industry is 
almost totally comprised of agencies of the latter type and among 
the most notable of such semi-state bodies are the Industrial 
Development Authority (IDA), An Coras Trachtala Teoranta (CTT), 
the Irish Goods Council and EOLAS.
During the last decade issues related to the impact of new 
technology-based sectors has moved to the forefront. Research 
on the effects on the rate of innovation of various kinds of policies 
outlined above has also highlighted the fact that governments tend 
to adopt a narrow view of various kinds of policies which influence 
a nation’s technological capabilities and pattern of development. 
They also tend to compartmentalize problems associated with
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stimulating and effecting development and with its concomitant 
social and economic impact.257
In this connection, it has been suggested that governments tend to 
assume that a nation’s technological capabilities are influenced by 
various forms of technology policy rather than by policies in other 
related areas, such as entrepreneurship, economic and trade policy 
instruments - government expenditure and investment competition 
and protection.258
However, such policies may have a greater effect on the rate of 
innovation than policies purely concerned with research and 
development in the narrow sense. However, in accordance with 
underlying assumptions many countries have geared their policy 
instruments increasingly towards promoting industrial research and 
development.
Furthermore, while explicit attention has been given to national 
issues and the national context, regional and local areas are 
increasingly seen as important. The regional and local area’s role 
in the promotion of activities to stimulate science and technology
257OECD, 1987
2580 ’Connor, 1989
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development is seen as one of the key stimulants to economic 
growth.259
6.4 PROMOTION OF INNOVATION
Before discussing the promotion of innovation and the creation of 
an environment for innovation it is necessary to consider the 
changing social and economic environment in which initiatives 
aimed at improving the indigenous capacity of a country are being 
undertaken.
The developed world’s economy is undergoing radical change and 
the process of adjustment has had major impacts particularly on 
the nature of work. These developed countries are moving from an 
industrial era to an information era, or from a society based on 
energy and raw materials to a society based on brain power and 
the flow of data. Figure 19 outlines the kind of transition that has 
taken place. In this kind of society, it is suggested that people or 
"human capital" are the primary resource. The focus is on 
individuals, and on their skills as entrepreneurs or innovators. In 
this connection, economic redeployment is seen to be restricted by
2590'Connor, 1989
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FIGURE 19: COMPARISON OF THE AGRICULTURAL SOCIETY. 
INDUSTRIAL SOCIETY, AND THE INFORMATION SOCIETY*
Key
Characteristics
Agricultural
Society
Industrial
Society
Information
Society
Time period 10,000 years and 
continues today 
in most of the 
world
200 years 
(began circa 
1750)
? years 
(began circa 
1955)
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Basic Resource
Food Energy Information
Main Type of 
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Farmers Factory
workers
Information
workers
Key social 
institution
Farm Factory Research
University
Basic
Technology
Manual
Labour
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Engine
Computers
Electronics
Nature of Mass 
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One-way 
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One-way 
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that are 
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*0'Connor, Joyce (1989) 'Creating an Environment for Enterprise', paper presented at conference, 
Entrepeneuring the Midlands, (Bord na Mona), Feb 27th, 28th, 1989
the scarcity of people with the necessary skills and requisite 
qualities or people capable of responding to the challenge of 
creating new business, either with or without new technology, and 
directing growth within established firms.260 261
Accompanying this shift from an industrial society there has been a 
move towards the important role of technology and the way in 
which it can help further economic growth and development. New 
technology has changed the development potential of small and 
medium sized enterprises. The exploitation of their development is 
dependent on overcoming the disadvantages inherent in the lack of 
technical and managerial expertise, of technological facilities and 
support structures as well as socio-cultural factors such as the 
absence of an entrepreneurial tradition.
In the creation of new enterprises or the further development of 
existing ones, the limitation in many places is the absence of a 
strong climate for nurturing ideas and entrepreneurship. An 
example to support this view is the success of the American 
experience of California’s Silicon Valley, a scientific industrial area. 
This demonstrated that the supporting environment, the climate 
that activates entrepreneurial activity is all important.
260Cooper, 1970
Roberts, 1968
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Encouraged by such success, regions in Europe, including Ireland, 
are launching initiatives to promote science and technology 
development in their own local economies.
The success of these initiatives shows that there is are some basic 
principles involved, that is, that they are usually based on a careful 
consideration of a country’s needs and of its existing industrial 
base.
It has been suggested that in creating the climate and environment 
for building on indigenous strengths, countries need to become 
aware of their strengths, to nurture those that are emerging and to 
strengthen those that clearly exist. So while being receptive to new 
ideas, the strengths which already exist must not be neglected.262
It is appropriate at this stage to indicate what is meant by "high 
technology" and science and technology development. High 
technology is difficult to define and isolate statistically. Basically 
however it describes the application of
new and old technology to whatever we do.263
2620 ’Connor, 1989
2630 ’Connor, 1989
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Clearly both new and traditional industries and services can be and 
are improved by better technology.
What is important to emphasise, especially in relation to the 
industrial applications of biotechnology developments, is that not 
enough attention is placed on "high technology" industries per se. 
Rather the emphasis needs to be on the process of technological 
innovation and diffusion and on its impact for promoting industrial 
development and sustainable economic growth.
It is important therefore to become aware of and build on the local 
indigenous strengths rather than concentrate purely on the 
attraction of high technology businesses from outside the country.
Clearly, the key role which small and medium enterprises play and 
will increasingly play in the Irish context, in economic growth, in 
terms of output, new employment and sustained economic growth 
must be emphasised. The key issues which Ireland must address 
in this context relate to the questions as to whether they can first 
successfully exploit the results of research and development in new 
technologies and second whether the climate for entrepreneurship 
becomes more encouraging.
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It has been argued that systems of support are necessary for small 
and medium sized enterprises in the changing contemporary 
industrial world, but what is required will vary according to the 
different types of small and medium enterprises.264 265
It has further been suggested that differentiation of type of 
enterprise, often overlooked is extremely important when 
considering systems of support and the mediation and transfer of 
technology.266
It has been discussed that in order to directly stimulate 
technological development in the firm, governments have a 
remarkable tradition of public intervention in the form of grants and 
infrastructures. It is important however, to briefly look at the role of 
entrepreneurship as a complementary tool in economic 
development strategies.
264FAST Programme, 1988
2660 ’Connor, 1989
2660'Connor, 1989
6.5 THE ROLE OF THE ENTREPRENEUR
The important role of entrepreneurship as a vehicle of economic 
growth is now generally accepted. Schumpeter, (1950), pointed to 
the essential role of the entrepreneur in business formation and 
business development. He saw business as an evolutionary 
process, in which old industries were continually being placed by 
new ones in a series of upheavals which he called "creative 
destruction". In his view the entrepreneur played the pivotal role in 
the process and was responsible for recurring booms and 
recessions which, he argued, were due to the upsetting impacts of 
innovations. The main function of the entrepreneur "consists" of 
getting this done. While economists generally dislike theories that 
emphasise the role of the individual rather than of conditions that 
enable individuals to act, the central role of the entrepreneur is now 
generally recognised.
The entrepreneurial society has brought about a change in values 
and has resulted in new cultural role models. It also offers new 
ways of operating within both established and new organisations. 
The structure of the corporation is changing and is attempting to 
facilitate an entrepreneurial approach.
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The phenomenon of entrepreneurship is relevant to this context. 
This essentially means that one does not have to leave an 
organisation to become an entrepreneur. Rather one may and is 
encouraged to innovate and adopt an entrepreneurial style within 
the established, existing organisation.
In discussing entrepreneurship and/or intrepreneurship, it is 
important to see that both the entrepreneurial and intrapreneurial 
individual and the type of organisational structure that will support 
such individuals are mutually dependent on each other. It is also 
important to underline that entrepreneurship or intrepreneurship is 
just one way in which firms can revitalise themselves.
In this connection the question as to whether governments should 
provide incentives to those organisations willing to adopt serious 
entrepreneurial programmes must be addressed. This emphasis 
on intrapreneuring would then get beyond the barriers that have 
hampered traditional discussions of industrial policy as to what 
types of industry should be supported. The emphasis would be on 
where it should properly be focussed, namely on those industries 
and specific companies willing to undertake systematic 
programmes of long-term demonstrated, institutionalised creativity 
and innovation.
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6.6 IMPORTANCE OF EXPLOITING LOCAL 
RESOURCES FOR INNOVATION
It is entrepreneurs / intrapreneurs who will enable regions to keep 
their competitive edge, using all the resources available to them to 
make solutions and create new products and processes. The 
results of studies however do highlight that the important conditions 
for science and technology development within a regional context 
are the technological infrastructure and the entrepreneurial network 
that encourages the creation of indigenous technology based firms 
and supports their survival.267 268 However, the science and 
technology development activities of a region are dependent on a 
number of interrelated factors.269
* the pool of potential entrepreneurs / intrapreneurs
* the relative costs of doing business
* the level of activity in the industrial sector
* regional economic conditions
267Roberts, 1968
268Roberts & Berry, 1985
2690 ’Connor, 1989
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* quality of the labour force
Research indicates that it is not possible to give one single factor as 
a causal explanation as to why some regions and communities 
have been more successful than others in nurturing science and 
technology development and benefiting from its development.270
Evidence from various states in North America and Europe 
suggests that the following factors interacting together in a 
supportive climate increase the likelihood of success.271
* Research development and technology transfer
* Human capital including education and training
* Entrepreneurial training and assistance
* Financial capital
* Information gathering and dissemination
270O’Connor, 1989
271 O’Connor, 1989
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Hence, strategies for developing the technological level of a region 
are multi-faceted. Furthermore it is clearly important to play close 
attention to developments elsewhere. While the importance of 
basic research is recognised, the regions should also ensure that 
mechanisms are in place for scanning and evaluating what is going 
on elsewhere in the world and for applying that information to the 
development of technologies in the region. As the Japanese 
experience highlights, most of the important basic research in any 
given field is going on outside the region.
O’ Connor, (1989) suggests that there are factors over which a 
community has very little control, such as population, industrial 
base, presence of research institutes and proximity to high 
technology centres. In this regard she suggests that science and 
technology development objectives and strategies should be 
adjusted accordingly. For example, areas without an existing "high- 
technology" base choose the strategy to bring in branch 
manufacturing or assembly plants rather than research institutes. 
Over time, these plants can help create a skilled workforce and 
technical infrastructure. This, in turn, will help attract more 
sophisticated operations and encourage spin-offs. The mid-west 
region in Ireland is a successful example of this approach.
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Science and technology development initiatives need to take a 
realistic view. In any region a number of complementary strategies 
need to be considered. Most local strategies involve infrastructural 
developments, the establishment of centres of technical and 
financial information as well as incubator units. In the mid-west 
region of Ireland, for example, there is a Technological Park which 
has both a university and an innovation centre and is 
complemented by government support agencies which provide 
other technical and financial assistance to existing companies as 
well as training interventions for members of their workforces.
6.7 IMPACT OF TECHNOLOGY TRANSFER ON
INNOVATION
In this era of rapid technology change, the economic health of a 
region will depend on its abilities to "capture" knowledge in science 
and technology and to foster innovation and entrepreneurship. As 
suggested in Section 6.4 knowledge and its utilisation are replacing 
the possession of a natural resource base as the key to economic 
prosperity.
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Any reason which chooses to remain competitive in this next phase 
of industrial development must adapt to this new order and devise 
mechanisms to exploit the economic potential of developed 
knowledge and technology. Therefore, managing the technology 
transfer process is an important key to development.
O’Connor (1989) points out that the most technology transfer takes 
place at the enterprise to enterprise level and it is in the enterprise 
that the competence to manage technology transfer must reside.
Because of this, training in the process of technology transfer within 
the firm is essential. Technology transfer however, is not a one­
time event, it should be a continual process of learning, evaluation 
and action. It is with this in mind that training intervention for all 
employees needs to be structured.
6.8 ROLE OF UNIVERSITY/RESEARCH 
CENTRES FOR INNOVATION
A desire to strengthen their local economies by claiming a share of 
the jobs in the high-growth, high-technology science and 
engineering fields has acted as a catalyst for regions and
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universities to attract and expand high-technology organisations in 
their areas. In some cases the universities also act as incubator 
units promoting entrepreneurial internships to facilitate the early 
stages of development of a high-technology industry.
Many of the efforts have involved the creation of "research parks" or 
science and technology centres in which a number of high- 
technology organisations share a common campus. Frequently, 
this places them in a position to call on the expertise of researchers 
at a nearby college, university, government faculty or an industrial 
complex with a substantial R & D facility. A case in point in Ireland 
is the Plassey Technological Park.
However, in order to ensure that the positive impact of universities 
for innovation is realised, the universities must be structured to 
preserve traditional academic values with teaching and research 
while meeting the commercial needs of business.
It is important to note that another vehicle for technology 
development that builds on the resources already in place in the 
university system is the growing number of university-industry 
research and consultancy arrangements. Thus through 
interventions in technological innovation, third level educational
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institutions can become agents for innovation and major 
contributors to industrial strategy and development.
A Technological Park can be seen to attempt consciously to create 
an environment supportive of new ventures in high technology as 
well as providing a service to mediate technology to prospective 
entrepreneurs. An issue here is that on a practical level, universities 
frequently do not have the ethos, management-style or structure 
that is appropriate for the development of new small companies. A 
central issue for third level administrators to address relates to the 
way in which administrative policies may be adjusted so as to 
create an environment in which the academic, within limits, will be 
able to act on his/her own initiative and in an entrepreneurial 
manner.
In the creation of new enterprises the limitation in many places is 
the absence of a strong climate for nurturing new ideas and 
entrepreneurship. The growth of high technology firms can be 
maximised within the context of a supporting environment - an 
environment with a strong excitement about converting good ideas 
into successful businesses.
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Many new technology based firms which played a crucial role in the 
evolution of the US semi-conductor industry were established in 
such areas. In the Boston areas of the US, in particular, 
biotechnology development was,linked to private venture capital 
companies and to university departments. It is argued however 
that a centre of "knowledge" in the form of an R & D unit for a 
multinational "branch" plant also acts as a catalyst and encourages 
entrepreneurial activity.
6.9 THE EVOLUTION OF 
IRISH SCIENCE AND TECHNOLOGY POLICY
It was not until the late 1960s that science and technology policy 
became a real issue in Ireland. In the mid 1960s there was a 
beginning of consciousness planning in science and technology 
leading to the publication of the Irish Science & Economic 
Development Report in 1966. One year later, the National Science 
Council was set up to support individuals, teams or university 
departments that were involved in research. Little emphasis was 
placed on transferring the results of this research to Irish industry 
and in the next decade this gap was recognised as a fundamental 
weakness.
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In 1973, the National Science Council’s report, Science, Technology 
and Industry in Ireland (1973), emphasised the importance of both 
supporting research itself and stimulating technology transfer and 
promoting indigenous R & D. The 1970s witnessed the emergence 
of the National Board for Science and Technology, and the already 
existing institutions, An Foras Taluntais (AFT; Agricultural Institute), 
the Institute for Industrial Research and Standards and An Foras 
Forbatha continued to grow in parallel with an increased research 
effort at the Irish universities.
However, the 1980s saw increasing concern with the state of public 
finance, and as an era of fiscal rectitude dawned, science and 
technology drifted into a crisis situation.
Fortunately, the availability of the first EC Framework programme 
funds at this time helped ease the situation. This programme 
(1984-1987) was not only a welcome source of funding for research 
but it also brought Irish researchers in contact with European 
partners for collaborative projects. Such extended contacts 
broadened the awareness of knowledge in areas such as 
information technology and biotechnology among other fields, and 
the need to take strategic initiatives in such fast developing fields 
became obvious.
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The European Council’s launch of the S.P.R.I.N.T. programme 
(Strategic Planning for Innovation and Technology Transfer) in 
1987, for example, was designed to give further impetus to 
innovation throughout Europe.
To date, thirteen joint-venture/collaborative agreements have 
involved commercial or technological exchanges between firms and 
research institutes in Ireland, and other member states of the 
European community. (See Appendix C).
These agreements provide valuable linkages between firms and 
large institutions. Even though the main phase of the ESPRIT 
programme is due to run from 1989 - 1993 many activities are up 
and running such as the European Venture Capital Association 
(EVCA), a non-profit making organisation, with 160 members 
including the Industrial Credit Corporation, Allied Irish Investment 
Bank and the Development Capital Corporation (Ireland).
The second EC Framework programme (1987-1991) and third EC 
Framework programme (1990-1994) further contribute to the 
development of science and technology in Ireland. To discuss the 
various individual programmes that are involved in both the second 
and third framework programmes would be exhaustive. Thus for 
the purpose of this study, the main programmes under the second
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TABLE 15
BIOTECHNOLOGY RESEARCH PROGRAM M ES AS PART OF THE  
EU R O PEA N  SECOND FRAM EW ORK PROGRAM M E (1987-1991)
(1) BAP (Biotechnology)
(2) BRIDGE (Biotechnology)
(3) ECLAIR (Agro-industrial technologies)
(4) FLAIR (Food Technologies)
(5) AGRICULTURAL RESEARCH
(6) HUMAN GENOME ANALYSIS
(7) STEP (Environmental Protection)
(8) MEDICAL AND HEALTH RESEARCH
(9) ESPRIT (Information Technologies)
(10) STD (Science and Technology for Developing 
Countries)
SOURCE:
COMPILED FROM  PERSONAL CONSULTATION WITH EOLAS; THE IRISH 
SCIENCE AND TECHNOLOGY AGENCY (1990)
framework programme relevant to biotechnology development are 
listed in Table 15.
The current government gives a high priority to science and 
technology and has increased the expenditure in certain areas of 
science and technology which are related to economic growth (see 
Section 6.10.3).
The appointment in 1986 of the first Minister for Science and 
Technology was a firm indication that the state as becoming more 
confident about a practical role for science and technology.
In 1986 a series of Programmes for Advanced Technology 
(P.A.T.S.) were established, to enhance industrial development and 
competitiveness in a particular sector or niche, through advanced 
technology, and also to raise the international profile of Irish 
research and development. The PATS attempt to develop new 
technologies and transfer them to industry, through the provision of 
contract research and services. It is the aim of each PAT to
become self-sustaining in time. At present, three PATS are
underway and these include BioResearch Ireland (Biotechnology), 
Advanced Manufacturing Technology and Optronics Ireland. The 
minister for Science and Technology has since announced three
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new PATS, in April 1990. These will be in the areas of Power 
Electronics, Software Technology and Advanced Materials.
Since taking office in 1987, there have been significant changes in 
the administration of Irish Science and Technology. The major 
science policy and research funding agency, the National Board for 
Science and Technology (NBST) has been merged with the 
Institute for Industrial Research and Standards (IIRS) to form Eolas 
- the Irish Science and Technology agency.
Further rationalisation was witnessed when An Foras Taluntais and 
its sister agency, ACOT, (the Agricultural and Food Development 
Agency) were merged to form the Agricultural and Food 
Development Agency, TEAGASC, while An Foras Forbatha, with 
responsibility for physical planning, as absorbed into the 
Department of Science and Technology to become the 
Environmental Research Unit.
The restructuring of Irish agencies has been directed towards 
providing a cost effective support for Irish Science and Technology 
and the shift in emphasis has been towards applying the results of 
research to the benefit of the Irish economy. The allocation of IR£ 
111 million through EC structural funds to science and technology
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(1990) and the inclusion of support from the International Fund for 
Ireland and the new EC Framework Programmes, means that a 
high level of activity is expected in Irish Science and Technology.272
6.10 GOVERNMENT POLICY AND THE STATE 
SUPPORT FRAMEWORK FOR INNOVATION IN 
BIOTECHNOLOGY IN IRELAND
While the innovation process as outlined in Appendix D could be 
used as a model to describe the support framework for innovation 
in Ireland under the headings of idea phase, research and 
development and market phases, as well as their subheadings, 
such an analysis would be both protracted and tedious.
Thus for the purpose of this study, the issue is treated by 
examining the critical policy areas for biotechnology and the main 
agencies which support biotechnology innovation in Ireland.
Government policy is a critical factor as it establishes the 
environment in which bio-industry must developed. Ryan (1988) 
suggests that the critical policy issues for biotechnology are:
272EOLAS, 1990; Personal Communication
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* Industrial Policy
* Biotechnology Research Policy
* Education and Training
* Regulation of Biotechnology
However, one of the limitations of national policy on biotechnology 
In any country is that the sector is becoming dominated by 
multinational companies. Investment in manufacturing by these 
companies can be made in almost any country. As a result, an 
important aspect of government policy has been to create an 
environment which is attractive to multinational biotechnology 
companies. The critical elements in this environment are the 
technical skills and infrastructure, the regulatory environment, and 
the grants and tax packages available. These factors are however 
also very Important and relevant to the development of indigenous 
industry.
Additional relevant factors for the latter include new enterprise 
development assistance, availability of risk capital and technical 
assistance to start-up companies.273
273Ryan, 1988
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Each of the critical policy areas for biotechnology in Ireland outlined 
above are elaborated in the following subsections.
6.10.1 INDUSTRIAL POLICY IN IRELAND
In 1979, the Irish government commissioned the National Economic 
and Social Council (NESC) to undertake a fundamental review of 
Irish industrial policy. The major part of this review was undertaken 
by the Telesis Consulting Group. Since its publication 1982, the 
Telesis Report and the NESC’s comments on it, has brought about 
an unprecedented debate on various aspects of industrial policy.
The government has contributed to this debate and the publication 
of the White Paper on Industrial Policy274, was largely designed to 
give a new impetus to industrial development in Ireland. The White 
Paper (1984) incorporated innovation into one of the major strands 
of industrial development strategy. However, the new effect of this 
has been a slight shift in the restructuring of grant-aid, away from 
capital intensive grant aid and an improvement in grant-aid toward 
product and market development.275
274N.E.S.C., 1984
275IDA, 1989
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Ultimately, the 10% corporal tax introduced in 1981 continues an 
inbuilt bias against conducting R & D in Ireland, thus hitting at the 
very heart of the innovation process.
Recommendations with regard to technological industrial policy in 
Ireland were given by the Sectoral Development Committees 
Report on the Technological Capacity if Irish indigenous 
industry.276
The Irish government has adopted some of the suggestions of this 
report by providing incentives for firms to access new and 
emerging technologies, in their areas of operation, including larger 
grants for higher risk projects, support for prototype development 
and certification.
The development and application of new technologies, including 
biotechnology are now seen as providing a range of opportunities 
to develop a strong and internationally competitive industrial sector 
in Ireland, both from Irish and foreign owned industry.
Since 1970 the implementation of a policy of attracting foreign 
manufacturing industry to Ireland has resulted in a significant 
change in the Irish industrial economy. The implementation of this
276Sectoral Development Committee, 1985
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policy is carried out by the Industrial Development Authority (IDA). 
Among the industry sectors targeted by the IDA for development 
are chemicals and healthcare (including pharmaceuticals).
International companies have been attracted to Ireland by a 
combination of tax incentives and grants, and a technical 
educational infrastructure which can supply graduates with the 
required skills (see also Section 6.10.3). The grant package 
includes up to 60% capital grants, 100% training and 50% R & D 
grants.
Biotechnology industrial policy has been approached by the 
creation of the National Biotechnology Programme (1987) as part of 
the government’s efforts to develop science and technology in 
economically important sectors.
The National Biotechnology Programmes’ objectives include the 
following:
(1) To encourage research activity in Ireland both by home- 
based and overseas companies.
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BIORESEARCH BIOTECHNOLOGY RESEARCH  CENTRES IN  
IRELAND
TABLE 16
, x v - î \  : P "  , • <*' ' i ':  :■ . .v  • '  •• •
NATIONAL DIAGNOSTICS CENTRE
(UNIVERSITY COLLEGE GALWAY) i-Ssssg
NATIONAL CELL AND TISSUE CULTURE CENTRE 
(DUBLIN CITY UNIVERSITY)
NATIONAL FOOD BIOTECHNOLOGY CENTRE 
(UNIVERSITY COLLEGE CORK)
NATIONAL AGRICULTURAL AND VETERINARY 
CENTRE (UNIVERSITY COLLEGE DUBLIN)
NATIONAL PHARMACEUTICAL BIOTECHNOLOGY 
CENTRE (TRINITY COLLEGE DUBLIN)
SOURCE: BioResearch Ireland (1990); Personal Communication
BIOTECHNOLOGY - RELATED RESEARCH SPECIALISATIONS 
OF IRISH COLLEGES AN D  RESEARCH INSTITUTIONS
TABLE 17
INSTITUTION RESEARCH AREAS
(TEAGASC)
Agricultural Institute
* Kinsealy Agricultural Centre
* Moorepark Research Centre
* Oakpark Research Centre
* Western Research Centre
UNIVERSITY COLLEGE CORK 
UNIVERSITY COLLEGE DUBLIN
UNIVERSITY COLLEGE GALWAY
ST. PATRICK'S COLLEGE, 
MAYNOOTH
DUBLIN CITY UNIVERSITY 
TRINITY COLLEGE DUBLIN
Micropropogation of trees and ornamental plants; 
protoplast culture and mutagenesis, plant breeding; 
Plant pathology and mycology, Protein engineering; 
Cheese starter culture technology; Physiology and 
Biochemistry of lactic acid bacteria.
Crop breeding
Embryo Transfer Technology
Applications in dairy and food industries; plant biotech; 
nitrogen fixation; virology; protein chemistry.
Fermentation/chemical engineering; enzymology; plant 
pathology; mammalian reproduction; enzymology; Im 
munodiagnostics; waste utilisation/fermentation; 
Immunology.
Enzymology; Immunodiagnostics; Waste utilisation/ 
fermentation; Immunology.
Microbial Crop Protection; Plant Tissue Culture, 
Cellular Biotechnology
Monoclonal antibodies; Cell culture to pilot scale; 
Fermentation Technology
Genetic engineering; Diagnostics; Virology; Microbial 
Pathogenicity.
SOURCE: Ryan, Jim. (1988): "Development of Irish Industrial
Biotechnology" Intl. Industrial Biotech, 8:1, Jan/ 
Feb,1988, p.8
TABLE 18
AGENCIES INVOLVED IN  DEVELOPM ENT OF 
BIOTECHNOLOGY IN IRELAND
AGENCY FUNCTIONS MECHANISMS
BIORESEARCH
IRELAND
IDA IRELAND
EOLAS THE IRISH 
SCIENCE & 
TECHNOLOGY 
AGENCY
Development and Market­
ing of Irish Biotechnology 
Research
Development of Irish Mani 
facturing and Service indus­
try and promotion of Irelan 
as a location for overseas 
industry
Promotion of Irish Science 
and Technology and Provi­
sion of Technical Services tc 
Industry
Staffing and equipping 
research centres. Marketing 
and management of biotech­
nology research services
Up to 60% capital grants; 
100% training grants; 50%
1 R  & D grants, low cost 
finance; assistance with 
company development and 
planning licensing and joint 
venture agreements
Basic and strategic research 
grants to university re­
searchers.
Encouragement of univer- 
sity-industry co-operation 
Analytical and technical 
advisory services to chemi­
cal, pharmaceutical and 
other industries.
SOURCE: Ryan, J.: "Development of Industrial Biotechnology in 
Ireland" in International Indusrial Biotechnology, 8:1 (1988)
(2) To establish a significant reputation for Irish biotechnology 
research and thus help attract overseas companies to locate 
in Ireland.
(3) To engage in the transfer of biotechnology from Irish 3rd 
level colleges to industry.
The programme objectives are to be achieved by establishing, 
equipping and staffing centres of biotechnology expertise dealing 
with research topics in which there is existing Irish expertise and 
which are of relevance to Irish industry.
To date, five research centres have been established in the area of 
biotechnology (see Table 16). These centred are maintained, 
managed and marketed by BioResearch Ireland, a contract 
research organisation set up under the National Biotechnology 
Programme. These research centres as to the existing research 
institutes and agencies involved in the development of 
biotechnology in Ireland (see Tables 17 and 18).
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6.10.2 BIOTECHNOLOGY RESEARCH POLICY IN
IRELAND
With the appointment in 1987 of a Minister of State for Science and 
Technology, a special science and technology budget was 
established to promote industrial development through the use of 
science and technology. This budget is funded by the office of 
science and technology within the Department of Industry and 
Commerce and is largely administered by EOLAS. Among the 
initiatives funded from this budget are a series of programmes in 
Advanced Technology; what is significant for the purpose of this 
study is the Biotechnology PAT. This programme draws together 
teams from industry, the state sector and higher education 
industries to develop expertise in identified niche areas.
The total allocation to publicly funded science and technology in 
1989 was IRE 420.9 million.277
Table 19 shows that education and training/manpower has 
increased its share of the total budget from 37% in 1980 to 50% in 
1989. Expenditures on supporting university-based researchers
277EOLAS, 1990; Personal Communications
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are in biotechnology related fields. Thus biotechnology related 
research in universities will benefit from this increase in expenditure.
The healthcare sector has increased its share of the total science 
and technology budget by 2% to a total of 16.4%, while 
environment and forestry and timber showed marginal increases 
over the same nine year period.
Agriculture has decreased its share of the total science and 
technology budget by ten percentage points between 1980 and 
1989. (See Table 19).
What is significant about these figures is that those sectors where 
the impact of biotechnology is most promising receive the highest 
percentages of the total science and technology budget, thus 
indicating the government’s commitment to biotechnology research 
policy.
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TABLE 19
CHANGES IN SECTORAL SHARE OF TOTAL SCIENCE AND  
TECHNOLOGY BUDG ET (1980 -1989)
SHARE OF TOTAL S & T 
1980 1989
BUDGET
Percntage 
Point Change
INCREASES
Education and Manpower 36.6 50.0 +13 .4
Health 14.2 16.4 +2.2
Environment 1.3 1.5 +0.2
Forestry & Timber 0.5 0 .6 +0.1
DECREASES
Building & Construction 0.7 0 .6 -0.1
Transportation 0.4 0 .2 -0.2
Economic & Social 1.4 1 .1 -0.3
Marine 1 .1 0.7 -0.4
Energy 1 .0 0 .2 -0.8
Manufacturing 16.6 14.7 -1.9
General Public Services 9.7 7.5 -2 . 2
Agriculture 16. 5 6.5 -10. 0
SOURCE: EOLAS (1990), Personal Communication
6.10.3 EDUCATION AND TRAINING POLICY IN
IRELAND
Uniquely in Europe, almost half the Irish population is under twenty 
five years of age, and almost one million young people are now in 
full-time education. Approximately half the graduates from second 
level education go on to third level studies. Consequently, 
education and training forms a high proportion (50%) of the overall 
government spending on science and technology (see Section 
6.10.3, Table 19).
Irish higher education colleges have long established strengths in 
the biomedical and agricultural sciences. Government policy has 
been to further develop those aspects of the educational 
infrastructure which are relevant to industrial growth. This has 
resulted in a large growth in technical education, including the 
establishment of Regional Technical Colleges and refurbishment 
and expansion of technology-related facilities in existing colleges.
Over half the 38 degree and certificate awarding institutions in 
Ireland were established in the last twenty years. The emphasis on 
technical education has resulted in 30% and 63% increases in the
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number of science and engineering undergraduates respectively in 
the last ten years.278
Apart from courses in the biotechnology-related disciplines, there 
are currently eight courses specifically on biotechnology in Irish 
colleges.
Four of these are undergraduate courses in chemical or 
biochemical engineering (B.E.), biotechnology and chemical 
technology. The remaining four are M.Sc. courses, three of which 
deal with biotechnology in general and one with genetics.
The 1988 output from these courses and other relevant disciplines 
from six of the major colleges is shown in Table 20.
Further graduates will have obviously qualified from the Colleges of 
Technology, and the Regional Technical Colleges.
278Ryan, 1988
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TABLE 20
BIOTECHNOLOGY-RELATED GRADUATE O UTPUT FROM  SIX  
OF THE M AJOR COLLEGES1 D U R IN G  1988
BSc (Hons.) MSc PhD
Biochemistry 56 13 10
Chemistry 79 26 27
Microbiology 56 12 3
Biology 2 94 14 20
Pharmacy/Pharmacology 65 5 9
Food Science 24 11 3
Genetics 13 3 2
Biotechnology 31 17 -
Analytical Science 29 - -
Biochemical Engineering3 39 - -
M. Applied Science 23 24 -
Industrial Microbiology 23 13
TOTAL: 532 138 74
1 = UCD, UCC, UCG, TCD, DCU, ST. PATRICK'S COLLEGE MAYNOOTH
2 = ZOOLOGY, BOTANY OR BIOLOGICAL SCIENCES 
3 =  UCD AND CORK RTC
SOURCE:
Adapted from "Irish Biotech News" 
Sep t 1989, pp. 5
6.10.4 REGULATION OF BIOTECHNOLOGY IN
IRELAND
The major regulatory considerations are those relating to the use of 
recombinant organisms, and to authorisation of biological products 
for medical or veterinary use.
Government policy on recombinant DNA (rDNA) has been to 
ensure reasonable safeguards without unnecessarily hindering 
research progress, or industrial use of genetically engineered 
organisms.279
The minister for industry and commerce in his opening address to 
a biotechnology seminar in 1987 addressed the issue of regulation 
in biotechnology in Ireland.
In fostering the development of biotechnology, we have 
been careful to regulate developments involving genetically 
engineered organisms. We recognise that in many 
countries industry has suffered because of over-restrictive 
regulations on the use of these genetically-engineered 
organisms, and more particularly because of over- 
bureaucratic procedures for licensing of such work. In 
Ireland, we have been careful to streamline these activities 
and procedures without in any way reducing our safety 
standards. We will, at the international level, continue to be 
on the alert for, and will oppose the adoption of, any
279EOLAS, 1990; Personal Communication
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proposals that might to lead to over-elaborate licensing 
procedures 2Q0
Regulation of the research in recombinant DNA (rDNA) was the 
responsibility of the Medical Research Council from 1974 until 1981 
when a National Recombinant DNA Committee was established.
The committee is representative of government departments, 
research and regulatory interests (including EOU\S, the Agricultural 
Institute and the National Drugs Advisory Board), and also 
members from the higher education sector, trade unions, an the 
Confederation of Irish Industry.
The committee uses as its guide-lines for the work the "Guide-lines 
for Research involving Recombinant DNA molecules" issued by the 
US National Institutes for Health (NIH). These procedures are also 
applied to industrial situations with relevant modifications.
As in most OECD countries, "large scale" is defined as over 10 litre 
volumes of cultured organisms. The NIH guide-lines on 
containment levels appropriate to the volume in use are applied 
where relevant.
280Reynolds, 1987
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Good Industrial Large Scale Practice procedures (GILSP) are also 
recommended by the committee. A guide to the committee’s 
procedures has been published (NBST, 1987).
When a company applies for permission to use recombinant 
organisms in their processes, the committee acts by advising the 
local planning authorities on the specific conditions to be met 
regarding the plant’s design and construction, process operation 
and worker safety. In cases where industrial applications have 
been granted, the recommendations have been incorporated into 
the planning approval for the company.281
The existing legal framework provides a basis for action by 
government if it is felt necessary. The relevant laws are the Water 
Pollution Act (1977), the Dangerous Substances Act (1972), 
Destructive Insects and Pests (Consolidation) Act (1958), and also 
relevant EEC directives and regulations.
Research institutions conducting or sponsoring rDNA research are 
responsible for ensuring that the research is carried out in 
conformity with the provisions of the guide-lines. They are required 
to establish an Institutional Biosafety committee. At least two of the
281 R yan,1988
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members of these committees must not be affiliated with the 
institution.
Approval for the medical preparations is administered by the 
National Drugs Advisory Board (NDAB), while veterinary 
preparations are the responsibility of the Department of Agriculture. 
The guide-lines for applications to NDAB have been published.282
6.11 VENTURE CAPITAL AND INNOVATION IN
IRELAND
In 1983, a report by the then National Board for Science and 
Technology (now EOUVS) on finance for small innovative 
manufacturers in Ireland addressed five key issues with regard to 
financial support for such companies (see Tables 21).
To discuss in detail each of the financial issues arising from this 
report is beyond the scope of the present study. Nonetheless, the 
development of a venture capital supply system targeted to the 
needs of high risk and/or high technology projects, such as 
biotechnology is extremely important when considering financial
282NDAB, 1987
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TABLE 21
FIVE KEY ISSUES OF FINANCIAL SUPPORT FOR INNOVATIVE 
SMALL MANUFACTURERS IN IRELAND
ISSUE DESCRIPTION
1 Financial institutions may need to develop new lending 
mechanisms more suitable for first-time entrepreneurs 
and innovative small firms.
2 The government may need to stimulate the development of a venture capital supply system targeted to meet the 
needs of high-risk and/or high technology projects.
3 Private financial institutions and public sector 
development agencies must become more responsive to 
the needs of innovative small firms.
4 A range of climatic or environmental factors, notably in 
the area of taxation, must play a more central role in 
stimulating innovation.
5 The financial supply system must be better co-ordinated and more effective in catering for innovative small firms.
SOURCE: NBST (1983) "Finance for Innovative Small 
Manufacturers", NBST report, pp.32
support for innovative small firms, which comprise part of the total 
population of the present study.
For this reason, an outline of the role of the Irish venture capital 
industry in assisting the development of indigenous Irish industry is 
given in the following sub-section, along with some recent venture 
capital investment patterns in Ireland.
6.11.1 THE ROLE OF THE IRISH VENTURE 
CAPITAL INDUSTRY 
IN ASSISTING 
THE DEVELOPMENT OF INDIGENOUS IRISH
INDUSTRY
In Ireland, as indeed in other countries, venture capital activity has 
been practiced for a very long time on an ad hoc basis by such 
investors as private individuals, industrial companies, banks and 
other financial institutions. The emergence of a dedicated venture 
capital industry as such has taken place during the last ten years. 
It has evolved from what could most aptly be described as "equity 
stake" type of investment activity where the focus by the investor
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was usually on an established business and where investor 
participation in the investment was minimal.
During the last ten years, the industry has developed to the point 
where it has become reasonably well established, and there are a 
number of well funded organisations engaged in venture capital 
investment in accordance with the now internationally accepted 
meaning of that term, that is risk investment with a capital gain as 
the primary objective, in a start-up or established business, run by 
one or more entrepreneurs where the investor assists the company 
in maximising the development potential of the company.
Significant events in the evolution of the Irish venture capital 
industry have included the formation of equity stake investment 
vehicles by Ireland’s two main banking groups, the Bank of Ireland 
(BOI) and Allied Irish Banks (AIB) in the late sixties and early 
seventies.
Both of these vehicles were formed with the support of other 
financial institutions as minority shareholders. This was followed by 
the formation of the Development Capital Corporation (DCC), as an 
independent venture capital and development capital company in 
1976. In more recent years, as venture capital activity has 
expanded, some UK venture capital organisations have become
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involved, with 31 having a permanent presence and some others 
participating in syndicated financings with Irish based venture 
capital investors.
In November 1980, the industry was given a boost by the 
introduction of the Unlisted Securities Market (USM). This made it 
more easy for young companies to achieve a public flotation and 
therefore brought improved prospects of marketability of their 
investment to both the venture capital investor and the 
entrepreneur. The marketability of one’s investment and the 
associated high public profile given to the entrepreneur when 
his/her company achieves a successful flotation are important 
contributors to the whole process of breeding entrepreneurs and 
encouraging the development of successful new businesses.
Another development which has become significant during these 
formative years of the industry has been the beginning of co­
operation between venture capitalists and some universities and 
3rd level educational institutions. This has already led to the 
establishment of some new high-technology businesses with 
venture capital backing.283
283DCC, 1990; Personal Communication
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6.11.2 LEGAL AND FISCAL ENVIRONMENT
The government has also played a major part in providing the 
necessary legal and fiscal environment in Ireland for venture capital 
investment and in actively participating through state sponsored 
funds. The three main incentive schemes that exist to encourage 
private investment in the area are the Business Expansion Scheme, 
the Research and Development Scheme, and the Share Acquisition 
Scheme.
6.11.3 BUSINESS EXPANSION SCHEME (BES)
This scheme was introduced in 1984 to encourage high risk 
investment in developing companies and enables the individual to 
subscribe for ordinary shares in a company or a designated fund 
and to deduct up to IRE 25,000 per annum in computing taxable 
income, within the regulations imposed by the scheme. However, 
with the rising uptake of the scheme there has been criticism 
regarding the reduced risk nature of some of the more recent 
investments. The recent Finance Bill (1989) introduced a number of
326
provisions designed to reorientate BES investments back to its 
original objectives.
6.11.4 RESEARCH AND DEVELOPMENT 
SCHEME
Like the BES, the Research and Development Scheme provides 
annual deduction of up to IR£ 25,000 to individuals investing in a 
research and development company. This is separate from, and 
additional to the BES deduction.
6.11.5 SHARE ACQUISITION SCHEMES
These schemes enable employees to acquire shares in their own 
company in tax favourable ways. Under the Share Option Scheme, 
an individual may be granted an option to buy shares in the future 
at a price which must not be less than the market value on the date 
the option is granted.
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In addition, regulation to implement the EEC directive on 
Undertakings for Collective Investment in Transferable Securities 
(UCITS) took effect in June 1989.
Furthermore, venture backed companies in Ireland may achieve a 
quotation on the International Stock Exchange of the UK and 
Republic of Ireland, most commonly on the Unlisted Securities 
Market (USM). In addition, the Smaller Companies Market (SCM) 
has been operating since 1986 in Ireland and is similar to the Third 
Market in the UK. Venture Capital Investments are also commonly 
exited through corporate acquisition.
6.11.6 VENTURE CAPITAL INVESTMENT 
PATTERNS IN IRELAND
The latest survey of venture capital activities in Europe, conducted 
by the European Venture Capital Association284 reveals that 
progress in Ireland is failing to keep pace with that in the rest of 
Europe.
284EVCA, 1990
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European countries venture capital companies raised just over ECU 
5.8 billion in 1989, a 67% rise on the 1988 figure. In Ireland 
however, new funds raised by the industry in 1989, at ECU 13.8 
million (IRE 18 million), was virtually half the level raised in the 
previous year.
In part this can be explained by timing differences. Investment 
patterns in Ireland may also be running at a slower pace than the 
European average, possibly due to earlier recessionary climates, 
but are still showing a reasonable level of momentum.285
On the down side as far as smaller start-up companies are 
concerned, 1989 was an apparently disastrous year for seeking 
funds. Ireland’s venture capitalists put more into supporting 
takeovers and buyouts than in previous years. While there was a 
slight increase in funds to finance expansions, the volume of "seed" 
and "start-up" investments was insignificant.
These figures however should be treated with caution, as the 
survey286 on which the data is based, takes a very narrow definition
285EVCA, 1990
286EVCA, 1990
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of venture capital, not in terms of investment strategy but in the 
agencies which are included in the survey.287
Furthermore, total investment in Ireland in 1989 was £ 30 million, 
slightly above the £27 million invested in 1988. Buyouts 
represented 55% of the total amount invested, although their 
average value is disproportionately high.
From these findings it appears that the Irish venture capital industry 
still finds it hard to identify sufficient projects which provide good 
prospects to justify the risks of investment.
Critics of the industry argue that true venture capital is about taking 
interest in a number of risk projects in the full knowledge that while 
some of the investments will fail, they will be more than offset by 
those that succeed. However, this argument can be rejected on 
the basis that to a large extent this approach is inhibited by the 
small size of the Irish market. It is also certainly true that venture 
capital companies are increasingly in competition for investment 
opportunities with a number of others, including the Business 
Expansion Schemes (see Section 6.11.3), accountants and 
solicitors, who also have access to private savings.
287
Four Irish venture capital companies, supplemented by estimates for the 
activities of others made by Venture Economics Ltd. which compiled the survey 
for EVCA.
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For a discussion of the potential use of venture capital 
organisations by companies involved in biotechnology R & D see 
Section 4.7.2.
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CHAPTER 7: 
RESEARCH 
METHODOLOGY
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7.1 INTRODUCTION
This section of the present thesis, describes the research design of 
the study, focusing on the general research method, the research 
population and specific procedure employed.
7.2 CHARACTERISTICS OF RESEARCH DESIGN
The most relevant of the presuppositions that determine 
one's research perspective is that methodological issues 
must always be answered within the context of a particular 
research setting.
Hence, methodologies are neither appropriate or inappropriate until 
they are applied to a specific research problem.
A qualitative methodological research approach was taken for this 
study, based on a framework of "direct research".289
(1) The research has been as descriptive as possible.
(2) The research has relied on simple, direct methodologies.
288Downey and Duane, 1979
289Mintzberg, 1979
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(3) The research has been as purely inductive as possible (that 
is, inferring of general case from particular information 
received during field work).
(4) The research has been systematic in nature with a well 
defined focus, related to the research study objectives (see 
Section 1).
(5) The research has measured in real organisational terms. 
The systematic nature of the research does not mean a 
detached approach was taken, on the contrary, measuring 
in real organisational terms means "getting out into the field", 
into real organisations, which questionnaires often will not 
do. Thus by measuring in real organisational terms the 
research has focussed on the organisations inherent 
complex and dynamic nature.
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7.3 METHODOLOGY
7.3.1 DESK RESEARCH
"Desk research" is an established method of covering secondary 
data. It is essential for the researcher to thoroughly appraise 
existing literature relative to the subject under investigation as a first 
step. The fundamental reason of this,
... will either be to orientate and educate the research 
executive or to avoid unnecessary repetition where research 
might already have been done.290
Moreover, desk research has the attractive advantages of being,
... non-reactive or unobtrusive ... it is economical, 
comparatively speedy, and can be undertaken with 
complete confidentiality.291
All relevant secondary sources of data were appraised prior to the 
commencement of the actual field study. Such preliminary 
investigative work provided a useful indication of relevant
290Newson & Smith, 1980
291Chisnall, 1981
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parameters of the study - an essential requisite for the development 
of the overall research strategy.
Secondary sources of data included journals books and reports 
relevant to the subject area of the study. In addition to these 
sources, preliminary interviews and telephone calls were made to 
individuals working or studying in the subject area.
The sources which were principally drawn on are listed as follows:
Journal of Product Innovation Management
Research and Development Management
Journal of Marketing
Managing Technological Innovation (Twiss 1980)
"New Products Management for the 1980s" (Booz, Allen and 
Hamilton, 1982)
"Marketing Management" (Kotler, 1986)
"Competitive Strategy" (Porter, 1980)
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OECD Reports
Bio/technology Journal
The Economist
Financial Times
Irish Times
Irish Biotech News
Research Management Journal
Research Policy Journal
Eolas {formerly, NBST) Reports
The relevant articles contained in the above sources provided 
useful further references. The "Anbar Management Services 
Abstracts" were also used to cite further relevant material.
Any references unavailable in the Dublin City University library were 
invariably obtainable using the "inter library loan" facility. This
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service proved to be invaluable, as it provided the means of 
appraising various British and American literature.
7.3.2 EXPLORATORY TELEPHONE ENQUIRIES
Due to the paucity of secondary data on the biotechnology industry 
in Ireland, it was considered necessary to also obtain primary data 
at this early stage.
Thus preliminary, informal, exploratory telephone calls and face-to- 
face interviews were made with individuals in relevant institutions 
including academic research institutions, the Industrial 
Development Authority, FAS, BioResearch Ireland, Eolas, and the 
Business Innovation Centre (Dublin).
With enquiries such as these it was indeed not possible to do other 
than acquire what may be termed a "general impression" rather 
than a complete picture of the specific research field.
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7.3.3 SAMPLE DESIGN
The first stage in sample design was to define as closely as 
possible the population to be covered by the research enquiry. 
The population to be studied comprised of those Healthcare and 
Food & Drink companies operating in Ireland, involved in 
biotechnology research and development either through in-house 
or contracted research and development, as a means towards 
innovation.
This criterion was used to screen potential respondents, because 
areas of enquiry of the study necessitated direct experience of this 
early stage of the innovation process.
From preliminary primary research involving exploratory telephone 
enquiries and personal interviews with relevant members of Irish 
organisations (including the Industrial Development Authority, 
BioResearch Ireland and Eolas), it was established that 
biotechnology research and development in Irish industry is mainly 
in the health care (including pharmaceuticals) and food and drink 
(alcoholic beverages) industries. As indicated in Section 1 these 
two sectors of Irish industry are extremely important to the Irish 
economy. Furthermore, these two sectors are among those
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industries in which the impacts of biotechnology developments can 
be seen, and in which biotechnology will have important effects in 
the future. (See Section 4.4)
Thus, these two industry sectors, namely the health care (including 
pharmaceuticals) and food and drink (alcoholic beverages) 
industries in Ireland were chosen as the focus of the study.
One of the decisive factors in sample design is the nature of 
the sampling frames available - the lists, indexes, maps or 
other population records from which the sample can be 
selected at each sampling stage.292
Yate’s (1953) five criteria provided the researcher with useful 
standards by which to judge the suitability of the available sampling 
frames. These may be summarised as follows.
(1) ADEQUACY
The sample frame should adequately cover the population to be 
surveyed, that is of course, relative to the purposes of the study.
(2) COMPLETENESS
292Moser and Kalton, 1977
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If the sample frame does not include some of the population 
members who should be included, "missing elements" will have no 
chance of being selected, so the sample will be unrepresentative to 
that extent.
(3} DUPLICATION
With some frames it is possible for an element to be entered more 
than once. If the risk of duplication occurs, some sort of weighting 
system should be applied to avoid bias.
(4) ACCURACY
A sample frame should contain accurate, up-to-date information.
(5) CONVENIENCE
It is convenient to have the frame in an accessible place; moreover, 
it is also preferable if it is arranged in a very suitable way of 
sampling.
Although no sampling frames can not be expected to satisfy all 
these exacting requirements, they alert the researcher to the basic 
problems which may arise.
341
The International Biotechnology Directory 1988293 was used as a 
first stage in the sample design. In total, eighty companies plus 
research institutes, operating in Ireland in various industry sectors 
were listed. However, this directory did not satisfy the five criteria of 
suitable sampling frames outlined previously, notably in its 
accuracy and completeness.
Furthermore, this directory referred to companies with different 
levels of involvement in biotechnology. The levels of company 
involvement in biotechnology in Ireland ranges from
(i) Supply houses that solely distribute biotechnology products, 
to;
(ii) Manufacturers of biotechnology products (usually the parent 
company is involved in the innovation process and 
subsequently allocates the production of biotechnology 
products), to;
(iii) Those companies in control of their biotechnology research 
and development programmes.
293Coombs & Alston, 1988
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TABLE 22
PRINCIPAL SAMPLING FRAMES RELEVANT TO THE SAMPLE 
DESIGN OF THE PRESENT STUDY
DIRECTORY / LIST TITLE YEAR
¡¡si
t
if
: W S
•J
l i l i l í
KOMPASS DIRECTORY 1989
INTERNATIONAL BIOTECHNOLOGY 1988
DIRECTORY
(COOMBS & ALSTON)
NBST DIRECTORY OF IRISH RESEARCHERS 1988
MANUFACTURERS, DISTRIBUTORS OF 
DIAGNOSTIC PRODUCTS
IDA LIST OF HEALTHCARE SECTOR 1989
COMPANIES IN IRELAND
To add to this the International Biotechnology Directory (1988) 
does not specify the level of involvement in biotechnology of each 
company listed. This fact alerted the researcher to the problems of 
using the directory as a sampling frame, as some of the companies 
listed are not relevant to the purposes of study, notably those 
companies that solely distribute biotechnology products and those 
companies only involved in manufacture (i.e. with no research and 
development activities in biotechnology in Ireland).
Hence, to obtain a suitable sampling frame, which would include 
those companies operating in Ireland in both the health care and 
food and drink industry sectors, which are involved in 
biotechnology research and development in Ireland as a means 
towards innovation, it was considered essential to compile one.
To this end a number of individual directories and lists were used 
as a starting base. The principal directory used was the Kompass 
(1989) Directory, from which those companies in Ireland operating 
in the health care, and food and drink industries were selected. 
Other relevant directories were employed to add to this list, and 
also to serve as confirmation that the final list adequately 
completely and accurately covered the population (see Table 22).
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A useful list of information relative to the purposes of this study was 
obtained from the School of Biological Sciences, Dublin City 
University294. This list included those companies that were invited 
to an open day at Dublin City University in October 1989. The 
purpose of this open day was to introduce companies operating in 
Ireland to recent biotechnology graduates of Dublin City University. 
Thus, this list included companies in Ireland that are involved in 
biotechnology in different industrial sectors. This list is extremely 
accurate as it was compiled by academics who are familiar with the 
biotechnology industry in Ireland. Hence, companies included in 
this list in the health care and food and drink industry sectors were 
taken, and supplemented the "starting base" list obtained through 
reference to the main lists and directories (see Table 8).
Thus a combination of the sampling frames referred to in Table 22 
and the Dublin City University Biotechnology open-day (1989) list 
were used to obtain a complete list of those companies in Ireland in 
the health care and food and drink industry sectors, as these 
"collectively" were considered to be representative of the initial 
population under survey. A combination of lists naturally gave rise 
to problems of duplication of companies. Thus a rigourous, 
double-checking procedure was adopted to ensure that this was 
avoided.
O Q A
Personal communication, 1989
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Finally it should be noted that when a complete list of the 
companies operating in the Irish health care and food and drink 
industries was compiled, certain companies were automatically 
omitted as a result of information received from the Industrial 
Development Authority and BioResearch Ireland.
Such information from these two agencies indicated that certain 
companies included in the list were not involved in biotechnology 
research and development in Ireland.
After omitting these companies from the compiled list, it was 
considered necessary to carry out a preliminary survey, employing 
a short postal questionnaire to confirm which of these companies in 
the "reduced" list were actually involved in biotechnology research 
and development in Ireland.
This preliminary survey was considered necessary as even though 
information regarding certain companies’ involvement in 
biotechnology was obtained from relevant agencies, such agencies 
could not confirm the biotechnology involvement of the remaining 
companies in the "reduced" list. (In fact, BioResearch Ireland are at 
present compiling an up-to-date Irish Biotechnology Directory due 
to the fact that such information is not readily available at present; 
which the present study may contribute to).
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Thus the preliminary postal survey aimed to establish those 
companies in Ireland, in the health care and food and drink 
industries, actively involved in biotechnology research and 
development (in Ireland) as a means towards innovation and thus 
establish a suitable sampling frame, relative to the purposes of the 
study. To this end a postal questionnaire was sent to all companies 
in the final "reduced" list.
7.3.4 POSTAL QUESTIONNAIRE
A questionnaire is a method of obtaining specific 
information about a defined problem so that the data, after 
analysis and interpretation result in a better appreciation of 
the problem.295
Questionnaires can be employed in three basic ways; by personal 
contact, by telephone or by post. The choice of a postal 
questionnaire for this preliminary primary research stage was 
considered most appropriate for the information required.
The design of the questionnaire for this preliminary research stage 
was guided by certain principles. The first stage in this design 
process was to define the information required and therefore
295Chisnall, 1981
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establish the type and scope of questioning required. As stated 
earlier in Section 1.2, the survey aimed to establish those 
companies in the Irish Healthcare and Food & Drink industry 
sectors, that are involved in biotechnology research and 
development as a means towards innovation.
Faber and Hauck (1964) have stated three basic conditions which 
are necessary for ensuring a true response to questions.
(i) Respondents must be able to understand the question.
(ii) They must be able to provide the information requested.
(iii) They must be willing to provide the information.
A preliminary version of the postal questionnaire was developed as 
a first stage and pre-tested on ten companies from each of the two 
industry sectors. By such preparatory testing, the researcher was 
able to ensure that the basic guide-lines outlined above, were 
observed. In fact, due to the brevity and nature of questions asked, 
the initial draft of the questionnaire was employed in the final 
"preliminary research" questionnaire. (See Appendix F. For the 
purpose of each question, see Appendix G).
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The ability of selected respondents to provide accurate information 
was indisputable; all were either company chief executives or 
research and development managers who were all au fait with the 
nature of the problem which the postal survey posed. Their 
willingness to provide this information was clearly reflected by the 
high response rate (100%) achieved by the pilot test. In the light of 
this, it was considered unnecessary to alter the final questionnaire.
In the case of a postal questionnaire, particular care must be taken 
to ensure that the respondent is able to understand the question, 
as of course there is no opportunity to seek clarification of 
confusing terms with an interviewer.
The general form of questionnaires lies between two extremes. 
They may be either (i) highly structured (close-ended), with a series 
of formal questions designed to attract answers of limited response 
or (ii) unstructured (open-ended) where formal questions are 
designed to be replaced by a freer style of investigation.
The majority of the preliminary postal questionnaire employed in 
this study was highly structured due to the nature of the enquiry 
only requiring such depth of questioning.
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7.3.5 POSTAL SURVEY
RESPONSE RATE ACHIEVED
In postal surveys, "response rates" may be defined as the 
proportion of contacted respondents who complete and return the 
questionnaire. Among the problems in the use of postal surveys, 
one of the most serious drawbacks over the years has been the 
low response rate, estimated to be as low as 25%296
For this postal survey, as Table 23 shows, a highly acceptable 
response rate of 82% was finally achieved. In order to achieve 
such a successful result, various techniques, as discussed in 
Section 7.3.6 were carefully employed.
It is interesting to note that the first mailing achieved a 59% 
response rate (N = 61) which was effectively then increased by 
23% (N = 24) by the telephone follow-up procedure discussed in 
Section 7.3.6 to achieve a total response of 82%.
CONTRIBUTORY FACTORS
296Boyd et al„ 1977
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TABLE 23
POSTAL SURVEY RESPONSE RATE 
SAMPLE SIZE N =  104
N u m b e r  Received %  Response Rate
INITIAL MAILING 
(Further to 
pre-notification by 
telephone)
61 59%
FOLLOW-UP
(By telephone)
24 23%
TOTAL 85 82%
Aside from methods specifically employed to improve the response 
rate of postal questionnaires, discussed below in Section 7.3.6, 
certain other contributory factors arguably also influenced the 
favourable survey response rate result. Ognibene’s (1970) study 
suggests that surveys are more likely to be effective with special 
interest sample populations. The postal survey rate of 82% was 
undoubtedly also aided by the fact that the subject of innovation 
through biotechnology was of particular interest to the population 
under survey, most of whom were professional research and 
development managers or company chief executives.
Evidence also suggests that people with higher levels of education 
and higher IQs are more likely to respond297; research and 
development managers naturally fall into this category.
7.3.6 METHODS OF IMPROVING RESPONSE
Kanuk and Berenson’s (1975) review of the empirical studies to 
increase postal survey response rates reveals the limited evidence 
on which most widely accepted techniques are based. The efficacy 
of the different techniques is a point of dissension among
2970gnibene, 1970 and Macek & Miles, 1975
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researchers. Research concerned with increasing postal response 
has variously been directed at three phases of the postal survey 
process:
(1Î PRELIMINARY - NOTIFICATION
The effect of contact with the respondent before receipt of the 
questionnaire.
(2) CONCURRENT TECHNIQUES
The effect of all of the techniques embodied in or peripheral to the 
time the respondent receives the questionnaire; all of these are 
considered concurrent.
(3) FOLLOW-UP EFFORTS
The effect of reminders at the time at which the respondent is 
deemed to be a non-respondent by failure to answer the 
questionnaire.
The following sections further elaborate on each stage of this 
process of "three-phase" approach (see Figure 20)
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FIGURE 20: "THREE-PHASE" APPROACH 
TO POSTAL QUESTIONNAIRE SURVEYS
Telephone Request for Permission 
to post questionnaire
Postal Survey
Telephone Follow-Up
PRELIMINARY NOTIFICATION
One of the most valuable tools for increasing response to postal 
surveys is to pre-notify respondents of forthcoming mailing. Pre­
contact by letter, postcard, telephone or earlier personal contact all 
appear to increase response rates: but the maximum
improvements are evident from pre-contacting by telephone.298 In 
the light of this evidence a telephone pre-notification procedure was 
adopted for this postal survey. Moreover, this chosen method also 
had the added advantage of ensuring that questionnaires would 
only be addressed to those persons qualified to deal with them 
effectively.
Contact made with each respondent carefully followed a set 
procedure, which was designed to accomplish the following:
(1) To convey the fact of individual attention to the 
respondent-299 This is very important as the degree of 
personalisation is thereby increased.
pqqLinsky. 1975)
Dilman, 1978
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(2) To explain the nature of the study, create interest, assure 
confidentiality and express the intention of forwarding a 
postal questionnaire.
(3) To provide an opportunity for the respondent to pose 
questions and allay any doubts.
(4) To emphasise that the respondent is individually important to 
the success of the study.
(5) To elicit the respondent’s promise to co-operate, and thus 
create a sense of obligation and prior commitment.
(6) To alert the respondent to the impending arrival date of the 
questionnaire.
CONCURRENT TECHNIQUES
All efforts were made to ensure that the questionnaire was of a high 
quality reproduction, as it is of course, imperative that the 
respondent form an initially favourable attitude to the survey. 
Confidentiality was another extremely important matter that had to 
be given due consideration. For this reason, the fact that the 
information received would be treated with the strictest of
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confidentiality was printed on the cover page of the questionnaire in 
bold black print. The cover letter attached to this survey, as 
submitted In Appendix E, was deliberately kept short and easy to 
read, whereas at the same time it was used to involve and win 
further the cooperating of the respondent. The objectives of this 
letter may be listed as follows:
(1) To remind the respondent of his/her pre-notification and 
commitment to responding.
(2) To give a reasonable explanation of the subject of the study 
and of the respondent’s place in it.
(3) To further follow the standard practice of assuring 
respondents that responses would be treated as strictly 
confidential, a matter of concern to the respondents 
considering the nature of the enquiry.
(4) To draw the attention of the respondent to the eventual use 
of the information as part of the researcher’s worthwhile 
pursuit towards the attainment of masters degree in 
Business Studies (MBs) and the fact that the researcher had
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a particular interest in the subject area having studied 
biotechnology as an undergraduate.
The covering letter was then reproduced on high-quality letter 
headed Dublin Business School stationary. As is customary, pre­
addressed reply-paid envelopes were included with the postal 
questionnaire.
FOLLOW-UP EFFORTS
A follow-up may be considered as one of a variety of reminders 
between the researcher and the respondent. Research favours the 
telephone follow-up procedure for producing the best response 
rate, and for being quick, efficient and easy to control.300 301
For these reasons a telephone follow-up procedure was chosen, 
this was carried out three weeks after the postal date. The pre­
notification procedure, discussed earlier in Section 7.3.6, had 
already established a personalised frame of reference from which 
these follow-up calls were made. This final procedure successfully 
increased the response rate by 23% (see Table 23).
300Sheth and Roscoe, 1975
301 Lang et al„ 1975 *
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7.4 PRELIMINARY RESEARCH POSTAL SURVEY
RESULTS
As stated in Section 7.3.5 a postal response rate of 82% was 
achieved which comprised 85 individual questionnaire responses. 
Each of the 85 questionnaires were screened to determine if the 
respondents satisfied certain criteria in order to be included in the 
major part of the research study. The criteria to be satisfied 
included that,
(1) The individual company operates in the health care or food 
and drink sector in Ireland (obviously this criterion was 
established when constructing the sampling frame).
(2) The individual company is actively involved in biotechnology 
research and development in Ireland, as a means towards 
innovation, either through in-house or contracted research 
and development activities.
Of the 85 responses received, a total of 19 companies were found 
to be involved in biotechnology research and development (as 
defined in the questionnaire, see Appendix D) as a means towards
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innovating products or processes. Thus the stipulated sample 
requirement effectively ruled out all other companies.
Tables 24 and 26 (Section 8.2) list the results of the postal survey (it 
should be noted that only those companies which satisfied the 
criteria to be included in the major part of the research study are 
considered in the results of the postal survey).
Due to the fact that the number of companies satisfying the criteria 
to be included in the major part of the research study totalled 19, 
and considering the time period for the research, all of the 19 
companies comprise the sample population.
Each company was contacted two weeks after receiving the 
completed preliminary research questionnaire, to establish if the 
company was prepared to contribute further information to the 
research study.
This stage of the research required that most of the nineteen 
companies (17 out of 19) were sent an interview outline prior to 
committing themselves to an interview.
In certain cases where company policy was not to discuss 
information relevant to the study, it was necessary for the
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researcher to assure the respondent of complete confidentiality and 
to indicate that specific references to individual companies would 
not be made.
The major part of the research study involved in-depth interviews 
with 18 of the 19 companies; the remaining one company in the 
alcoholic beverages sector, permitted two interviews (one R & D 
manager, one marketing manager) but was only prepared to 
discuss very general aspects of the research enquiry.
7.5 DEPTH INTERVIEWING
The postal questionnaire discussed in Section 7.3.5, usefully served 
the purpose of identifying those companies operating in Ireland in 
the Healthcare and Food & Drink industry sectors, which are 
involved in biotechnology research and development (either in- 
house or contract) as a means towards innovation.
However, this postal survey was not intended to provide a detailed 
insight into the actual innovation strategies employing 
biotechnology of such companies. Such a relatively new and 
complex system and subject area may not be adequately covered
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by a postal survey alone as the parameters for enquiry are 
obviously very difficult to precisely define and thus a direct research 
approach employing "depth interviews" was necessarily required.
"Depth" interviewing describes a wide range of different types of 
interviews. Interview types can be classified to cover a range of 
possibilities. Such classifications cover such varied descriptions 
as: clinical, free, focussed, non-directive, extended, unstructured, 
semi-structured and intensive.
Collectively, these interviews represent a "less structured - more 
intensive" interview type, than a standardised questionnaire 
administered interview.302
This classification delineates three broad types of informal 
interviewing which can be visualised along a scale of increasing 
formality. At one end there is the "true depth" or clinical interview, 
which is more akin to the psychoanalyst’s approach, requiring 
several sessions, it is generally speaking not commonly used for 
conventional market research purposes.
With regard to the non-directive approach to interviewing where, 
although the interviewer retains the initiative regarding the course of
302Sampson, 1978
359
the interview, the respondent is given maximum freedom to 
respond as he/she wishes, without reasonable bounds of 
relevance.
The "semi-structured" or "focussed" interview aims to cover a given 
set of topics in a more or less systematic way. Although the 
respondent is still allowed to respond freely, as the name suggests, 
much tighter control is exercised by the interviewer.
Informal interviewing is open to criticism on the grounds that it is 
more vulnerable to the personal influence or bias of the interviewer, 
than the formal methods. Interviewer bias,
... occurs when the influence of the interviewer on the 
respondent is such that it results in responses that do not 
accurately /e//ecf the attitudes and opinions of the 
respondent. 3
Informal interviewing is additionally relatively slower and more 
expensive than the formal methods. However, informal methods 
can delve into a subject area and get a richer understanding than 
the formal interview.
303Chisnall, 1981
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This need to explore and acquire a fuller understanding of a 
relatively new complex subject area prompted the researcher to 
turn to depth interviewing.
The interviews were semi-structured, guided by a list of questions 
determined a priori and which served as an aide memoir for the 
researcher (a copy of the aide memoir used throughout the 
interview sessions is listed in Appendix H). In most cases (16 out of 
19) both research and development and marketing managers in 
the sample companies were interviewed. Tape recordings were not 
made but the researcher took notes in shorthand. The researcher 
usually began with an open-ended invitation to tell about work 
related activities, and then directed discussion towards major 
aspects of technology policy and innovation strategy. On average, 
each interview with one company executive took two hours to 
complete.
It should be noted that each respondent was sent an interview 
outline prior to the interview date to allow the respondent to 
prepare for the interview. An interview outline was also required in 
most cases before the individual company executive would agree 
to participate in depth interviews.
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In some cases, the research also involved the study of documents. 
Obviously company literature and financial annual reports were 
appraised prior to the interview. However, one key set of 
documents was the "innovation charter1' or innovation activities 
schedule of the organisation studied, for a particular innovation. In 
some cases after repeated requests for permission, permission 
was given to read these documents on site and make notes. These 
official descriptions of the evaluation of certain projects were 
compared with the empirical interview data. Finally, occasional 
behavioural observations were made, for example when both the 
R & D and marketing managers were interviewed together, or in 
informal discussions during lunch at the research site. These 
observations, though not systematic, led to the formulation of new 
questions for further interviews and a wider scope appreciation of 
the subject area.
It should also be noted that after completing an interview the 
researcher made a type-written copy of the conversation/interview. 
A copy of this information was sent to the respondent (marked 
strictly private and confidential) to ensure that the information was 
not misinterpreted by the interviewer, and to provide the 
respondent with a further opportunity to contribute any further 
information which might be of use to the researcher. All in all
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approximately one hundred type-written pages of field notes 
resulted from these interviews.
The respondent then returned the information to the researcher 
indicating any discrepancies that may have arisen from 
misinterpretation of the information given. However, there were 
only four cases in which minor discrepancies occurred.
Figure 21 indicates the research process conducted during the 
"depth interviewing" process of the research study.
7.6 VALUE OF MULTIDIMENSIONAL RESEARCH
No research method is without bias of some kind. This study 
therefore employed a carefully designed multitechnique approach, 
in order to minimise some of these research problems. In this way, 
additional information was obtained, which otherwise would not 
have been derived from using one research approach in isolation. 
To summarise, all three basic market research data collection 
techniques were employed, in a series of linked operations as 
follows;
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FIGURE 21 : "SIX-PHASE" APPROACH 
TO DEPTH-INETRVIEWING USED FOR STUDY
Telephone call to establish permission 
to carry out depth interviews
Interview Outline Posted Indicating 
Topics to be discussed
Depth-lnterview(s)
(Average 2 hours)
I
V
Copy of Information received during 
Interview sent to respondent for 
clarification
Information sent back to researcher
Follow-up letter to respondent confirming 
receipt of information document
(1) Telephone:
The telephone was used in several ways; for exploratory 
preliminary enquiries (see Section 7.3.2), and for minimising 
the limitations of a postal survey by telephone pre­
notification and follow-up procedures.
(2) Postal Survey:
A postal survey was employed to accurately define the 
research population (see Section 7.3.5).
(3) Personal Communication:
"Depth interviewing" was employed in order to acquire a 
fuller, deeper understanding of innovation strategies 
employing biotechnology in the two industry sectors chosen 
(see Section 7.5).
As Chisnall (1973) states,
It is not so much a question of which method is best, as 
which set of methods is likely to result in an objective 
research programme.
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The researcher therefore considered it necessary to integrate 
postal, telephone and personal research techniques, in order to 
meet the needs of this particular study.
Further results of this multidimensional research are given in 
Section 8.
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CHAPTER 8: 
RESEARCH FINDINGS 
OVERVIEW AND 
IMPLICATIONS
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8.1 INTRODUCTION
This section of the thesis discusses the qualitative research data 
collected during the course of the present study. Each of the two 
industry sectors studied are discussed separately. For each 
industry the discussion focuses on:
(1) The level of biotechnological activity.
(2) Reasons for developing biotechnology as a means towards 
innovation.
(3) The type of innovation strategies employing biotechnology 
currently pursued.
Finally, the conclusions of the present study are presented.
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8.2 PRELIMINARY RESEARCH POSTAL 
QUESTIONNAIRE RESULTS
The purpose of the preliminary postal questionnaire was to 
establish those companies involved in biotechnology research and 
development in Ireland, either through in-house or contracted 
research and development activities, in the Irish Healthcare and 
Food and Drink Industries. Tables 24 and 26 represent the results 
of the preliminary research postal questionnaire.
Table 24 indicates that a total of eleven companies in the Irish Food 
and Drink industry are currently involved in biotechnology research 
and development in Ireland, either through in-house or contracted 
research and development activities. These companies are in the 
dairy, alcoholic beverages and food ingredients sectors (see Table 
25). Both foreign owned and indigenous companies comprise this 
population.
Considering that there are more than 900 companies in the Irish 
Food and Drink industry this result may at first appear quite 
surprising. However, a number reasons for this low involvement in 
biotechnology research and development are suggested.
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TABLE 24 FOOD & DRINK COMPANIES INVOLVED IN
BIOTECHNOLOGY R & D IN IRELAND
COMPANY TYPE/ 
R&D TYPE
INDIGENOUS FOREIGN TOTAL
IN-HOUSE R&D 
ONLY
- - -
CONTRACTED 
R&D ONLY
- - -
BOTH IN-HOUSE 
& CONTRACTED 
R & D
6 5 11
TOTAL 6 5 11
TABLE 25 FOOD & DRINK COMPANIES IN IRELAND INVOLVED IN 
BIOTECHNOLOGY R & D BY SECTOR
COMPANY TYPE/ 
SECTOR
INDIGENOUS FOREIGN TOTAL
DAIRY
PRODUCTS
6 1 7
ALCOHOLIC
BEVERAGES
- 2 2
FOOD
INGREDIENTS
- 2 2
TOTAL 6 5 11
TABLE 26 HEALTHCARE COMPANIES INVOLVED TN BIOTECHNOLOGY
R & D IN IRELAND
COMPANY TYPE/ 
R&D TYPE
INDIGENOUS FOREIGN TOTAL
IN-HOUSE R&D 
ONLY
- 1 1
CONTRACTED R&D 
ONLY
1 - 1
BOTH IN-HOUSE 
& CONTRACTED 
R & D
4 2 6
TOTAL 5 3 8
FIGURE 27 HEALTHCARE COMPANIES TNVOT.VED DL
BIOTECHNOLOGY R & D IN IRELAND BY SECTOR
COMPANY TYPE/ 
SECTOR
INDIGENOUS FOREIGN TOTAL
PHARMACEUTICALS 2 2 4
DIAGNOSTICS 3 1 4
TOTAL 5 3 8
Firstly, the majority of food companies in Ireland are mainly small 
indigenous companies; of the 900 or so companies in this sector 
only 100 can be termed large (ie 100 or more employees). 
Similarly, on the basis of turnover, only 13% sell over 20 million per 
annum. With the exception of dairy and alcoholic beverages, 
almost 70% of Irish food and drink firms have turnovers less that 4 
million.
Furthermore, the major sectors in the Irish Food industry are dairy 
and meat while fish and cereal products have become more 
important in recent years. The dairy and meat sectors are highly 
concentrated sectors dominated by large producer co-operatives.
Similarly, the manufacture of alcoholic beverages in Ireland is highly 
concentrated, undertaken by a small number of companies of 
various size, the larger companies being foreign owned.
Thus the number of companies in the Irish Food and Drink industry 
with the internal capacity to conduct biotechnology research and 
development is low, considering the high cost and risk of such 
research and development. This is reflected in the results of the 
postal questionnaire (Table 24).
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Another factor which may affect the capacity of a company to take 
technology on board is the proportion of employees with third- level 
training. A survey by Eolas found only 1 -2 % of the total workforce 
(42,000 employees) in the Irish Food and Drink industry have this 
level of training. However, the dairy and alcoholic beverages 
sectors were exceptions to this, with 6% of employees with third 
level training. (Eolas, 1988)
Furthermore, the Food and Drinks industry is a sector which does 
not spend heavily on research and development in any country. 
(Ryan, 1988)
Thus considering the above facts, it was expected that the number 
of companies in the Irish Food and Drink industry involved in 
biotechnology research and development would be low. It was 
also expected that the dairy and alcoholic beverages sectors 
would have more involvement in biotechnology research and 
development relative to other sectors such as confectionery, fish 
products etc. on the basis that:
(i) such sectors are dominated by large companies with the 
potential internal capacity to carry out research and 
development,
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(ii) the relatively high level of employees with third level training 
and
(iii) that the applications of biotechnology are at present most 
relevant to these sectors and are expected to have 
significant impact on the future.
This was reflected in the results of the postal questionnaire, with 
those companies involved in biotechnology research and 
development being mainly in the dairy sector. Two companies 
were found to be involved in biotechnology research and 
development from the alcoholic beverages sector; this result was 
not surprising considering the highly concentrated structure of this 
sector. A further two companies were found to be involved in 
biotechnology research and development in the food ingredients 
sector, both of which are foreign owned (see Table 25).
Table 26 indicates that a total of eight companies in the Healthcare 
industry are currently involved in biotechnology research and 
development in Ireland. This low number was not surprising due to 
the fact that healthcare companies in Ireland are mainly subsidiaries 
of international companies and consequently research and 
development activities are carried out abroad in the parent 
company or parent company country. However, several foreign
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owned Healthcare companies have added research and 
development functions to their manufacturing operations in Ireland 
or invest in research and development in Irish academic and 
research institutes. Of these, a total of 6 are currently involved in 
biotechnology research and development in Ireland, either by in- 
house or contracted research and development.
The number of indigenous healthcare companies in Ireland is low 
and may be related to several factors, including the small size of the 
home market, the dominance and control exercised by the 
multinationals over the Irish ethical pharmaceutical market, limited 
import substitution opportunities given the raw material base of 
most products, high technology and regulatory entry thresholds in 
many product areas and low levels of linkage in the industry.
However, of those Irish indigenous healthcare companies, five are 
currently involved in biotechnology research and development in 
Ireland. Interestingly, three of these are in the diagnostics sector, 
one of the healthcare sectors in which biotechnology developments 
have major commercial applications (Table 27)
From the results of the preliminary postal questionnaire, it was 
established that of those companies involved in biotechnology 
research and development, all of the companies in the Food and
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Drink industry and 6 out of 8 in the Healthcare industry are involved 
in both in-house and contracted research and development which 
suggests that linkage between industrial and research institutions in 
this technological field is very important. (Tables 24 & 24)
8.3 INNOVATION THROUGH BIOTECHNOLOGY 
IN THE HEALTHCARE INDUSTRY IN IRELAND.
This section discusses the findings resulting from qualitative 
research (depth interviews) with those healthcare companies 
operating in Ireland that are involved in biotechnology research and 
development in Ireland as a means towards innovation.
8.3.1 COMPANIES INVOLVED
There are currently eight healthcare companies operating in Ireland 
that are involved in biotechnology research and development as a 
means towards innovation. A distribution by relative size shows:
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3 large international companies (including one Irish 
international company). Turnovers (1989) range from 100- 
200 million pounds. All have considerable research and 
development budgets.
2 medium-sized companies (including one Irish indigenous 
company). Turnovers (1989) of approximately 50 million 
pounds. Both have limited research and development 
budgets.
2 small indigenous companies. Turnovers below 10 million 
pounds. Both have relatively small research and 
development budgets. (For the purpose of further 
discussion these companies are referred to as 
biotechnology "start-ups").
1 small indigenous company, turnover (1989) less than 5 
million pounds, with a very small research and development 
budget.
Each company interviewed indicated that it has a survival strategy 
which is primarily based on the attainment of a certain market share 
and a certain profit. Each company indicated that biotechnology is 
but one tool used in this strategy.
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8.3.2 REASONS FOR INVOLVEMENT IN 
BIOTECHNOLOGY
The precise reasons for involvement in biotechnology depend on 
the following factors which vary from company to company and 
include:
(1) New Product Development;
(2) Relevance of biotechnology concepts to current product 
lines and fields of activity;
(3) To strengthen market position;
(4) Part of a general approach for improved efficiency in 
production processes;
(5) Familiarity with Biotechnology Concepts;
(6) Innovation Oriented Top Management.
All companies interviewed indicate that they want to develop new 
products through biotechnology research and development.
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Screening of possible new products is the next and crucial step 
upon which further activities will depend.
Biotechnology is of relevance to all the interviewed companies’ 
product lines and fields of activity. The overriding motive for each 
company to develop biotechnology is a perceived need to increase 
know-how in order to improve its market position. Five companies, 
all involved in the large-scale manufacture of pharmaceutical 
products, point to the opportunities for process rationalisation. 
Process rationalisation includes improvements in raw material 
supplies, in waste disposal, purification and numerous 
manufacturing techniques, and is thus extremely important with 
regard to a company’s competitiveness.
Six of the companies interviewed are already familiar with 
biotechnology concepts and view biotechnology research and 
development as an addition to current research and development 
capabilities. Of these five companies, three are in the diagnostics 
sector and two in the ethical and over-the-counter pharmaceutical 
sectors.
For those three companies which in contrast to the preceding 
group are not already familiar with biotechnology concepts, the 
presence of an innovation-oriented top management is crucial in
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the decision to develop biotechnology in the company. The three 
such companies interviewed indicate that management creativity 
does not so much depend on training in biotechnological 
disciplines but on the capability of decision makers to see 
biological and economic factors in combination and on the 
availability of sufficient information to those decision makers. Two 
of these companies are in the human and veterinary 
pharmaceuticals sector; and are not familiar with biotechnology 
concepts as they have employed organic synthesis for the 
manufacturer of their products. The remaining company in this 
group has only started to become involved in the manufacture of 
clinical laboratory diagnostics for the diagnostics sector and thus 
has no former familiarity with biotechnology concepts.
8.3.3 INNOVATION STRATEGIES THROUGH 
BIOTECHNOLOGY IN HEALTHCARE 
COMPANIES
Two major items of interest emerged from the investigation of 
general company information. First is the relative success of most 
of the companies in the specific healthcare sub-markets, in which
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they are active. This reveals differences in strategic thinking and in 
innovative capability employing technology.
Second is the structure, organisation and management of 
corporate research and development. Among the healthcare 
companies involved in biotechnology research and development, 
there is wide difference on this front, particularly between those 
companies that are part of a multinational, and smaller independent 
companies. For this reason, effectiveness related to the direction of 
biotechnology research and development and secondly, internal 
communications in the companies were expected to differ and 
impact on the innovative capabilities and innovation strategies 
pursued.
The implications of company decisions to innovate through new 
biotechnology activities vary widely, according to general company 
outlook, the capabilities and resources available to the company 
and the competitive opportunities and threats faced by the 
individual company.
Three types of innovation strategies through biotechnology can be 
distinguished:
378
(1) Some companies plan to use new biotechnology for
changes or extensions of their current product lines or for 
diversifying into product groups where other companies are 
already competing.
Of the eight companies interviewed two healthcare 
companies pursue this strategy.
(2) Other companies have, thanks to their structure or 
management competence built up a capability to link 
together biological phenomena, technical possibilities and 
socio-economic issues and needs. This capability has in 
most cases, led to novel product lines.
Of the eight companies interviewed, four healthcare 
companies pursue this strategy.
(3) A third strategy aims at large future markets through long­
term accumulation of biotechnology know-how. Those 
companies pursuing this strategy see biotechnology 
developments as increasing the already existing 
biotechnological base of the company.
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Of the eight companies interviewed, two healthcare 
companies pursue this strategy.
Each of these innovation strategies employing biotechnology and 
the companies involved are discussed individually in the following 
sections.
(1) 'LOW INVOLVEMENT LONG-TERM PLANNERS'
Those companies who plan to use biotechnology for changes or 
extensions of their current product lines or for diversifying into 
product groups where other companies are already competing, 
have a relatively low involvement in new biotechnology at present. 
One of these companies is a subsidiary of a multinational company 
which develops, manufactures and markets a range of 
pharmaceutical bulk drug products, pharmaceutical intermediates 
and fine chemicals. The company’s main technological skills are in 
organic synthesis of these products. The company falls into the 
category of those companies not already familiar with 
biotechnology concepts and sees the presence of an innovation- 
oriented top management as crucial in the decision to develop 
biotechnology in the company. The company plans to diversify into 
product groups where other companies are already competing 
through biotechnology research and development. The area of
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biotechnology currently pursued is relatively new but already a 
number of pharmaceutical firms are active in this area. According 
to a company source, the decision to enter this area of 
biotechnology-related research is technology-driven rather than a 
response to market demand.
The Irish operation of this company has an innovation-oriented top 
management which has allocated a specific research and
development budget for this area of biotechnology related research 
and development. However, at present the scale of the research 
and development operation is small and is carried out through in- 
house activities only. The main reason for in-house activity only is 
the secretive nature of the research. Being a subsidiary of a
multinational company, the resources are available for this
exploratory research. The results of such exploratory research will 
be the next and crucial step upon which future activities depend.
The second company in this group employs biotechnology
research and development for changes or extensions in its current 
product lines. This company is a medium-sized Irish indigenous 
company which is involved in the development, manufacturing and 
marketing of both human and veterinary pharmaceutical products. 
This company falls into the category of those companies not 
already familiar with biotechnological concepts and sees the
381
presence of an innovation-oriented top management as crucial in 
the decision to develop biotechnology. The company involvement 
in biotechnology research and development is low in terms of the 
proportion of total research and development funds spent on 
biotechnology, but the company intends to increase expenditure in 
this area over the next few years. The company’s involvement in 
biotechnology is relatively recent, that is in the last two years. The 
company initially contracted out biotechnology research and 
development to academic research institutions both in Ireland and 
in the UK. The main reason for contracting out research and 
development in the particular area of biotechnology relevant to the 
company’s operations was lack of in-house capability and the 
relatively costly nature of the research involved.
The company considers the decision to enter biotechnology 
research and development as a offensive move considering the 
competitive opportunities facing the company. Already, basic 
research carried out at an academic research institution in Ireland 
has resulted in process improvements in the company’s 
manufacturing processes.
The company does not feel that involvement in state of the art 
biotechnology is essential to achieve its objectives in its products 
and markets and also indicated that an innovation strategy relying
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heavily on state of the art biotechnology would make the company 
vulnerable to rapid change in the technology. The company 
instead focuses on applied research in-house and contracts basic 
research to academic institutions if the basic research has not 
already been carried out at such institutions.
Thus, the late-to-market innovation strategy employed by this 
company is characterized by nimbleness in adopting the new 
developments in biotechnology as a result of a very flexible and 
integrated research and development in-house function.
(2) “MEDIUM INVOLVEMENT LONG TERM PLANNERS"
Four healthcare companies who plan to innovate or innovate 
through biotechnology pursue strategies which rely on the 
capabilities to link together biological phenomena, technical 
possibilities and socio-economic needs. In three of the companies 
pursuing this strategy, this has already led to the development of 
novel product lines. The remaining one company has only recently 
pursued biotechnology as a means towards innovation and falls 
into the category of those companies not already familiar with 
biotechnology concepts. This company again sees the presence 
of innovation-oriented top management as crucial in the decision to 
develop biotechnology in the company. In fact, three members of
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management have strong science backgrounds. This company 
has not developed products employing biotechnology as yet.
The remaining three companies employing such a strategy all 
operate in the diagnostics sector of the healthcare industry. One is 
a medium-sized foreign-owned independent company with a strong 
technology base. The other two companies are small indigenous 
biotechnology "start-ups".
Due to smaller costs and greater flexibility, all four companies 
represent a potential of considerable creativity in the innovation of 
products through biotechnology. This applies particularly to two of 
the small indigenous biotechnology "start-ups" which possess very 
specialised know-how and focus on few product lines.
The key strategic strength of all four companies is the ability to 
match technology with specific customer requirements or perceived 
customer needs. Furthermore, these companies believe their key 
strategic tasks are finding and maintaining a stable product niche 
and benefiting systematically from user experience.
Both biotechnology "start-ups" indicate the importance of 
innovation oriented top management in the decision to pursue 
biotechnology R & D programmes. It is interesting to note that the
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particular individuals primarily responsible for the formulation of 
innovation strategies in these two companies have both relevant 
scientific backgrounds and many years of international industrial 
experience in new product development in the healthcare industry. 
This "manpower strength" is cited by the companies as adding 
further impetus and direction to the companies innovation 
strategies.
The two biotechnology "start-ups" are particularly interesting in 
terms of products developed through biotechnology and the 
strategies employed.
These companies pursue a first-to-market strategy (see Section 
3.6) through their own innovative research and development 
programmes. Such a strategy has already resulted in the 
development of novel niche market product lines in the human and 
veterinary diagnostic market sectors. It was suggested in Section 
3.6 that companies employing a first-to-market strategy require 
state of the art research and development in the product area and 
both are involved in such state of the art diagnostic technology 
through in-house biotechnology research and development.
However, both of these companies rely on strong 
academic/industry linkages as well. It is interesting to note that one
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of these companies established a new campus biotechnology 
company to further develop successful collaboration between the 
parent company and academic researchers. The other company 
collaborates with academic research institutes both in Ireland and 
abroad, but is more involved with those abroad as it feels the 
relevant advanced technology required in diagnostic technology is 
not available in Ireland.
These companies also follow a second-to-market strategy with 
regard to new product development through the development of 
"me-too" products which are very much market driven products. 
Such products generate cash-flow which can be injected into their 
own programmes of research and development for innovative first- 
to-market products. One of these companies performs contract 
research in biotechnology to the diagnostic/healthcare industry at 
large. The second biotechnology "start-up" is involved in both 
contract research and development and manufacturing for 
multinational labels in the diagnostics sector. Again, these activities 
generate resources for the companies’ own research programmes. 
In this respect, these two companies are the closest equivalent to 
the American phenomenon, the New Biotechnology Firm (NBF) 
discussed in Section 4.6.1.
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Interestingly, one of these companies recently, (1989) raised new 
funds through a combination of rights issue and private placing to 
accelerate product and market development. It was suggested in 
Section 4.7.2 that due to the fact that management surrenders large 
portions of equity in return for a venture capital infusion, owners 
should be sure that investors share the same goals. The sources 
of this company’s venture capital are ideal for the first-to-market 
innovation strategy of this company, including among other 
investors, an Irish venture capital company and a UK publicly- 
quoted investment company which specialises in Biotechnology 
venture investments. This company has also sold an 18% equity 
stake to a UK biotechnology company and, as part of this 
arrangement, now acts as the European manufacturing centre for 
the UK company’s operations. This agreement provides cash for 
research and development for the biotechnology "start-up" and 
provides the UK company with the necessary manufacturing centre 
in Europe to generate revenues from international business. Thus, 
this co-operation has led to a successful mutually-beneficial 
symbiosis between the two companies.
Thus, the innovative small biotechnology "start-ups" are specialised 
in their technological strategies concentrating on product 
innovation in specific producer goods, that is diagnostic products.
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The medium-sized foreign-owned diagnostic company in this group 
also indicates that the presence of an innovation-oriented top 
management is essential in the decision to develop new products 
through biotechnology. The main technological strength of this 
company is cited as a strong in-house R & D capability as a result 
of a continuing policy of recruiting highly specialised R & D 
managers with several years international industrial experience in 
the diagnostics sector of the healthcare industry.
To add to this strong in-house R & D capability the company has 
acquired technology related to its current output from both US and 
UK companies. The US deal involved the purchase of a controlling 
interest in one of the US company’s operations and has thus 
significantly increased market access in the US. Of interest in 
considering the future innovation strategies of this company is the 
recent (1990) acquisition of this company by a large multinational in 
the diagnostic machinery sector. The change in majority stake in 
the company has already resulted in a considerable shift in the 
research and development activities of the company to fit in with 
the innovation strategies of the acquiring company. Thus, the 
development of new products, and the strategies employed to 
realise such products in the company may take a different direction 
in the future as a result of the recent acquisition. Interestingly,
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however, the acquisition has actually fuelled new product ideas not 
considered previously by the company.
(3) ‘ HIGH INVOLVEMENT/BROAD-FRONT LONG-TERM PLANNERS*
Two healthcare companies focus their innovation strategies 
employing biotechnology on large future international markets 
through long-term accumulation of biotechnology know-how. Such 
strategies are seen as increasing the already existing 
biotechnological base of the company.
These larger innovating companies are all large multinational 
companies. One company is a subsidiary of a multinational which 
develops, manufactures and markets therapeutic pharmaceutical 
products. The other company is an Irish indigenous international 
company developing, manufacturing and marketing ethical and 
over-the-counter pharmaceutical products, medical nutrition 
products and diagnostic reagents.
These companies are broad front in their technological activities 
related to biotechnology. Their key technological strengths are 
based on access to a network of research and development 
carried out in different research and development laboratories as 
part of the total company.
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In order to have optimal access to new biotechnology know-how 
and to reduce overheads, research and development co-operation 
between companies as well as skilled co-operation management is 
considered essential by these companies. These companies are 
unanimous in stating that the number of research and development 
co-operations has grown continuously and keeps growing. These 
co-operative ventures have led to a successful, mutually successful 
symbiosis between big and small companies, including small US 
biotechnology firms and one collaboration involving a Swiss 
microelectronics company.
The companies in this group are developing a number of products. 
Often the relevant know-how for one product development is not 
concentrated in one place, which forces companies to combine 
several co-operations and partners. Two of these large companies 
tend to co-operate internationally, the reasons given being lack of 
know-how in Ireland in particular areas and also the perception that 
university know-how often has strong national ties.
Co-operation also occurs at the distribution level. Two of the 
companies focusing their innovation strategies employing 
biotechnology on large future international markets have interesting 
products with a small market niche but are unable to add up the
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niches of various countries in order to have a global market of 
sufficient size and to reach break-even point.
The concept of globalisation in marketing referred to in Section 2.8 
is of paramount importance to these companies, and the world­
wide distribution networks of these companies are considered a 
critical condition for success in biotechnology innovations. 
However, these companies have to realise the realities of entry 
costs into the large markets and have therefore developed a 
strategy of licensing products to the major pharmaceutical 
marketing companies for the large markets and reserving niche 
markets for either joint ventures or direct marketing activities.
8.4 INNOVATION THROUGH BIOTECHNOLOGY 
IN THE FOOD AND DRINK INDUSTRY IN 
IRELAND
This section discusses the findings resulting from qualitative 
research (depth interviews) with these healthcare companies 
operating in Ireland that are involved in biotechnology research and 
development in Ireland as a means towards innovation
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8.4.1 COMPANIES INVOLVED
There are currently eleven companies in the food and drink industry 
operating in Ireland that are involved in biotechnology research and 
development as a means towards innovation. Two of these 
companies are in the alcoholic beverages sector, two are in the 
food ingredients sector and seven are in the dairy sector.
A distribution by relative size shows:
six large companies (all of which are indigenous) with 
turnovers (1989) between 100 and 300 million. These 
companies have considerable R & D budgets.
1 large autonomous unit of an international company with a 
turnover (1989) of 300 million pounds. This company has a 
considerable research and development budget;
4 large international companies with turnovers (1989) over 
300 million pounds. All of these companies have 
considerable research and development budgets.
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Each company interviewed indicated that it has a survival strategy 
which is primarily based on the attainment of a certain market share 
and a certain profit. Biotechnology was cited by each company 
interviewed as but one tool used in this strategy.
8.4.2 REASONS FOR INVOLVEMENT IN 
BIOTECHNOLOGY RESEARCH AND 
DEVELOPEMENT
The precise reasons for involvement in biotechnology depend on 
the following factors which vary from company to company and 
include:
(1) To strengthen market position;
(2) Relevance of biotechnology concepts to current product 
lines and processes;
(3) Familiarity with Biotechnology concepts;
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(4) New process development for in-house use as part of a 
general approach for improved efficiency in production 
processes;
(5) New Product Development.
The overriding motive for each company to develop biotechnology 
is a perceived need to increase know-how in order to improve its 
market position. Biotechnology is of relevance to all the interviewed 
companies’ product lines and processes. All of the companies are 
already familiar with biotechnology concepts and view 
biotechnology research and development as an addition to current 
research and development capabilities. All companies point to the 
opportunities for process rationalisation.
Of the total 11 companies, most (total 10) indicate that they want to 
develop new products through biotechnology research and 
development.
Three types of innovation strategies through biotechnology can be 
distinguished:
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(1) Some companies plan to use new biotechnology for process
rationalisation and "modest" changes or extensions of their 
current product lines.
Of the eleven companies interviewed, four companies 
pursue this strategy.
(2) Other companies plan to use new biotechnology for new 
process development, existing process rationalisation, for 
"modest" changes or extensions of their current product 
lines and for new product lines
Of the eleven companies interviewed, six companies pursue 
this strategy.
(3) A third strategy aims at large future markets through long­
term accumulation of know-how. This strategy is seen as 
increasing the already existing strong biotechnological base 
of the company.
Of the eleven companies interviewed, one company pursues 
this strategy.
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Each of these innovation strategies employing biotechnology, and 
the companies involved are discussed individually in the following 
sections.
8.5 INNOVATION STRATEGIES THROUGH 
BIOTECHNOLOGY IN FOOD AND DRINK 
COMPANIES
Again, two major items of interest emerged from the investigation of 
general company information. First is the relative success of most 
of the companies in the specific markets, in which they are active. 
As suggested already in Section 8.4 this reveals differences in 
strategic thinking and in innovative capability.
Second is the structure, organisation and management of 
corporate research and development. Among the food and drink 
companies involved in biotechnology research and development, 
there is wide difference on this front, particularly between those 
companies that are part of a multinational and smaller independent 
companies.
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For this reason, effectiveness related to the direction of 
biotechnology research and development and secondly, internal 
communications in the companies were expected to differ and 
impact on the innovative capabilities and innovation strategies 
pursued.
The implications of company decisions to innovate through new 
biotechnology activities vary widely, according to general company 
outlook, the capabilities and resources available to the company 
and the competitive opportunities and threats faced by the 
individual company.
(1) 'LOW INVOLVEMENT LONG-TERM PLANNERS*
Those companies who plan to use biotechnology for process 
rationalisation and "modest" changes or extensions of their current 
product lines have a relatively low involvement in new 
biotechnology at present as reflected in the proportion of total 
research and development funds spent on biotechnology research 
and development. All of these four companies are large indigenous 
companies involved in the dairy sector of the Irish food industry.
These companies’ main technological strengths are in dairy 
processing and they view biotechnology developments as primarily
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having major applications in dairy process rationalisation and for 
modest changes or extensions of their current product lines. It 
should be noted that “modest" changes or extensions refer to 
product developments aimed at increasing the quality, flavour, 
texture, stability or functionality of products. Such developments 
are extremely important in terms of competitive advantage for 
companies in the dairy sector.
Each company in this group has indicated that both strategies of 
process rationalisation and "modest" changes or extensions of 
current product lines through biotechnology are primarily market- 
driven. In particular innovation strategies employing biotechnology 
for process rationalisation result from pressure to reduce costs. 
Strategies employing biotechnology for "modest" changes or 
extensions of current product lines result from specific customer 
requirements or perceived customer needs.
All four of these companies are involved in both in-house and 
contracted research and development at research institutions.
These companies believe that close proximity to state of the art 
technology in dairy processing is essential to achieve their 
objectives in process rationalisation. To achieve this, such 
companies pursue a strategy of close collaboration with research
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institutions in Ireland and abroad. Collaboration with research 
institutions involves access to basic research in the particular area 
of interest, normally of a pre-competitive nature, and access to 
applied research in the particular area of interest through 
contracted research and development of a competitive nature.
The main reasons for collaboration with research institutions in 
order to access state of the art technology are, limited financial 
resources, lack of in-house expertise and the fact that dairy 
processing related biotechnology is changing and developing 
rapidly, which leads to reduced predictability as to the direction in 
which the technology will develop. Thus collaboration with 
research institutions minimises the risk associated with the 
adoption of the new biotechnologies by the companies.
In achieving their objectives of "modest" changes or extensions of 
current product lines through biotechnology such companies 
employ a strategy of applied or developmental research and 
development through both in-house and contracted research and 
development programmes. Contracted research and development 
programmes to achieve such objectives are placed at research 
institutions where the research programmes have a specific 
commercial application and in this sense are of a very applied 
nature.
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An alternative strategy to achieve objectives in process 
rationalisation and "modest" changes or extensions of current 
product lines is the licensing of technology (referred to in Section 
3.7). This strategy is employed by two of these companies, which 
have indicated that high development costs and long payback 
periods associated with the areas of biotechnology pursued are the 
main reasons for pursuing such strategic alliances.
(2) ‘ HIGH INVOLVEMENT LONG-TERM PLANNERS*
Those companies who plan to use new biotechnology for new 
process rationalisation, "modest" changes or extensions of their 
current product lines and for new product lines have a relatively 
high involvement in biotechnology at present, as reflected by the 
proportion of total research and development funds spent on 
biotechnology research and development.
Of the eleven companies interviewed, six companies fall into this 
group. Three of these companies are in the dairy sector; two being 
large indigenous companies, the other being part of a large 
multinational company.
A further two companies develop, manufacture and market 
alcoholic beverages, both are large international companies, one
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being a large multinational and the other a large autonomous unit 
of an international group.
The remaining company in this group operates in the food 
ingredients sector and is a subsidiary of an international company.
Process rationalisation efforts of these companies focuses on 
increasing efficiency of existing production processes as a result of 
pressure to reduce costs and price, and is very much market- 
driven, according to each company interviewed.
"Modest" changes or extensions of these companies’ current 
product lines focuses on increasing quality, functionality or flavour 
of certain products, as a result of consumer demand and is also 
indicated as being very much market-driven.
New process development of these companies focuses on 
alternative processes for some current product lines, and is part of 
a general approach to improve efficiency and possibly license such 
technology.
New product development of these companies focuses on 
developing new products to respond to changing consumer
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demand, identification of speciality markets and utilisation of by­
products resulting from existing processes.
All companies pursuing these innovative strategies indicate that 
close proximity to state of the art biotechnology in the areas 
pursued is essential to achieve their objectives in process and 
product development. A number of strategies are employed by 
these companies to develop know-how in state of the art 
biotechnology including in-house research and development 
through plant and capital investment, licensing-in of technology, 
and collaboration with research institutions, involving both pre- 
competitive and contracted competitive research and development.
Five of the companies focus on building up in-house know-how in 
biotechnology research and development through major 
investment in plant, capital and manpower. Due to their large size 
and access to resources, these companies feel they can pursue 
such a strategy. Those companies operating in the dairy sector 
have availed of state-supported plant and equipment grants to 
develop biotechnology. One company in this sector, being a 
subsidiary of a multinational, has access to several other research 
and development facilities, through which in-house know-how is 
built up. Such in-house activity is of a basic nature but with a 
specific focus for potential commercial developments. Basic
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innovative research in the past has led to the pioneering 
development of a process to utilise waste by-products from existing 
processes, resulting in the development of a high-value-added 
product with several applications. This process technology, being 
the first of its kind world-wide, has since been licensed out in 
several countries and provides major resources for further in-house 
process and product developments.
Those companies in the alcoholic beverages sector pursue a 
strategy of building up in-house capability in biotechnology through 
major plant, capital and manpower investment to obtain close 
proximity to the state of the art biotechnology in the areas pursued. 
Both companies have set up major central laboratories in Ireland, 
where all corporate research is carried out. Each of these 
companies indicate that this approach is taken to "internalise 
technological discontinuities" and has led to an increased 
effectiveness in internal communications and in the direction of 
biotechnology research and development pursued.
In all companies interviewed in this group, in-house biotechnology 
research and development programmes over the last five years 
have resulted in significant savings in all of the companies’ 
fermentation processes through increased yields employing 
genetically engineered microorganisms.
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Licensing of technology to access state of the art biotechnology 
and achieve company objectives in its products and markets is 
pursued by those companies in the dairy and alcoholic beverages 
sectors of the food and drink industry. Licensing of product and 
process technology is employed where the costs of development 
and the long pay-back periods of such developments are otherwise 
prohibitive.
A major strategy employed by those companies in the dairy, 
alcoholic beverages and food ingredients sectors interviewed is to 
access state of the art biotechnology through collaboration with 
academic research institutions in both Ireland and abroad. Apart 
from pre-competitive research, such collaborations involve 
proactive basic and applied research with specific commercial 
emphasis. Four particular pro-active biotechnology research and 
development programmes involving such collaboration with 
academic research institutions have resulted in major process 
rationalisation through cheaper alternative raw materials. It is noted 
that such collaborations are employed most frequently in cases 
where in-house capabilities are not available or the costs of in- 
house development is prohibitive.
(3) 'HIGH INVOLVEMENT/BROAD FRONT LONG-TERM PLANNERS'
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Of those companies involved in biotechnology research and 
development in the food and drink industry, only one company 
interviewed indicated that innovation through biotechnology is 
aimed at large future markets, through long-term accumulation of 
know-how in order to increase the already existing strong 
biotechnology base of the company. This company operates in the 
food and drinks ingredients sector of the Irish food and drink 
industry and is now part of a giant multinational corporation.
The overall objective of a division of this giant multinational is to 
become a major biotechnology company supplying the world food 
and drinks industry with biochemical ingredients. The Irish 
operation of this division pursues a strategy of innovation through 
biotechnology which contributes to the total research and 
development network of this division.
The Irish operation is broad front in its technological activities 
related to biotechnology. The company’s key technological 
strengths are based on access to a network of research and 
development carried out in different research and development 
laboratories as part of the total company. In order to have optimal 
access to new biotechnology know-how, research and 
development co-operation between individual companies in this 
division of the giant multinational, as well as skilled co-operation
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management is considered essential by the Irish operation of the 
division. This is reflected not only in the frequency of use of other 
research and development laboratories within the group, for 
particular new product and new process developments but also in 
the development of computerised in-house internal index systems 
to facilitate on-line information on research and development and 
new product/process developments.
The Irish operation of this division is involved in research and 
development collaborations with Irish academic institutions as a 
means of accessing particular technology not available in-house or 
through the research and development network of its parent 
company.
8.6 CONCLUSIONS
It was suggested in Section 1 of the present thesis that industry 
plays the pivotal role in transforming new biotechnology into an 
economic force. It is assumed that present industrial involvement 
levels and strategies are an indication of future economic 
developments. The present study set out to determine, in a 
pragmatic manner, the level of activity and types of innovation
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strategies pursued by Healthcare Companies (New High- 
Technology-based Companies) and Food and Drink Companies 
(Established Low-Technology-based Companies) operating in 
Ireland in the same generic field - biotechnology. Within this overall 
research objective, the study had a number of specific aims:
(1) To establish those Healthcare and Food and Drink 
companies in Ireland involved in biotechnology research and 
development as a means towards innovation;
(2) To establish the reasons for developing biotechnology;
(3) To determine the innovation strategies of these companies, 
through the use of biotechnology.
LEVEL OF BIOTECHNOLOGY ACTIVITY
The results of the present study indicate that on the whole there is a 
relatively low level of biotechnology activity in these two industry 
sectors. Several suggestions have been made in Section 8.2 as to 
why the level of activity is so low considering the total number of 
companies operating in these sectors. These suggestions include:
407
the small number of Food companies with the internal 
capacity to conduct biotechnology research and 
development, which is very costly;
the concentrated nature of certain sectors in the Food and 
Drink Industry (including the dairy and alcoholics sections)
the structure of the Healthcare Industry, which is mainly 
made up of foreign-owned subsidiaries of international 
companies, who tend not to locate their research and 
development facilities in Ireland.
8.6.1 REASONS AND STRATEGIES FOR 
DEVELOPING NEW BIOTECHNOLOGY
The overriding motive for a company to develop biotechnology is 
to increase know-how in order to improve its market position by 
using a technology which is relevant to its products and processes. 
Most companies indicate that they want to develop new products 
through biotechnology. Screening of possible products is the next 
and crucial step upon which further activities will depend. Long 
established companies involved high-volume production,
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particularly in the dairy and alcoholic beverages sector, point to the 
need for innovation in their production processes. They indicate 
that biotechnological techniques are a means towards such 
process innovation. Furthermore, companies in these sectors 
indicate the use of biotechnology in process development is a 
means of satisfying market demands for greater sophistication, 
uniformity and lower cost.
Three types of innovation strategies through biotechnology have 
been distinguished in each industry as a result of the present 
research study.
8.6.2 INNOVATION STRATEGIES THROUGH 
BIOTECHNOLOGY OF HEALTHCARE 
COMPANIES IN IRELAND INVOLVED IN 
BIOTECHNOLOGY RESEARCH AND 
DEVELOPMENT
(1) "LOW INVOLVEMENT LONG-TERM PLANNERS"
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These companies plan to use new biotechnology for changes or 
extensions of their current product lines or for diversifying into 
product groups where other companies are already competing.
(2) "MEDIUM INVOLVEMENT LONG-TERM PLANNERS"
These companies have, thanks to their structure or management 
competence, built up a capability to link together biological 
phenomena, technical possibilities and socio-economic issues and 
needs. This capability has, in most cases, already led to novel 
product lines.
(3) "HIGH INVOLVEMENT LONG-TERM PLANNERS"
These companies pursue an innovation strategy aimed at large 
future markets through long-term accumulation of biotechnology 
know-how. These companies see biotechnology developments as 
increasing the already strong existing biotechnological base of the 
company.
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8.6.3 INNOVATION STRATEGIES THROUGH 
BIOTECHNOLOGY IN FOOD AND DRINK 
COMPANIES IN IRELAND INVOLVED IN 
BIOTECHNOLOGY RESEARCH AND 
DEVELOPMENT
(1) "LOW INVOLVEMENT LONG-TERM PLANNERS"
These companies plan to use new biotechnology for process 
rationalisation and "modest" changes or extensions of their current 
product lines.
(2) "HIGH INVOLVEMENT LONG-TERM PLANNERS"
These companies plan to use new biotechnology for new process 
development, existing process rationalisation, for "modest" changes 
or extensions of their current product lines and for new product 
lines.
(3) "HIGH INVOLVEMENT/BROAD-FRONT LONG-TERM 
PLANNERS"
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These companies aim at large future markets through long-term 
accumulation of know-how. This strategy is seen as increasing the 
already strong biotechnological base of the company.
The results of the present research study indicate that high 
biotechnology involvement has begun to grow, not exclusively, but 
to a considerable extent within the framework of already strongly 
concentrated sectors such as dairy, alcoholic beverages and food 
ingredients, and also in globalised pharmaceutical companies.
These companies seek to use biotechnology as a way of 
consolidating and enhancing their comparative advantage in 
pharmaceuticals, dairy processing and fermentation technology, 
which they have gained through earlier phases of research and 
development. Thus, it was noted that biotechnology involvement in 
the Food and Drink industry is mainly in concentrated sectors 
(dairy, alcoholic beverages, food ingredients). Similarly, in the 
Healthcare industry, biotechnology has been adopted by those 
sectors shaped by globalisation (pharmaceuticals). These facts 
raise a number of important issues with regard to the place of small 
or medium companies in the future biotechnology industrial base.
The entrepreneurial potential of the medium-involvement long-term 
planners in the healthcare industry should, however, be noted.
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Such entrepreneurs are important if the markets, which could be 
created by the ubiquity of biological phenomena, are to be fully 
exploited. These companies have the flexibility to react quickly 
within market niches, which high-invoivement/broad front long-term 
planners in the healthcare sector may ignore due to the high 
adaptation costs.
These medium-involvement long-term planners in the healthcare 
sector have indicated that the key strategic task facing them is 
competence in large-scale marketing. Policy makers must 
investigate the implications of this finding for future biotechnology 
policy-making in Ireland.
This type of interdisciplinary research was carried out to integrate 
the disciplines of science and business. The study has found the 
results to be of interest to:
* Companies involved in the commercialisation of 
biotechnology: and
* Policy makers attempting to develop strategies for the 
diffusion of biotechnology in Ireland: and
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* Academics trying to make the discipline of business more
relevant to the development of new technologies.
For these reasons further research of this interdisciplinary type are 
recommended.
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APPENDIX A
COLLABORATION INVOLVING IRISH 
ORGANISATIONS UNDER THE AUSPICES OF 
S.P.R.I.N.T.
1. EOLAS (Dublin) and Industrial Science Division (N.I.)
2. The Innovation Centre (Limerick) and The Danish Innovation 
Centre, Newtech (Wales)
3. University College Galway 
University of Groningen, Netherlands 
University of Galleca, Feuga, Spain
4. Industrial Development Authority, Ireland and WVIB
Warlschaftsverband ind., Untemehmer, Baden, Germany
5. EOLAS (Dublin) and Technova (Lyon, France)
6. Technology Guidance Ltd., Dublin 
Shekell Moring International Licensing, UK
Regional Development Authority, Limberg
Belgium and Gotz Schaude Innovations, Beratung, Germany
7. EOLAS (Dublin); Technomedia (Udine, Italy) and Impiva 
(Valencia, Spain)
8. Shannon Development Co. Ltd. and Scottish Enterprise 
Board
9. Byrne, Lowe and Associates (Dublin); PAX Technology 
Transfer (London); Helicon Technology Marketing 
(Appledorn, Netherlands); Bree and Co. Marketing 
Consultants (Germany) and Durexport (Spain)
10. IDA,Ireland; Chambre Regionale de Commerce et D’lndustre 
de Lorraine (Nantes, France) and Danish Technical 
Information Service (Copenhagen)
11. EOLAS (Dublin); Danish TEchnical Information Service 
(Copenhagen); G.O.M. (Antwerp, Belgium) and Technical 
University of Eindhoven (Nethrlands).
12. IDA, Ireland and Ostbayerisches Technologies, Regensburg, 
Germany
13. EOLAS (Dublin); Offshore Service Metek Engineering and 
Contracting S.A. (Athens) and Laboratories National de 
Engeharia Civil, Portugal
SOURCE:
Kennedy, T. (1989): "Innovating Across Europe" in Technology 
Ireland, May pp.23-26
APPENDIX B
SUMMARY OF STATE SUPPORT FRAM EW ORK 
AVAILABLE FOR INNOVATION IN IRISH INDUSTRY
(1) Idea phase: Locating ideas and feasability studies
(A) INDUSTRIAL DEVELOPMENT AUTHORITY (IDA)
Joint ventures 
Licensing services 
National Linkage Programme 
Feasability Study Grants Scheme
(B) CORAS TRACI ITALA (C1T)
Market Research Grants
(C) IRISH GOODS COUNCIL (IGC)
Industrial Sub-Contract Service
(D) FAS
Training in Joint Ventures and Technology Transfer
Youth Enterprise Programme
New Product Development Training Programmes
(E) EOLAS
Inventions Service 
New Products Programme 
New Ventures Programme
(2) Research and Development Phase: Research, Development, Pilot
Production
(A) INDUSTRIAL DEVELOPMENT AUTHORITY (IDA)
Product and Process Development Scheme
(B) CORAS TRACHTALA
Product Design and Consultancy Service
(C) FAS
Young Scientists and Technologists Employment 
Programme
Product Development Programmes
(D) EOLAS
Inventions Service 
Development Support Scheme 
Research Programmes in Third Level Institutions 
and Contract Research.
(3) Market Phase: Planning, Testing, Launches
(A) CORAS TRACHTALA (CTT)
Market Research and Consultancy Grants 
Sales Personnel Recruitment 
Group Promotional Programme 
Marketing Support Services
(B) IRISH GOODS COUNCIL (IGC) 
Marketplace Programme 
Market Development Programme
(C) FAS
Overseas Marketing Training
W W W
 .u p ._____
D ublin  C ity  
UNIVERSITY
Ollscoil Chathair Bhaile Atha Cliath
D u b lin  B u s in e s s  S c h o o l
D u b l in  9, I r e l a n d .
Telephone: 370077. Facsimile: 360830. Telex: 30690.
APPENDIX C
D e a r
I  am a  r e c e n t  g r a d u a t e  o f  B i o t e c h n o l o g y  a t  t h e  D u b l i n  
C i t y  U n i v e r s i t y  ( 1 9 8 8 ) .  At  p r e s e n t  I  am i n v o l o v e d  i n  
r e s e a r c h  a t  t h e  D u b l i n  B u s i n e s s  S c h o o l ,  DCU, f o r  t h e  
a w a r d  M a s t e r  o f  B u s i n e s s  S t u d i e s .  The  s u b j e c t  o f  my 
r e s e a r c h  i s  " I n n o v a t i o n  T h r o u g h  B i o t e c h n o l o g y " .
I  e n c l o s e  a  c o p y  o f  t h e  q u e s t i o n n a i r e  w h i c h  y ou  k i n d l y  
a g r e e d  t o  c o m p l e t e .
The  f i n d i n g s  o f  my r e s e a r c h  a nd  a n y  r e c o m m e n d a t i o n s  I 
m i g h t  make  w o u l d  b e  made a v a i l a b l e  t o  a l l  c o n t r i b u t o r s .
You may r e s t  a s s u r e d  t h a t  a n y  i n f o r m a t i o n  g i v e n  w i l l  be  
t r e a t e d  a s  s t r i c t l y  c o n f i d e n t i a l .
I  w o u l d  b e  v e r y  g r a t e f u l  i f  yo u  c o u l d  s p a r e  t h e  t i m e  t o  
c o m p l e t e  t h e  q u e s t i o n n a i r e ,  a nd  r e t u r n  i t  t o  me i n  t h e  
s t a m p - a d d r e s s e d  e n v e l o p e  w i t h i n  14 d a y s  a s  I  h a v e  a 
d e a d l i n e  t o  m e e t .
T h a n k  y o u  f o r  y o u r  t i m e  a nd  c o - o p e r a t i o n  i n  t h i s  
m a t t e r .
Y o u r s  s i n c e r e l y ,
(DEIRDRE MULLEN).
M anagem ent Division
Head of Division: Professor P.M. Chisnall
APPENDIX D
This questionaire represents part o f preliminary research 
carried out by Deirdre Mullen (postgraduate research student 
at the Dublin Business School, D C U ) for the awardof Master 
of Business Studies.
The purpose o f the questionaire is to establish those 
companies in the healthcare and food and drink sectors 
actively involved in biotechnology research and development 
in Ireland, as a means towards innovation.
A ll replies are treated as strictly confidential and are for 
academic use only.
Thank you for your co-operation.
DEFINITION OF TERMS USED IN TH E FOLLOWING  
QUESTIONAIRE
INNOVATION:
BIOTECHNOLOGY
Refers to new product and/or new process developments, 
either new to the market or new to the company.
Refers to the application of scientific and engineering 
principles to the processing of materials by biological 
agents to provide goods and services. This term is 
understood to exclude biomedicine and agriculture - 
excepting those areas which now involve the application of 
cellular or molecular biology.
N O T E :  P L E A S E  T I C K  T H E  R E L E V A N T  B O X
Q .l (a) NAME OF COMPANY: -----------------------------------------
Q .l (b) NAME OF RESPONDENT: ___________________________
Q.2 IS YOUR COMPANY INVOLVED IN BIOTECHNOLOGY 
RESEARCH AND DEVELOPMENT?
YES NO
Q.3 IS THE FIRM: AN INDEPENDENT COMPANY 
A SUBSIDIARY OF A MULTINATIONAL
A PARENT COMPANY WITH 
  SUBSIDIARIES
Q.4 NUMBER OF EMPLOYEES:_____________________
Q.5 TURNOVER (1989): _____________________
Q.6 IS YOUR COMPANY INVOLVED IN ALL STAGES OF NEW
PRODUCT/PROCESS DEVELOPMENT?
YES NO
IF ANSWER IS NO, PLEASE INDICATE WHETHER YOUR COMPANY IS IN­
VOLVED IN R&D, MANUFACTURE OR MARKETING, OTHERWISE PROCEED 
TO NEXT QUESTION.
INVOLVED IN R&D
INVOLVED IN MANUFACTURING
INVOLVED IN MARKETING
Q.7 WHAT GENERAL AREA(S) OF BIOTECHNOLOGY R  & D  IS YOUR 
COMPANY PURSUING?
Q.8 W ITH REGARD TO BIOTECHNOLOGY R  & D, IS YOUR COMPANY?
INVOLVED IN IN-HOUSE R & D
INVOLVED IN CONTRACT R & D
Q.9 IS YOUR COMPANY'S BIOTECHNOLOGY R  & D INVOLVED IN:
NEW PRODUCT DEVELOPMENT
NEW PROCESS DEVELOPMENT
BOTH
Q.9 ARE YOUR NEW PROCESS DEVELOPMENTS FOR IN-HOUSE USE OR 
ARE THEY FO R COMMERCIAL USE?
TH ANK YO U FO R  YOUR TIME A N D  CO-OPERATION
APPENDIX E
PURPOSE OF INDIVIDUAL QUESTIONS ON 
PRELIMINARY RESEARCH POSTAL QUESTIONAIRE
Q.1 (A) AND (B) AND Q.2
Used for screening purposes and classification purposes.
Q.3 - Q.5
Sought background information on the company type, number of 
employees and turnover, with a view towards finding (a) potential 
variable(s) affecting responses/information from further research 
(i.e. depth-interviews) or differentiating the respondents.
Q.6
Concerned vertical integration. Full integration implies sufficient 
capital to fund the integration processes and that the company is a 
growing concern in which product sales fuel the next cycle of 
growth, in the case of indigenous companies. Although the 
subsidiaries of multinationals, as expected, are not fully integrated 
in their Irish operations, that is either R & D and/or marketing 
operations are carried out by the parent company.
Sought to find out the scope of biotechnology R & D and also 
served to screen the respondent companies.
Q.9
Examined whether biotechnology R & D was aimed at product or 
process development or both, as a means towards innovation.
APPENDIX F
OUTLINE OF "AIDE MEMOIR" EMPLOYED DURING 
DEPTH INTERVIEWS
SECTION I
This section seeked to gain further background information on the 
company, to add to the information already obtained through the 
preliminary research postal questionaire and information obtained 
from "desk research" (including company literature and company 
annual financial reports).
This section of the interview invited the respondent to talk about the 
business activities of the company and to provide further historical 
information on the company. This section also established the 
corporate strategy of the company.
SECTION II
This section of the interview seeked to obtain information on the 
research and development (R & D) activities and organisations of 
the company including biotechnology R & D. Specific questions 
are listed below which cover a given set of topics relating to R & D 
in a more or less systematic way. However, due to the "semi­
structured" nature of the interview, the respondent was allowed to 
respond freely but nevertheless guided by the 
interviewer/researcher. The interviewee/respondent was "guided" 
by suggesting areas in which responses were required
SECTION II R & D ACTIVITIES AND ORGANISATION
Q.1 Is the R & D function of the business considered an 
important function of the business operation?
Q.2 What are the key technological strengths of the company?
Q.3 What, in your opinion, is the principal contribution that R & D
makes to the company?
Q.4 Is the company’s research emphasis on basic, applied or 
developmental work?
Q.5 What is the size of the R & D department?
* Number of qualified technicians?
* Number of graduate scientists and engineers?
* Number of doctoral scientists and engineers?
Q.6 How are R & D staff organised, isit according to academic
discipline, techniques/equipment used, specific tasks etc.?
Q.7 How flexible is this schedule?
Q.8 How are R & D budgets calculated?
Q.9 Has the R & D expenditure been increasing, decreasing,
constant over the last five years of operations (where 
appropriate)?
Q.10 How are strategic objectives and plans in R & D efforts 
formalised?
Q.11 Is there a formal procedure for determining the allocations of 
funds to specific projects?
Q.12 What methods and criteria are employed for selecting, 
monitoring and evaluating specific projects?
Q.13 How many additional R & D departments of the company are 
involved in biotechnology R & D (in the case of subsidiaries 
and/or parent company with subsidiaries abroad)?
Q.14 What proportion of R & D effort does this represent?
Q.15 With regard to contract research carried out by external 
organisations/universities for the company:-
Where is such research carried out?
What are the expected impacts of such collaboration on te 
company’s R & D efforts? (suggest the following;)
* generating new lines of research?
* suggesting new ways of solving problems arising 
during the innovation process?
* providing information for use in more routine work 
(please specify)?
* other?
What research areas are explored through contract 
research?
Is Bioresearch Ireland involved in carrying out contract R & D 
for the company?
Q.16 Apart from contracted R & D what are the company’s formal 
links with academic or research institutions? (suggestions 
made by interviewer/researcher included the following)
* Consultancy services
* Use of equipment or facilities
* Exchange of personnel
* Support of studentships
* Other
Q.17 How frequently are such formal links employed?
Q.18 Do informal links with academic/research institutions exist, 
how did they originate? (suggestions made by researcher 
included the following)
* Education
* Attendance of conferences
* Membership of professional bodies
* Other
Q.19 How frequently are such contacts used?
Q.20 In general, what Is the Impact of such contacts on the 
company’s R & D efforts?
Q.21 How does biotechnology (as defined) figure in the structure 
of the R & D department?
Q.22 Has the company always been involved in the areas of 
technology currently pursued? (researcher suggested some 
reasons which are listed below;)1
EXTERNAL FACTORS RELATED TO MARKET SITUATION
response to customers’ direct request(s)
to meet customers’ perceived needs
response to competitors’ actions
to block market to competition
to enter new markets
to strengthen position in existing markets
the erosion of markets for existing products
1This part of Section II of the interview was adapted from a checklist devised by 
Roy Rothwell for his study of innovation in the textile industry (Rothwell, 1977)
other
INTERNAL FACTORS RELATED TO THE ECONOMICS OF THE COMPANY 
falling profit margins on existing business 
part of a general approach for improved efficiency 
other
EXTERNAL FACTORS RELATED TO SCIENTIFIC AND TECHNOLOGICAL 
DEVELOPMENTS
new scientific understanding
new technological capability
INTERNAL FACTORS RELATED TO THE SCIENTIFIC AND 
TECHNOLOGICAL DEVELOPMENTS IN THE COMPANY
accrued experience, expertise, investment in 
equipment/plant
falling returns on current research activity
problems with other research areas for commercialisation of 
existing/new products/processes
other
(Please elaborate)
AVAILABILITY OF FINANCIAL ASSISTANCE
through government grants
access to R & D finance, through venture capital, for 
example
finance support resulting from merger (where applicable)
Q.24 Was the decision to pursue biotechnology R & D considered 
more risky in terms of technical success compared to 
previous R & D activities?
Q.25 Is biotechnology R & D considered an OFFENSIVE or 
DEFENSIVE more commercially.
Q.26 Is biotechnology R & D expected to have a radical or more 
incremental impact on the company’s existing activity?
Q.27 Was the decision to pursue biotechnology research intended 
for use in product or process applications or both?
GOVERNMENT INITIATIVES
Q.28 Were there others already at work in the field of 
biotechnology R & D that you are involved in?
Q.29 Products/processes developed or being developed involving 
biotechnology R & D?2
Q.30 How close to the state of the art should the company be to 
achieve its objectives in its products and markets? What is 
the company’s present situation with regard to this?
Q.31 How much emphasis is given to advancing knowledge of 
biotechnology through basic as opposed to applied 
research?
Q.32 Is the company developing biotechnology capabilities 
beyond those strictly related to its current output?
Q.33 What area(s) of biotechnology is promising commercially 
from the perspective of the existing output or future output?
Q.34 Typical innovation process? (This question invited the 
respondent to discuss the innovation process of the 
company; the discussion was guided by referring to specific 
aspects of the process including:-
2
This question initiated a discussion of innovation strategies pursued in the past 
and those pursued at present and for the future; the respondent was invited to 
discuss examples of past, present and potential future innovations employing 
biotechnology R & D. The discussions also focused on specifics such as 
products marketed, patents sought/filed etc licensing of technology etc.
time scale?
how effective is the communication between the different 
functions?
how could communication be improved etc.?
SECTION III
This section of the interview seeked to obtain information on the 
innovation process pursued by the company, focusing on specific 
issues related to biotechnology.
Q.1 How important is innovation (as defined) to your company?
Q.2 Are both new product development and new process
development equally important or does one have a greater 
weighting over the other in the company?
Q.3 What percentage of products have been developed totally 
within the country in the last five years?
All products
R & D/marketing/production integration?
Over 50% of all products
Under 50% of all products
Q.4 Has the financial contribution to new product/process 
development been increasing, decreasing constant (allowing 
for inflation etc.) over the past five years?
Q.5 Who is primarily responsible for innovation strategy 
formulation?
Q.6 How do you generate new product/process ideas? (The 
researcher indicated possible ways of generating new 
product/process ideas:)
direct search?
exploratory consumer surveys?
technological forecasting?
creative group methods (if so, specify)?
"consumer engineering" (process of matching consumer 
needs to technological capabilities)?
other?
Q.7 What is the main initiating factor(s) for new product/process 
development in the company to date?
financial goals?
externally generated pressures such as competitive position, 
product life cycle, technology, regulation, material costs and 
availability?
specific market stimuli/opportunities such as lifestyle 
changes, customer requests, supplier initiatives?
Q.8 Where have your most successful new product ideas come 
from? (Researcher guided respondent by suggesting some 
sources of new product/process ideas:)
patents?
competition?
* acquisition (where relevant)? 
market needs?
users’ solutions (where relevant)?
technology?
business development manager(s)?
other?
Q.9 What in your opinion have been the main causes of new 
product failure in the company to date? (Again, respondent 
was guided by several alternatives but free to add specific 
causes of new product failure where applicable)
inadequate market analysis?
product defects?
lack of effective marketing effort?
higher costs than expected?
poor timing of introduction?
technical or production problems?
other?
Q.10 What are the main factors to be considered in idea 
screening and selection? (Researcher guided respondent 
with alternatives:)
product’s potential in terms of market size, sales growth 
etc.?
probability of technical success?
development or production costs?
complementary to existing capabilities?
other?
Q.11 Does the company have a specific innovation "charter" or 
does it depend on the particular project?
Q.12 What formal provisions exist for interactions between R & D 
and marketing departments during the innovation process? 
And how frequently are these formal provisions employed?
Q.13 Is there more emphasis on changing existing 
products/processes or developing radically new 
products/processes in the company?
Q.14 What impact has technological learning (through 
biotechnology) had on the company’s new product/process 
strategies, if at all?
Q.15 With regard to protection of new products/processes, is the 
patent route preferable to trade secrets? If not, why?
Q.16 Has your company ever licensed technology related to 
biotechnology R & D (either in or out of the company)?
Q.17 Have legal regulations in Ireland or abroad affected your 
innovation strategies?3
Q.18 With regard to biotechnology R & D, has the company 
received grant-aid from the government? (The researcher 
enquired as to the nature of the grant-aid)
* Scientist Employment Grant?
* Plant Capital?
* Equipment Capital?
* Specific Project Finance?
* Other?
Q.19 With regard to biotechnology R & D  has the company 
received venture capital either from the European Venture
^ h is  question initiated a discussion on regulation in biotechnology R & D  and 
marketing of products or use of processes.
Capital Association or other venture capital organisations in 
Ireland or abroad?
SECTION IV
This section of the field research included a "tour" of the R & D  
facilities and manufacturing plant (in most cases 16 out of 20). 
Further aspects of R & D and individual research projects for 
commercial applications, were discussed during the tour. This 
proved to be very useful in backing up the information received 
during the depth interview.
